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General introduction and outline of thesis 
 
 
8│Chapter 1  
Background  
Cell culture models play an important role in biomedical research and will continue to 
do so given the growing opposition to vivisection and the limited predictive value of 
animal models for human disease. Moreover, cell culture models can be easily 
established to mimic physiological or pathological processes, which is difficult to 
accomplish using in silico models. While non-cellular in vitro models are highly 
suitable for studying simple biochemical processes, cell culture models recapitulate 
many of the complex regulatory circuits governing protein activity in vivo and hence 
allow investigation of diverse physiological processes. Also, cell culture models offer 
the possibility to address fundamental research questions in a much more simplified, 
specific and controllable manner than can be achieved using in vivo models.  
Aging is a complex and multifactorial process driven by genetic and 
environmental factors and govern by various interacting molecular pathways that lead 
to the physiological decline of biological systems. A variety of experimentally 
tractable cellular models were employed in recent years to study the basic mechanisms 
of aging, knowledge of which is essential to the development of effective therapeutic 
interventions against age-related diseases1. Due to the complexity of striated muscle 
structure and function, standardized cell culture models are a real asset for studying 
skeletal and cardiac muscle biology and disease. Cultures of skeletal myoblasts or 
cardiomyocytes (CMCs) can mimic physiological or pathological conditions, making 
them well-suited for proof-of-concept studies and for developing novel therapeutic 
interventions for specific diseases2,3. Especially, cultured cardiac cell monolayers have 
become a popular model system for electrophysiological studies4 into the mechanisms 
of cardiac arrhythmias5-7 as well as drug-induced ventricular pro-arrhythmic effects8. 
Brown adipose tissue (BAT) represents a potential therapeutic target to treat obesity 
and associated metabolic disorders because of its capacity to ingest and combust 
glucose and fatty acids for thermoregulation9. The properties of BAT has been 
investigated using cultures of primary brown preadipocytes (BPAs). Although these 
studies have yielded new insights into adipocyte biology10-12, the full potential of BAT 
culture models has not been utilized due to the scarcity of starting material and the 
limited proliferation capability of primary BPAs. A potential solution to this problem 
would be to establish lines of BPAs by cellular immortalization. Although cell 
immortalization offers the possibility to produce virtually unlimited cell sources by 
inducing cell cycle reentry and by bypassing cell senescence, generation of robust cell 
lines that can recapitulate (most of) the properties of the primary cells from which 
they were derived requires a thorough understanding of the mechanisms of cell 
quiescence, proliferation, differentiation, senescence and apoptosis. 
 
Cell cycle 
To divide, a cell must grow, copy its genetic material (DNA), and physically split into 
two daughter cells. Cells perform these tasks in an orderly and tightly regulated series 
of events known as the cell cycle, which is divided into two major phases, the 
interphase and the mitotic phase. During the interphase, the cell grows and duplicates 
its nuclear DNA. The interphase is divided in three subphases. During gap phase 1 
(G1 phase), the cell grows physically larger, copies organelles except for the nucleus 
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and synthesizes the molecular building blocks needed for the next subphase. In the 
synthesis (S) phase, the cell copies its chromosomal DNA and duplicates a 
microtubule-organizing structure called the centrosome, which helps to separate the 
DNA during the mitotic phase. During gap phase 2 (G2 phase), the cell grows more, 
makes additional macromolecules and organelles, and begins to reorganize its 
contents in preparation for mitosis. In the mitotic phase, the cell’s chromosomal DNA 
is equally separated into two new daughter nuclei and the cell’s cytoplasm and 
organelles are split after the formation of a cleavage furrow producing two new 
daughter cells. The segregation of duplicated chromosomes into daughter nuclei is 
called karyokinesis; the separation of cytoplasm and organelles is called cytokinesis.  
The cell cycle is controlled by the activity of cyclin-CDK (cyclin-dependent 
kinase) complexes. CDKs are always present but need to be activated by phase-
specific cyclins. Mitogens induce the synthesis of cyclin D early in the G1 phase. 
Cyclin D associates with CDK4 and CDK6 resulting in the hyperphosphorylation of 
the retinoblastoma protein pRB and the disruption of complexes between this pocket 
protein and several members of the E2F family of transcription factors. This allows 
these EF2 family members to form a complex with the in transcription factor DP 
(dimerization partner) and to induce the expression of various genes involved in cell 
cycle progression including the gene encoding cyclin E which is necessary for G1/S 
transition. CDKs are further activated during cell cycle by cyclin A and B to drive 
transition from S phase to G2 phase and from G2 phase to M phase, respectively. The 
activities of cyclin-CDK complexes are regulated by CKD inhibitors including the 
INK4 family (p15, p16, p18 and p19) and CIP/KIP family (p21, p27 and p57) which 
bind to CDKs and inactive the complexes (Figure 1).  
 
Figure 1. Cell cycle regulation. 
The CDK-cyclin complexes promote cell cycle progression, while the CDK inhibitors stop it. 
CDK4/6-cyclin D is activated in phase G1, CDK2-cyclin E in phase G1/S, CDK2/1-cyclin A 
in phase S/G2 and CDK1-cyclin B in phase M. The CIP/KIP family (p21, p27 and p57) 
inhibit a wide range of cyclin-CDK complexes, yet the INK4 family (p15, p16, p18 and p19) 
specifically diminish CDK4/6 activity. 
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Cell fates 
 
The fate of a cell is determined by the changes in its gene expression pattern and 
associated activities, which will lead to cell proliferation, quiescence, differentiation, 
senescence or death (Figure 2). Mitotic cells such as cells in the skin and gut 
repetitively progress through phases G1, S, G2 and M of the cell cycle. Mitotic cells 
can also enter the G0 phase of the cell cycle. This state of cell cycle arrest is observed 
in quiescent, (terminally) differentiated and senescent cells. Quiescent cells such as 
adult stem cells, fibroblasts and lymphocytes are temporarily arrested in G0 phase and 
readily reenter the cell cycle when exposed to mitogens. Dormant cells are quiescent 
cells showing very low metabolic activity, which is frequently interpreted as being in 
a deeply quiescent state. Cells like adipocytes, cardiomyocytes and neurons are 
believed to lose the capacity to enter the cell cycle and to permanently reside in the G0 
phase of the cell cycle once they are fully differentiated. However, recent studies have 
shown that both self-renewal of cardiac tissue and regeneration upon damage mainly 
results from the cell cycle reentry and proliferation of existing cardiomyocytes13-18. In 
general mitotic cells will stop dividing and become senescent after a limited number 
of divisions. Senescent cells cannot replicate anymore because of telomeres shorting, 
irreparable DNA damage, nutritional deficiency, harmful chemicals, oxidative stress 
or physiologic stress. Except for the stem, progenitor and precursor cells that escape 
from death by being converted in more differentiated cell types, all other cells finally 
die because of natural turnover or due to injury, including the death of the organism. 
Cell deaths can occur by various different mechanisms. Two of the major types of cell 
death are apoptosis and necrosis19. Apoptosis, also known as programmed cell death, 
is a normal physiological, non-inflammatory process to remove unwanted cells. In this 
process, apoptotic bodies are formed to confine cell organelles and other parts, which 
will be phagocytosed by macrophages. Necrosis, also known as unprogrammed cell 
death, is a less orderly process than apoptosis, in which cells and organelles swells 
resulting in membrane rupture. As a consequence, the cellular content is released in 
the extracellular space triggering an inflammatory response and possible causing 
further damage to adjacent cells20. A major difference between normal somatic cells 
and transformed cells is their proliferation potential. Normal somatic cells in culture 
have a limited ability to multiply themselves known as the Hayflick limit (see below), 
while transformed cells have evaded normal cellular senescence due to mutations 
resulting in acquisition of unlimited proliferation ability, evasion of apoptosis, growth 
factor independency, non-responsiveness to growth inhibitors, promotion of 
angiogenesis and invasive capacity. Immortalized cells have not necessarily 
undergone neoplastic transformation, but have accumulated sufficient mutations to 
proliferate unlimitedly. Upon transplantation immunocompromised mice, transformed 
cells will form tumors in contrast to immortalized cells. More details about cellular 
senescence, quiescence and immortalization are described below. 
 
 




Figure 2. Possible cell fates.  
Under normal conditions, cells adopt one of five distinct cell fates: they can remain in the cell 
cycle and continue to proliferate or leave the cell cycle and become quiescent, differentiated 
or senescent or undergo apoptotic or necrotic cell death. Under pathological conditions, cells 
can escape from senescence or apoptosis and become immortalized or transformed following 
the activation of endogenous oncogenes and/or the inactivation of endogenous tumor 
suppressor genes. Cell immortalization can also be brought about by oncogenic viruses or via 
genetic engineering. 
 
Cellular senescence  
Senescence as a common stress response  
Normal mammalian somatic cells such as fibroblasts, myoblasts and preadipocytes, 
grown in culture fail to proliferate after a finite number of divisions and ultimately 
encounter senescence. This phenomenon was first found in human fibroblast cultures 
by Hayflick21 and later referred to as replicative senescence22-24. Replicative 
senescence is thought to be the result of progressive telomere shortening as a cell-
intrinsic mechanism25,26. Cellular senescence can also be stimulated by various types 
of cell stress like lack of nutrients, harmful chemicals (e.g. cytostatic drugs), oxidative 
stress or physiologic stress (e.g. caused by aberrant expression of tumor suppressor or 
oncogenes and excessive growth factor stimulation), which block the proliferation of 
cells27-29. This type of senescence is referred to as premature or induced senescence30. 
These findings have led to a distinction between “replicative senescence” which is 
induced by a cell-intrinsic mechanism, and “stress-induced premature senescence” 
which is triggered by extrinsic factors31. In many cases, replicative and premature 
senescence are interconnected. Telomere shortening is, for instance, accelerated by 
oxidative stress. Actually, cells may suffer cumulative damage from multiple stresses 
during culture. Senescence will be triggered when cellular damage has reached a 
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certain threshold, whatever has caused the damage. Senescent cells undergo dramatic 
changes in morphology and function. They generally become enlarged and flattened, 
have an increased lysosomal content, suffer from mitochondrial dysfunction and 
secrete increased amounts of inflammatory, growth-promoting, and remodeling 
factors. They may also form senescence-associated heterochromatin foci, often 
display a chronic DNA damage response, are incapable of synthesizing DNA for 
mitosis, show high resistance to apoptosis and are unresponsive to mitogenic stimuli. 
However, senescent cells are still metabolically active for months or even years27,32-35. 
 
p53 and pRB as key regulators of senescence 
Molecular pathways of senescence are complex involving multiple layers of 
regulation with cooperative changes. The p53 tumour suppressor protein and the 
pocket proteins (i.e. pRB, p107 and p130) have been shown to play critical roles in the 
induction of senescence. The p53 protein is an important cell cycle regulator of both 
the G1/S and G2/M checkpoints by activating CDKN1A transcription. CDKN1A 
codes for p21 protein, which is a member of the CIP/KIP family of tumor suppressor 
proteins. These proteins inhibit various cyclin-CDK complexes required for promotion 
of the cell cycle (Figure 3). Hypophosphorylated pRB controls the G1/S checkpoint 
by directly binding to and inhibiting various E2F family members thereby repress 
gene transcription required for transition from the G1 to S phase of the cell cycle. In 
actively dividing cells, the suppressive effect of pRB on E2Fs is lost due to 
hyperphosphorylation of pRB by cyclin D-CDK4 and cyclin D-CDK6 complexes. In 
senescent cells the activity of these complexes is inhibited by members of the INK4 
family of tumor suppressor proteins36. (Figure 3). 
Numerous studies have explored the roles of p53 and pocket proteins in the 
induction and maintenance of senescence in mouse embryo fibroblasts (MEFs). 
Suppression of p53 expression allows cells to escape from senescence and leads to 
their indefinite expansion37. Inactivation of pRB alone is not enough to ease 
senescence of MEFs, while accompanying ablation of other pocket proteins including 
p107 and p130 strongly increased their proliferation capacity38,39. This demonstrates 
that the inactivation of either p53 or all three pocket proteins is sufficient to block the 
initiation of senescence. Suppression of either p53 or pRB in senescent MEFs is not 
enough to maintain senescence but leads to reactivation of the cell cycle37,40. 
Collectively, these findings suggest that p53 and the pocket proteins control cellular 
senescence in a hierarchical manner, in which the activation of pocket proteins is 
downstream of that of p53. Indeed, as mentioned before, p53 actives p21, which in 
turn inhibit cyclin-CDK complexes involved in the phosphorylation and inactivation 
of the pocket proteins. However, MEFs lacking p21 still undergo senescence and have 
a lifespan similar to wild-type cells41, which shows that p21 is not the only link 
between p53 and pocket protein activity in the regulation of senescence (Figure 3). 
 
Cellular quiescence  
 
As indicated above, cells can enter into either of three different G0 states. While 
senescent and (terminally) differentiated cells have permanently excited the cell cycle 
(irreversible G0 arrest), quiescent cells only temporarily reside in the G0 phase 
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(reversible G0 arrest) and reenter the cell cycle in response to normal physiological 
stimuli42. The notion that terminally differentiated cells are irreversibly arrested in G0 
has been challenged by the finding that mature hepatocytes dedifferentiate and reenter 
the cell cycle after injury of the liver and contribute to its regeneration43-46. Similar 
observation have recently been made for terminally differentiated cardiomyocytes13-18. 
Hence, not only quiescent cells but also terminally differentiated cells can exit the G0 
phase and resume cell division. 
In quiescent cells, p53 has been considered as main molecular regulator of cell 
cycle arrest47. Similar to senescence, the mechanism by which p53 mediates 
quiescence is dependent on the activation of p21, a CDK inhibitor and critical 
component of the pRB-E2F pathway48. In addition to p53, quiescent cells typically 
feature lower levels of pRB-E2F pathway activators, such as cyclin D49-51 and high 
levels of pathway repressors, such as p2148. The disruption of all three pocket proteins 
and the acute loss of pocket protein function in quiescent cells lead to cell 
proliferation38-40,52. pRB deficiency in quiescent skeletal stem cells leads to an 
increase of proliferation and a loss of terminal differentiation capacity38,53. All of the 
above suggest that the RB-E2F pathway plays a pivotal role in quiescence. Among the 
E2F family of transcription factors, E2F1, -2 and -3 are considered “E2F 
transcriptional activators” and E2F4 and -5 are deemed “E2F transcriptional 
repressors”54. In cell cycle-arrested cells, hypophosphorylated pRB prevents cell cycle 
reentry by binding and repressing E2F1, -2 and -3, which activate genes required for 
the transition from G1 into S phase. In addition, hypophosphorylated p130 and p107 
form complexes with E2F4 and -5. The complexes bind to the promotors of E2F target 
genes and recruit chromatin remodeling factors that block transcription55,56. In 
quiescent cells that are stimulated with mitogens, cyclin-CDK complexes 
phosphorylate pRB thereby releasing E2F1, -2 and -3. Similarly, phosphorylation of 
p130 and p107 abolishes their interaction with E2F4 and -5 repressors57,58. Especially 
E2F4-p130 complexes are very prominent in resting (i.e. G0-arrested ) cells 
suggesting that they play a pivotal role in the maintenance of cell quiescence59-61 
(Figure 3). 
Figure 3. Participation of cell cycle regulators in cell cycle arrest.  
p53 activates CDK inhibitors (e.g. p15, p16 and p21), which in turn disrupts cyclin-CKD 
complexes involved in the inactivation of the pocket proteins (pRB, p107 and p130). This 
allows the pocket proteins to arrest cell in a non-proliferative state by blocking the 
transcription of E2F target genes. LT, large tumor antigen. mdm2, mouse double minute 2. 
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Simian virus 40 LT antigens & cell immortalization 
 
Simian virus 40 (SV40) is a small double-stranded non-enveloped DNA virus with a 
circular genome and an icosahedral capsid in the family of Polyomaviridae. The SV40 
genome is composed of three main regions: (i) an early region encoding large tumor 
antigen (LT), 17kT and small tumor antigen (ST), (ii) a late region encoding the viral 
coat proteins (VP1, VP2, VP3 and VP4) and the agnoprotein (Agno) and (iii) the 
regulatory region containing the early and late promotor and the origin (Ori) of 
replication (Figure 4A). LT, 17kT and ST are produced from alternative splice 
products of the early viral pre-mRNA and are co-expressed in infected cells. The 
amino-terminus of LT contains a J domain which contributes to viral DNA 
replication62. Downstream of the the J domain, there is a LXCXE motif that can 
directly bind to the pocket proteins (i.e. pRB, p107 and p130)63,64. The J domain 
cooperates with the LXCXE motif to disrupt the interaction between E2F family 
members and the pocket proteins63. The DNA-binding domain (DBD) of LT 
recognizes Ori sequences and this interaction is essential for the initiation of viral 
DNA replication. The helicase domain works as DNA helicase to unwind the dsDNA 
template for viral replication and it also interacts with p5365. ST contains a J domain 
followed by a cellular protein phosphatase 2A (PP2A) binding region which contains 
two zinc fingers. ST binds the A and C subunits of PP2A and displaces the B subunit, 
thereby inhibiting the pro-apoptotic activity of PP2A66,67. 17kT shares several 
regulatory domains with LT that mediate some of its most important functions 
including stimulation of cell proliferation by binding to pocket proteins68 (Figure 4B). 
LT plays an essential role in multiple steps of the viral life cycle. After 
infection, LT induces host cells to enter the S phase thereby creating optimal 
conditions for the replication of viral DNA. Meanwhile, LT works as the DNA 
helicase and then utilizes the host’s replication machinery to replicate the viral DNA. 
Besides, LT is also involved in transcription and virion assembly. Given the capability 
of LT to incite cell proliferation, LT has been successfully used to immortalize 
multiple primary cell types with no/limited proliferative capacity in vitro69-71. Our 
current understanding indicates LT’s ability to drive cell proliferation is mainly due to 
its interaction with the pocket proteins and p5372,73. Quiescent cells including 
differentiated cells are trapped in G0 by the pocket proteins42. Hypophosphorylated 
pocket proteins bind to E2Fs and thereby block gene expression required for 
nucleotide synthesis, DNA replication, cell cycle progression and apoptosis. When 
cells are mitogenically stimulated, pocket proteins become phosphorylated allowing 
E2F-mediated S phase gene transcription. Instead of disrupting E2F-pocket protein 
complexes by pocket protein hyperphosphorylation, LT binds to hypophosphorylated 
pocket proteins setting free the pocket protein-bound E2Fs resulting in E2F-dependent 
gene expression and cell cycle reentry74. The p53 level in normal cells remains very 
low because it binds to Mdm2 which induces ubiquitination and subsequent 
degradation of p5372,75. Besides Mdm2, many other proteins affect the biological 
activity and stability of p53 through various types of post-translational modifications. 
Different cellular stress conditions lead to stabilization of p53 allowing it to act as a 
transcriptional activator of genes mediating apoptosis or cell cycle arrest76,77. LT 
inactivates p53 by covering its DNA-binding domain and thus block the expression of 
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p53-dependent genes, which leads to cell cycle reentry and avoids cell cycle arrest as 
well as apoptosis78 (Figure 3). 
Exposure of SV40 particles to chemical mutagens has resulted in the recovery 
of several temperature-sensitive LT mutants (ts-LTs) that can cause cell 
immortalization/transformation at permissive temperatures (≤ 34°C) but fail to do so 
at nonpermissive temperatures (≥ 37°C)79,80. These ts-LTs have been used to control 
the activity of LT allowing conditional immortalization of primary mammalian cells.
 
 
Figure 4. Structure of SV40 
(A) Genomic structure of SV40. The circular double-stranded DNA genome contains three 
main regions: the regulatory region, an early region encoding LT, 17kT and ST, and a late 
region encoding the viral coat proteins VP1, VP2, VP3 and VP4 as well as the agnoprotein. 
(B) The functional domains of SV40 T antigens. The J domain is shared by all three antigens. 
LT also contains a pocket protein-binding LXCXE motif, a DNA-binding domain (DBD), a 
p53-binding helicase domain. 17kT shares several regulatory domains with LT including a 
pocket protein binding domain. ST contains a J domain followed by a PP2A-binding region 
with two zinc-fingers. 
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For instance, ts-LT tsA58, which carries an alanine to valine substitution at amino 
acid position 438 that abolishes its binding to and inhibition of p53 at nonpermissive 
temperatures81 was expressed in transgenic mice to generate conditional immortalized 
cell lines from different tissues82,83. 
 
Cell cycle regulation in cardiomyocytes 
In the embryonic and fetal hearts of vertebrates, including mammals, cardiomyocytes 
have high cell cycle activity and are capable of DNA synthesis, karyokinesis and 
cytokinesis resulting in cardiomyocyte division and an increase of cardiomyocyte 
number. However, the proliferative capacity of postnatal hearts differs from various 
species. Zebrafish have cardiomyocyte proliferative capacity throughout life. A 
complete regeneration of heart tissue lost from the resection of the ventricular apex 
can be managed in adult zebrafish through the proliferation of pre-existing 
cardiomyocytes15,84. In contrast, mammalian cardiomyocytes lose their proliferative 
capacity shortly after birth and the expansion of postnatal mammal heart driven by 
non-mitotic growth produces multinucleated or polyploid cells and hypertrophic 
cells85-88. In mice, during the first week of postnatal period, the majority of 
cardiomyocytes undergo karyokinesis in the absence of cytokinesis, which generates a 
population of binucleated cardiomyocytes85. In this event, cardiomyocytes enter the M 
phase of the cell cycle and perform nuclear division, but they do not undergo 
cytokinesis86,88. In contrast, the timeline of human cardiomyocyte proliferative 
capacity is not clear, however, more than half of all adult human cardiomyocytes are 
polyploid as a result of DNA duplication without nuclear division87. The 
polyploidazation results from shuttling between G1, S and G2 phase without entering 
into the M phase. Although damage-induced cardiomyocyte proliferation in adult 
mammals has been observed13,89,90, the growth of stressed and injured mammalian 
hearts is largely caused by hypertrophy. Under physiological and pathological 
hypertrophy-stimulating conditions, cardiomyocytes enter the G1 phase of cell cycle 
where the grow in size by synthesis of extra RNAs and proteins, but they fail to 
undergo S phase91-93 (Figure 5).  
This different behavior of antenatal and postnatal cardiomyocytes is due to the 
developmental changes in cell cycle activity86,94. The cell cycle of cardiomyocyte is 
tightly controlled by transcription factors and regulators thereof like the pocket 
proteins, which play an essential role in cell cycle exit and differentiation of 
cardiomyocytse95. For example, p107 and p130 interact with E2F family members to 
inhibit DNA synthesis in the fetal and neonatal cardiomyocytes, respectively96. 
Moreover, pRB silences multiple proliferation-promoting genes in adult 
cardiomyocyte to maintain their post-mitotic state by interaction with heterochromatin 
protein 1γ97,98. Apart from the pocket proteins, transcription factors such as Meis1, 
MEF2D, FoxO1, and FoxO3, inhibit cell cycle progression by increasing the 
expression of p21, p27, p15, and p1699-102. In contrast, transcription factors, such as 
E2F1, E2F2, E2F4, CASZ1, GATA4, Tbx20, and FoxM1, stimulate cell cycling by 
increasing the expression of cyclins99,101,103-106. Besides, PI3K-AKT, Wnt/β-catenin 
and YAP signaling pathways play important roles in cardiomyocyte proliferation107-111. 
Manipulation of the cell cycle in post-mitotic cardiomyocytes may be an attractive 
strategy to obtain large numbers of cardiomyocytes for in vitro studies, cardiac cell 
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therapy and the regeneration of injured hearts from inside by re-awaking cell cycling 




Figure 5. Cell cycle activities in cardiomyocytes. 
In a typical cell cycle, cell successively enters the G1 phase (for synthesis of RNAs and 
proteins), S phase (for DNA synthesis), G2 phase (for additional growth) and M phase (for 
karyokinesis and cytokinesis) resulting in two individual cells. In the presence of 
hypertrophic stimuli, cardiomyocytes enter the G1 phase and grow in size by synthesis of 
RNAs and proteins, but they fail to enter the S phase. Polyploidazation results from shuttling 
between G1, S and G2 phase without entering into the M phase. Multinucleation occurs when 
cardiomyocytes enter the M phase and perform karyokinesis, but are withdraw from the cell 
cycle before cytokinesis. 
 
  
18│Chapter 1  
Aim and outline of thesis 
 
The aim of this thesis is to develop and use cell culture models for fundamental and 
applied biomedical research. Cell immortalization is a promising approach to produce 
large number of cells from same amounts/scarce primary staring material by inducing 
cell cycle reentry or bypassing cell senescence. Accordingly, a major part of this 
thesis was dedicated to the generation of robust cellular model systems by cell 
immortalization for addressing fundamental and applied research questions in a 
reproducible, flexible and standardized way. 
Bypassing cellular senescence is a prerequisite for cell immortalization. It is 
therefore important to have a better understanding of the mechanism of senescence 
before immortalizing cells. A variety of proteins and pathways were found to be 
involved in senescence. However, the role of heterochromatin proteins and their 
contribution to abnormal chromatin organization in cell senescence is largely 
unknown. Chapter II of this thesis uses premature MEFs as a senescence model 
system which is derived from progeria disorder mice and studies the role of 
heterochromatin proteins and the associated chromatin organization in DNA damage 
response (DDR)-induced senescence. 
In order to get familiar with the properties of immortalized cells including their 
culture conditions, proliferation and differentiation, an existing line of immortalized 
human myoblast is cultured and its differentiation is investigated in Chapter III. With 
the aid of this cell line, a novel non-destructive quantitative assay to monitor cell 
fusion is developed. 
Cardiac cell therapy, tissue engineering and in vitro studies into cardiac 
arrhythmias or for testing the potential cardiotoxicity of drugs require large numbers 
of functional and homogeneous cardiomyocytes. Progress in these areas of research is 
impeded by the limited availability of heart tissue and the very low mitotic activity of 
cardiomyocytes highlight the urge to develop new/rich source of cadiomyocytes for 
both basic and translational research. Chapter IV describes the generation and 
characterization of a immortalized atrial myocyte cell line with preserved 
cardiomyogenic differentiation capacity. Through controlled expansion and 
differentiation of this cell line, large numbers of functional cardiomyocytes are 
generated, hence providing an attractive cell model for cardiac research. 
BAT is regarded as a potential target to treat obesity and associated metabolic 
disorders because of its capacity to take up and combust glucose and fatty acids for 
thermoregulation. However, its cellular and molecular investigation has been 
hampered due to high cellular heterogeneity and a limited availability of cell material. 
In Chapter V, monoclonal lines of immortalized BPAs are generated by using mouse 
BAT as starting material. The long-term proliferation and high adipogenic capacity of 
the cell lines provide an attractive model system for fundamental and applied research 
into BAT. 
Besides immortalized cell lines, primary cardiomyocytes were also used to 
solve research questions. In Chapter VI, neonatal rat ventricular myocyte cultures are 
established as an in vitro model for investigating the action potential-prolonging and 
associated proarrhythmic effects of Kv11.1 blockers. In this study, a newly designed 
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and synthesized compound LUF7244 is shown to prevent drug-induced proarrhythmic 
effects as by an allosteric mechanism.  
Finally, Chapter VII provides the summary and conclusions drawn from each 
study of this thesis, as well as future perspectives related to the application of 
immortalized cells. 
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Heterochromatin protein 1 (HP1) interacts with various proteins, including lamins, to 
play versatile functions within nuclei, such as chromatin remodeling and DNA repair. 
Accumulation of prelamin A leads to misshapen nuclei, heterochromatin 
disorganization, genomic instability, and premature aging in Zmpste24-null mice. Here, 
we investigated the effects of prelamin A on HP1α homeostasis, subcellular 
distribution, phosphorylation, and their contribution to accelerated senescence in 
mouse embryonic fibroblasts (MEFs) derived from Zmpste24−/− mice. The results 
showed that the level of HP1α was significantly increased in Zmpste24−/− cells. 
Although prelamin A interacted with HP1α in a manner similar to lamin A, HP1α 
associated with the nuclease-resistant nuclear matrix fraction was remarkably 
increased in Zmpste24−/− MEFs compared with that in wild-type littermate controls. In 
wild-type cells, HP1α was phosphorylated at Thr50, and the phosphorylation was 
maximized around 30 min, gradually dispersed 2 h after DNA damage induced by 
camptothecin. However, the peak of HP1α phosphorylation was significantly 
compromised and appeared until 2 h, which is correlated with the delayed maximal 
formation of γ-H2AX foci in Zmpste24−/− MEFs. Furthermore, knocking down HP1α 
by siRNA alleviated the delayed DNA damage response and accelerated senescence in 
Zmpste24−/− MEFs, evidenced by the rescue of the delayed γ-H2AX foci formation, 
downregulation of p16, and reduction of senescence-associated β-galactosidase 
activity. Taken together, these findings establish a functional link between prelamin A, 
HP1α, chromatin remodeling, DNA repair, and early senescence in Zmpste24-deficient 
mice, suggesting a potential therapeutic strategy for laminopathy-based premature 
aging via the intervention of HP1α. 
 
  





Hutchinson–Gilford progeria syndrome (HGPS), an autosomal dominant human 
disorder with disastrous premature aging features, is predominantly caused by a de 
novo G608G point mutation in LMNA gene. LMNA gene encodes for A-type lamin 
proteins, which are components of the nuclear lamina, a scaffolding network lying 
beneath the inner nuclear membrane and further extending into the nucleoplasm. The 
G608G mutation activates a cryptic splice donor in exon 11 of LMNA gene, resulting 
in a 50-aa internal deletion (Δ50) in prelamin A that contains a proteolytic cleavage 
site required for lamin A maturation. The Δ50 prelamin A left behind is permanently 
modified by a farnesyl group, also called progerin.1,2 A more severe progeria disorder, 
restrictive dermopathy (RD), has homozygous deficiency in Zmpste24, a zinc 
metalloproteinase responsible for the final cleavage step of prelamin A, resulting in a 
partially processed farnesyl full-length prelamin A instead of mature lamin A.3 
Recapitulating HGPS, Zmpste24-deficient mice exhibit severe growth retardation, hair 
loss, osteoporosis, dilated cardiomyopathy, muscular dystrophy, lipodystrophy, and 
their lifespan is shortened to 4–6 mo.4 Thus one common characteristic of HGPS and 
RD is incomplete processing of prelamin A into mature lamin A. Lamin A as a type-V 
intermediate filament protein has head, tail, and connected rod domain structure and 
usually forms a head–tail dimer, which plays essential roles in nuclear membrane 
strength and shape, positioning of the nuclear pore complexes, lamina assembly, 
anchoring chromatin, and dynamic chromatin organization.5 Progerin interferes with 
the integrity of the nuclear envelope, thus leading to misshapen nuclei with lobulation, 
thickening, and blebbing. Such irregular nuclei are also observed in cells derived from 
old healthy individuals.6-8 Reducing farnesyl prelamin A accumulation on the nuclear 
lamina by farnesyltransferase inhibitor (FTI) or accelerating autophagic degradation of 
progerin through rapamycin ameliorates cellular senescence in HGPS cells and 
premature aging in Zmpste24-deficient mice.9-13 Further studies revealed interphase 
aneuploidy chromatin, loss or aggregation of peripheral heterochromatin, abnormally 
clustered centromeres, and mislocalized telomeres in fibroblasts isolated from HGPS 
patients and Zmpste24-deficient mice.14 These abnormalities in chromatin organization 
are related to epigenetic changes, including the trimethylation of histone H3 at Lys9 
(H3K9me3) and Lys27 (H3K27me3), histone H4 at Lys20 (H4K20me3) and the 
acetylation of histone H4 at Lys16 (H4K16ac).15,16 These histone modifications are 
key factors for heterochromatin organization or chromatin remodelling. Changes in 
H3K9me3 patterns have also been observed in fibroblasts isolated from another 
progeriod syndrome mandibuloacral dysplasia (MAD) and in cells derived from old 
healthy individuals.7,17 These findings clearly demonstrate that prelamin A 
accumulation leads to abnormal organization and function of heterochromatin, which 
may contribute to the phenotypes in progeria. 
Mammalian heterochromatin protein 1 (HP1), including HP1α, HP1β, and 
HP1γ, are non-histone chromatin-associated proteins, which bind to histone H3 that is 
tri-methylated at lysine 9 (H3K9me3) via their N-terminal chromo domain (CD) to 
control heterochromatin high-order organization.18,19 HP1 requires dimerization via 
their C-terminal chromo shadow domain (CSD) and interacts with many nuclear 
proteins that possess a conserved PxVxL penta-peptide motif to trigger a variety of 
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functions, ranging from replication, transcription, chromatin organization, and nuclear 
architecture, to chromosomal maintenance.20,21 Via the CD region, HP1 directly or 
indirectly associates with lamins, such as lamin B receptor (LBR), LAP2β and lamina-
associated polypeptides (LAP2α).22-24 It not only anchors the peripheral 
heterochromatin to the inner nuclear membrane, but also mediates nuclear envelope 
reassembly in a dynamic manner.25 
Progeriod cells are characterized by accumulation of irreparable DNA damages 
and defective DNA repair.26 Recently, heterochromatin-mediated DNA damage 
response (DDR) has been found important for genome integrity; the superstructure of 
heterochromatin impedes DNA repair as a barrier, and most of heterochromatin 
components, such as KRAB-associated protein 1 (KAP-1), HP1, play important roles 
in the heterochromatin DDR.27-29 ATM phosphorylates KAP-1 at Ser824 (pS824-
KAP-1), alters KAP-1 affinity for chromatin, and facilitates heterochromatin 
remodelling in DDR.27,30 Recent findings also link HP1 proteins to the DNA damage 
response. All 3 HP1 isoforms are mobilized and recruited to various types of DNA 
damage sites.31,32 In response to DNA damage, HP1β is rapidly mobilized by casein 
kinase 2 (CK2)-mediated phosphorylation of its CD region at Thr 51 (pT51-HP1β). 
The phosphorylation disrupts hydrogen bonds that fold the CD around H3K9me3, 
releasing HP1β from heterochromatin and possibly leading to heterochromatin 
relaxation.29 Inhibition of CK2 or a constitutively Thr51 mutant HP1β diminishes γ-
H2AX signals.29 Moreover, KAP-1 directly binds to HP1α CSD region.27 Cells lacking 
HP1 fail to form discreet pS824-KAP-1 foci after DNA damage.33 Previously we have 
shown that KAP-1 phosphorylation is compromised and leads to delayed DNA 
damage-induced chromatin remodelling and accelerated senescence in Zmpste24-
deficient mice.34 However, it is still unclear whether the defective KAP-1 
phosphorylation is the unique regulatory mechanism underlying the genomic 
instability and accelerated senescence in progeria mice. Therefore it would be 
interesting to explore the roles of HP1 in mechanisms linking abnormal lamin A, 
delayed chromatin remodelling, defective DNA repair, and premature aging. In this 
study, we investigated the effects of prelamin A accumulation on HP1 expression, 
subcellular distribution, phosphorylation, and their impacts on premature senescence. 
We found that the level of HP1α associated with the nuclear matrix was significantly 
increased in Zmpste24−/− cells. Upon DNA damage, HP1α phosphorylation was 
significantly compromised, leading to delayed formation of γ-H2AX foci in 
Zmpste24−/− MEFs. Knocking down HP1α alleviated the delayed DNA damage 
response and accelerated senescence in Zmpste24−/− MEFs. Our findings establish a 
functional link between prelamin A, HP1α, heterochromatin repair, and early 
senescence in Zmpste24-deficient mice and suggest a potential therapeutic strategy for 
laminopathy-based premature aging via the intervention of HP1α. 
 
Materials and Methods 
 
Cell culture and drug treatments 
Zmpste24−/− mice were generated by Zhou et al. previously.4 Genotyping of mice for 
the mutant Zmpste24 allele was performed by PCR as described previously.15 Mouse 
embryonic fibroblasts (MEFs) were obtained from 13.5-d Zmpste24+/+ and Zmpste24−/− 
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embryos. Littermate-matched Zmpste24+/+ and Zmpste24−/− MEFs were cultured in 
complete Dulbecco modified Eagle medium (DMEM) (pH 7.4) supplemented with 10% 
fetal bovine serum. Early passage (passage 3) of Zmpste24−/− MEFs without showing 
senescence phenotypes were employed in all experiments.15 To induce DNA damage, 
MEFs were treated with either 4 μM Camptothecin (CPT, Sigma C9911) or DMSO for 




Commercial available antibodies used in this experiments are as follow: lamin A/C 
(Santa Cruz Biotechnology, sc-20681, http://www.scbt.com/datasheet-20681-lamin-a-
c-h-110-antibody.html), HP1α (Millipore, 05–689, 
http://www.millipore.com/catalogue/item/05-689; Abcam, ab77256, 
http://www.abcam.com/hp1-alpha-antibody-chip-grade-ab77256.html), HP1β (Abcam, 
ab10811, http://www.abcam.com/CBX1-HP1-beta-MAC353-antibody-ChIP-Grade-
ab10811.html), HP1γ (Millipore, 05–690, 
http://www.millipore.com/catalogue/item/05-690), γ-H2AX (Upstate, 05–636, 
http://www.millipore.com/catalogue/item/05-636), H3K9me3 (Abcam, ab8898, 
http://www.abcam.com/histone-h3-tri-methyl-k9-antibody-chip-grade-ab8898.html), 
H3 (Abcam, ab1791, http://www.abcam.com/histone-h3-antibody-chip-grade-
ab1791.html), HMGB1 (Cell Signaling, 3935, 
https://www.cellsignal.com/products/3935.html), P16 (Santa Cruz Biotechnology, sc-
81156, http://www.scbt.com/datasheet-81156-p16-1e12e10-antibody.html), α-tubulin 
(Cell Signaling, 2144, http://www.cellsignal.com/products/2144.html), β-actin 
(cwbiotech, CW0096A, http://www.cwbiotech.com/en/scart/cproduct.aspx?id=4283). 
pT50-HP1α polyclonal antibody was made by Abmart (Shanghai, http://www.ab-
mart.com/index.php) against the phospho-peptide, C-SEEHN(pT)WEPEK. It was 
diluted 1:300 for immunoblotting and 1:100 for immunofluorescence staining. 
Secondary antibodies used are as follows: Horseradish peroxidase (HRP) labeled Goat 
anti-rabbit (Pierce, 31460, http://www.pierce-antibodies.com/Goat-anti-Rabbit-IgG-H-
L-Secondary-Antibody-Polyclonal-31460.html), HRP labeled Goat anti-Mouse IgG 
(Pierce, 32430 http://www.pierce-antibodies.com/Glutamic-Acid-Decarboxylase-65-
antibody-Polyclonal-PA532430.html), HRP labeled Goat anti-Rat IgG (Pierce, 31470, 
http://www.pierce-antibodies.com/Goat-anti-Rat-IgG-H-L-Secondary-Antibody-
Polyclonal-31470.html), HRP labeled Rabbit anti-Goat IgG (Pierce, 31402, 
http://www.pierce-antibodies.com/Rabbit-anti-Goat-IgG-H-L-Secondary-Antibody-
Polyclonal-31402.html), Alexa Fluor 488 donkey anti-goat IgG (H+L) (Invitrogen, 
A11055s, http://www.lifetechnologies.com/order/catalog/product/A11055), Alexa 
Fluor 488 donkey anti-rat IgG (H+L) (Invitrogen, A21208, 
http://www.lifetechnologies.com/order/catalog/product/A21208), Alexa Fluor 488 
donkey anti-mouse IgG (H+L) (Invitrogen, A21202, 
http://www.lifetechnologies.com/order/catalog/product/A21202), Alexa Fluor 555 
donkey anti-mouse IgG (H+L) (Invitrogen, A31570, 
http://www.lifetechnologies.com/order/catalog/product/A31570), Alexa Fluor 594 
goat anti-rabbit IgG (H+L) (Invitrogen, A11012, 
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http://www.lifetechnologies.com/order/catalog/product/A11012). All reagents were 
used at the dilutions recommended by the manufacturers or mentioned above. 
 
Co-immunoprecipitation 
Cell extracts were prepared in modified RIPA buffer (20 mM Tris, pH 7.5, 300 mM 
NaCl, 0.5% Nonidet P-40, 1% Triton X-100, 1 mM EGTA, 1 mM DTT). Protein A 
conjugated Sepharose beads (Roche 11719394001) were washed twice with ice-cold 
PBS and pelleted by centrifugation at 2000 × g for 1 min at 4 °C. Two micrograms of 
the antibody of interest and lysates from 1 × 107 MEFs were incubated for 2 h at 4 °C 
with rotation. The antibody conjugate was then incubated with 50 μL of the pre-
washed Sepharose beads overnight at 4 °C with rotation. The excess unbound protein 
was removed by washing 3 times with 500 μL modified RIPA buffer; Sepharose beads 
were pelleted by centrifugation at 2000 × g for 2 min at 4 °C. Co-immunoprecipitated 
proteins were eluted off the Sepharose beads by adding 50 μL of 1 × loading buffer (1% 
SDS, 100 mM DTT, 50 mM Tris, pH 6.8) and boiling for 3 min. The elute was 
centrifuged at 2000 × g for 4 min, and the supernatant containing co-
immunoprecipitated proteins was collected and analyzed by western blotting. 
 
Western blotting 
Whole-cell lysate was prepared by suspending the MEFs in 1 volume of suspension 
buffer (10 mM Tris-HCl, pH 7.5, 0.1 M NaCl, 1mM EDTA, 1 mM DTT, pH 8.0, 
protease inhibitors), followed by adding 1 volume of Laemmli buffer (0.1M Tris-HCl, 
pH 7.0, 4% SDS, 20% glycerol,1 mM DTT, protease inhibitors) and boiling for 5 min. 
Twenty micrograms of total proteins were electrophoresed through 10% SDS 
polyacrylamide gels and transferred to PVDF membrane (Millipore). The membrane 
was incubated with primary antibodies overnight at 4 °C, and then probed with 
appropriate secondary antibodies linked to HRP for 1 h at room temperature. Antibody 
binding was visualized by enhanced chemiluminiscence kit (Pierce 34095). Relative 
blot band intensity was measured by ImageJ and normalized to corresponding controls 
as indicated. For statistical analysis, at least 3 independent immunoblots were 
quantified and 2-tailed t test was used for P values. 
 
Real-time PCR 
Total RNA was extracted with the Trizol® reagent (Invitrogen, 15596-026) according 
to the manufacturer’s protocol. RNA quantity was monitored by UV 
spectrophotometry and agarose gel electrophoresis. One microgram of total RNA was 
transcribed to cDNA using the iScript™ cDNA Synthesis Kit (Bio-rad, 70-8891). 
Quantitative RT-PCR (Q-PCR) was run on the 7500 Fast Real-Time PCR System 
(Applied Biosystems), with the use of the SsoFast™ EvaGreen Supermix kit (Bio-rad, 
172-5200). Mouse HP1α and β-actin primers are as follows: HP1α (232 bp) forward, 
5′-GAAAGAAGAC CAAGAGGACA G C-3′; reverse, 5′-TTGTTTCACC 
CTCCTTCATC T-3′. β-actin (517 bp) forward, 5′-ATATCGCTGC GCTGGTCGTC-
3′; reverse, 5′-AGGATGGCGT GAGGGAGAGC-3′. All Q-PCR reactions were 
performed in triplicate in the final volume 10 μl for 40 cycles according to the 
following protocol: each cycle at 95 °C for the initial 30 s, then at 95 °C for 5 s, and 
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60 °C for 5 s. The obtained results were averaged, and gene expression levels were 
normalized to β-actin. 
 
Subcellular fractionation 
MEFs were suspended (4 × 107 cells/ml) in buffer A [10 mM HEPES (pH 7.9), 10 
mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT, complete 
protease inhibitors (Roche), and 1 mM PMSF (Sigma)]. After the addition of 0.1% 
Triton X-100, cells were incubated on ice for 5 min. Nuclei were obtained by 
centrifugation at 1300 × g for 4 min at 4 °C. The supernatant containing the cytosolic 
extract (S1) was collected by centrifugation at 20 000 × g for 15 min at 4 °C. Nuclei 
were then washed twice with ice-cold buffer A and lysed in buffer B (3 mM EDTA, 
0.2 mM EGTA, 1 mM DTT, complete protease inhibitors [Roche], and 1 mM PMSF 
[Sigma]) for 5 min on ice. The pellet (P2) containing the chromatin and nuclear matrix 
protein was obtained by centrifugation at 1700 × g for 4 min at 4 °C. The supernatant 
consisting of nucleoplasmic protein (S2) was also collected. To obtain nuclear matrix-
associated proteins, cell nuclei (P1) were resuspended in buffer A plus 1 mM CaCl2 
and digested with 5 units of micrococcal nuclease (MNase, Sigma, N3755) at 37 °C 
for 5 min; the reaction was stopped by the addition of 1 mM EGTA. By low-speed 
centrifugation as described above, the pellet obtained after digestion consisted of the 
nuclease-resistant chromatin and nuclear matrix-associated proteins (P2'); the 
supernatant contained the nucleoplasmic and nuclease susceptible chromatin-
associated proteins (S2'). The fractions were dissolved in 1× loading buffer (1% SDS, 
100 mM DTT, 50 mM Tris, pH 6.8) and sonicated for 15 s. Equal amounts were 




MEFs were seeded in 8-chamber slides to 70% confluence, treated with CPT for 1 h 
and allowed to recover for indicated time. The slides were washed twice with PBS and 
fixed with 4% paraformaldehyde in PBS for 10 min at 4 °C, followed by 10 min 
permeation with 0.2% Triton X-100/PBS. The slides were blocked in 1% BSA/PBS 
with 5% normal serum overnight at 4 °C, and then incubated with primary antibody 
diluted in 1% BSA/PBS overnight at 4 °C in a humid box. After washing 3 times with 
PBS, the slides were incubated with FITC- or TRITC-coupled secondary antibodies 
diluted in 1% BSA/PBS for 40 min at R.T. and then washed 3 times with 
1%Tween20/PBS to remove unbound antibodies. The slides were mounted with 
ProLong Gold antifade reagent with DAPI (Invitrogen, P36935), sealed with nail 
polish, and analyzed by Olympus Fluoview FV1000 immunofluorescence microscopy. 
Photos were processed with Photoshop CS®. Focus counting was performed by 100 
cells randomly chosen for each experiment. Two-tailed Student t test was used for P 
values where applied. 
 
RNA interference 
HP1α sense and antisense RNA are 5′-GGAUACAGUC UGAGAGUUAT T-3′ and 5′-
UAACUCUCAG ACUGUAUCCT T-3′ respectively. Transfection was performed in 
triplicate in 6-well plates with lipofectamine RNAiMAX Reagent (Invitrogen, 13778-
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100) according to the manufacturer’s instructions. Forty-eight hours post-transfection, 
the cells were treated with 4 μM CPT for 1 h, and harvested at indicated times for 
western blotting and immunofluorescence microscopy analysis as described above. 
 
Senescence-associated β-gal assay 
Senescence-associated β-Galactosidase activity was accessed with cellular senescence 
assay kit (Mirus, MiR2600). Briefly, cells were seeded in 6-well plates, fixed at room 
temperature for 5 min with 2 mL of 1× fixing solution, washed twice with 1× PBS, 
and stained with 2 mL of freshly prepared 1× β-Galactosidase detection solution at 
37 °C for 16 h in dark room. The cells were washed twice with 1× PBS, overlaid with 
70% glycerol/PBS, and photographed. Blue-stained MEFs were counted in more than 




The level of HP1α is increased in Zmpste24−/− MEFs 
HP1 proteins serve as linkers, connecting peripheral heterochromatin to inner nuclear 
membranes.24,25 To investigate whether HP1s are involved in defective DNA repair 
and premature aging, we first examined levels of HP1 isoforms and H3K9me3 by 
western blotting in Zmpste24−/− MEFs and wild-type littermate controls. To eliminate 
epigenetic alterations induced by cellular senescence, early-passage Zmpste24−/− MEFs 
(passage 3), which have similar proliferative potential as wild-type littermate controls 
(data not shown and ref. 15), were used throughout this study. Compared with wild-
type littermate controls, a more than 40% increase in HP1α level was observed in 
Zmpste24−/− MEFs, whereas HP1β and HP1γ were much less affected (Fig. 1A and B). 
Consistent with our previous report,35 the level of H3K9me3, a HP1-binding 
heterochromatin marker, was significantly elevated, whereas levels of H3K9me1 and 
H3K9me2 were hardly affected (Fig. S1 A and B). To evaluate whether the elevated 
HP1α protein is attributable to the transcriptional regulation of HP1α by prelamin A, 
the mRNA level of HP1α was examined by real-time reverse-transcription PCR. As 
shown, the level of HP1α mRNA was not affected in Zmpste24−/− MEFs (Fig. 1C), 
indicating that prelamin A modulates HP1α in a post-translational manner. 
Collectively, these data suggest that the presence of prelamin A stabilizes HP1α 
protein in Zmpste24−/− MEFs.  
 
HP1α interacts with prelamin A in Zmpste24−/− MEFs 
Given that lamin A and prelamin A bind to HP1α and LAP2α in HEK293 cells,36 we 
reasoned that prelamin A might increase the binding capacity to HP1α, thus stabilizing 
it. To this end, co-immunoprecipitation (Co-IP) was performed in identical early 
passage of Zmpste24−/− MEFs and wild-type littermate controls to investigate the 
interaction of endogenous prelamin A and HP1. Since lamin-containing nuclear matrix 
(NM) is insoluble in RIPA buffer containing 150 mM NaCl, and raising the salt 
concentration to 500 mM completely abolishes the interaction between A-type lamins 
and HP1, RIPA buffer containing 350 mM NaCl was used for the Co-IP. As shown in 
Figure 2A, HP1α, HP1β, and HP1γ were detected in the anti-lamin A/C 
immunoprecipitates by western blotting. However, the pull-down levels are 
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comparable between Zmpste24−/− MEFs and wild-type littermate controls, suggesting 
that prelamin A might bind to HP1 isoforms in a similar capacity as lamin A. 
Reciprocally, endogenous lamin A/prelamin A was detected in the anti-HP1α 
immunoprecipitates. Interestingly, the anti-HP1α immunoprecipitates also pull down 
lamin C (Fig. 2B), which is encoded by an alternate splicing variant of LMNA gene 
and shares the N-terminal 566 aa with lamin A,37 suggesting that HP1 interacts with 
lamin A/prelamin A through domains beyond C-terminal lamin A-specific region. 
Nonetheless, these data have roled out the possibility that prelamin A directly 




Figure 1. Increased level of HP1α in Zmpste24−/− MEFs. (A) Representative immunoblots 
showing protein levels of HP1α, HP1β, HP1γ, H3K9me3 in Zmpste24−/− MEFs and wild-type 
littermate controls at passage 3. (B) Relative levels of HP1α, HP1β, HP1γ, H3K9me3 in 
Zmpste24−/− MEFs comparing with wild-type littermate controls. Data (mean ± s.e.m.) 
represent 3 independently derived lines of MEFs in separate experiments. *P < 0.05, **P < 
0.01, 2-tailed Student t test. (C) Real-time RT-PCR analysis of HP1α mRNA expression in 
Zmpste24−/− MEFs and wild-type littermate controls. HP1α mRNA abundance was calculated 
by 2-△△Ct normalized to β-actin. Data represent 3 independently derived lines of MEFs in 
separate experiments. 
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Figure 2. HP1 interacts with endogenous prelamin A in a similar manner as lamin A. (A) 
Immunoblots showing endogenous HP1α, HP1β, HP1γ in the anti-lamin A/C 
immunoprecipitates from Zmpste24−/− MEFs and wild-type littermate controls. Data represent 
1 of 3 independent experiments. (B) Immunoblots showing endogenous lamin A/prelamin 
A/lamin C in the anti-HP1α immunoprecipitates in Zmpste24−/− MEFs and wild-type 
littermate controls. Data represent 1 of 3 independent experiments. 
 
HP1α is mainly distributed in nuclease-resistant nuclear matrix and fraction in 
Zmpste24−/− MEFs 
Accumulation of prelamin A jeopardizes the nuclear lamina and matrix structure, 
resulting in disturbed heterochromatin organization.14,15,38 Although prelamin A has 
similar binding capacity to HP1 as lamin A, it may jeopardize the overall nuclear 
matrix structure and consequently mis-localize HP1 proteins and, thus, modulate their 
stability. Therefore, we further investigate whether HP1α is mislocalized in the nuclear 
matrix fraction of Zmpste24−/− MEFs. A well-established subcellular fractionation 
strategy was applied to separate cell extracts into fractions including cytoplasm (S1), 
nucleoplasm (S2), chromatin and nuclear matrix (P2), nucleoplasm and nuclease 
susceptible chromatin (S2'), and micrococcal nuclease (MNase)-resistant nuclear 
matrix (P2').16 α-tubulin, β-actin, high-mobility group protein B1 (HMGB1), lamin 
A/C served as controls for the cytoplasmic, nucleoplasmic, euchromatin-bound, and 
nuclear matrix fractions, respectively. As expected, in wild-type MEFs, α-tubulin was 
detected only in cytoplasm fraction, whereas β-actin was present in all cytoplasmic 
and nuclear fractions (Fig. 3A). For nuclear proteins, lamin A/C was resistant to 
MNase digestion and remained exclusively in nuclear matrix fraction (P2'). In contrast, 
the euchromatin-bound protein HMGB1 was absent from the nuclear matrix fraction 
(P2') and was completely released into nucleoplasmic fraction (S2') after MNase 
treatment. Although sensitive to MNase, after digestion, HP1 and H3K9me3 were still 
partially retained in the nuclear matrix fraction (P2') (Fig. 3A). Similarly, HP1 
distribution was examined in Zmpste24−/− cells; as shown in Figure 3B, the level of 
HP1α protein retained in the nuclear matrix fraction (P2') of Zmpste24−/− MEFs was 
much higher than that of wild-type controls. Concomitantly, the level of HP1α 
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released into the nucleoplasm and suspensible chromatin fraction (S2') was much 
lower in progeriod cells than that in wild-type cells. Likewise, H3K9me3 distribution 
was shown in a similar manner as HP1α (Fig. 3B). Notably, subcellular distributions 
of HP1β and HP1γ were not much affected in Zmpste24−/− MEFs. Altogether, these 
findings suggest that the increased HP1α in progeriod cells is mainly distributed in 
prelamin A-enriched nuclear matrix fraction (P2'), which might mislead the 
heterochromatin to the dis-organized nuclear matrix, thus disturbing the formation and 
function of heterochromatin. 
 
Figure 3. Increased HP1α was mainly localized in nuclease-resistant chromatin 
and nuclear matrix fraction in Zmpste24−/− MEFs. (A) Subcellular fractions of 
MEFs: S1 (cytoplasmic), S2 (nucleoplasmic), P2 (chromatin + nuclear matrix), S2' 
(nucleoplasmic + nuclease susceptible chromatin), P2' (nuclear matrix + nuclease 
resistant chromatin), and TCE (total cell extraction) as described in the “Materials and 
Methods”. Representative immunoblots showing the subcellular distribution of HP1α, 
HP1β, HP1γ, HMGB1 (euchromatin marker), H3K9me3 (heterochromatin marker), 
and LaminA/C (nuclear matrix marker). (B) Immunoblots showing increased levels of 
HP1α in nuclease-resistant chromatin and nuclear matrix fraction, whereas no 
significant changes of HP1β and HP1γ in various nuclear fractions. Data represent 1 of 
3 independently derived lines of MEFs in separate experiments. 
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HP1α phosphorylation is compromised following DNA damage in Zmpste24−/− 
MEFs 
In addition to heterochromatin mis-organization, sustained DNA damage checkpoint 
response is another hallmark of progeriod cells, which is a driving factor of cellular 
senescence.26 We and others recently found that the irreparable DNA damages 
accumulated in Zmpste24-dificient mice are indeed associated with heterochromatin, 
indicating a defective heterochromatin repair.34,35 Recent reports showed that HP1 is 
mobilized via phosphorylation, which alters heterochromatin organization, and then is 
recruited to DNA damage sites.29,32 Therefore we asked whether HP1α 
phosphorylation is affected in progeriod cells. It has been reported that residues Thr 51 
in human HP1β and Thr50 in HP1α are both crucial in regulating the binding of HP1 
to H3K9me3 and the remodeling of heterochromatin in response DNA damage.29 
Given the high similarity of chromodomain regions surrounding Thr 51 in HP1β and 
Thr50 in HP1α in both humans and mice (Fig. S2A), a polyclonal antibody that 
recognizes mouse HP1α phosphorylated at residue Thr50 (pT50-HP1α) was raised as 
described in “Materials and Methods”. The specificity of the anti-pT50-HP1α antibody 
was tested by SAP (shrimp alkaline phosphatase) treatment (Fig. S2B). By western 
blotting, pT50-HP1α dynamics were examined in Zmpste24−/− MEFs with 
Camptothecin (CPT) treatment, a radiomimetic reagent, which induces DSBs into 
progeriod cells as described before.39 γ-H2AX was examined as a sensitive marker for 
the presence of DSBs. CPT treatment induced rapid increase of γ-H2AX level in both 
Zmpste24−/− MEFs and wild-type controls (Fig. 4A). Thereafter, the level of γ-H2AX 
decreased at 4 h and returned to almost background level at 8 h in wild-type controls, 
but it remained significantly higher in Zmpste24−/− MEFs at 4 and 8 h (Fig. 4A). 
Although total level of HP1α did not show obvious changes within 8 h, CPT treatment 
induced a dynamic change of pT50-HP1α in wild-type MEFs, which peaked at 30 min 
and gradually decreased thereafter (Fig. 4A and B). However, the level of pT50-HP1α 
was significantly reduced and the kinetics delayed in Zmpste24−/− MEFs, whereby it 
maximized around 2–4 h after CPT treatment (Fig. 4A and B). Of note, the delayed 
pT50-HP1α kinetics in Zmpste24−/− MEFs is consistent with the delayed γ-H2AX level 
upon CPT treatment. To confirm the delayed pT50-HP1α kinetics after DNA damage 
in progeriod cells, we further employed immunofluorescence confocal microscopy. 
Within 30 min post-CPT treatment, pT50-HP1α and γH2AX foci were stochastically 
distributed throughout the nucleus in both Zmpste24−/− and wild-type control cells, and 
most of them co-localized with each other (Fig. 4C). The number of pT50-HP1α foci 
maximized around 30 min after DNA damage in wild-type cells; however, this was 
significantly delayed, until 2 h, in progeriod cells (Fig. 4D). Collectively, these 
findings confirm defective DNA repair evidenced by defective H2AX phosphorylation 
in progeriod cells and further imply that delayed pT50-HP1α might lead to defective 
mobilization of HP1α and cause delayed chromatin remodeling and, therefore, delayed 








Figure 4. DNA damage-induced pT50-HP1α phosphorylation is compromised 
in Zmpste24−/− MEFs. (A) Representative immunoblots showing levels of γH2AX, 
HP1α and pT50-HP1α at indicated time points in Zmpste24−/− MEFs and wild-type 
littermate controls treated with 4 µM camptothecin (CPT). (B) Relative levels of HP1α 
and pT50-HP1α after CPT treatment in Zmpste24−/− MEFs and wild-type littermate 
controls. Data represent 3 independently derived lines of MEFs in separate 
experiments. (C) Representative photos of immunofluorescence confocal microscopy 
showing pT50-HP1α and γH2AX foci after CPT treatment at indicated time points. 
Scale bar, 5 μm. (D) The number of pT50-HP1α foci per cell after CPT treatment 
in Zmpste24−/− MEFs and wild-type controls. At least 100 cells were counted. Data 
represent mean ± s.e.m., *P < 0.05, **P < 0.01, 2-tailed Student t test. 
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Figure 5. Knocking down HP1α promotes DNA damage response and attenuates 
cellular senescence in Zmpste24−/− MEFs. (A) Representative photos showing γH2AX 
foci at indicated time points in Zmpste24−/− MEFs and wild-type littermate controls 
treated with HP1α siRNA or mock siRNA. Scale bar, 5 μm. (B) The number of 
γH2AX foci per cell at indicated time points in Zmpste24−/− MEFs treated with HP1α 
siRNA. At least 100 cells were counted. Data represent mean ± s.e.m., *P < 0.05, 
**P < 0.01, 2-tailed Student t test. (C) Representative immunoblots showing levels of 
HP1α and P16 in Zmpste24−/− MEFs and wild-type littermate controls treated with 
HP1α siRNA or mock siRNA. (D) Quantification of P16 level in (C). Data represent 
mean ± s.e.m., n = 3, *P < 0.05, 2-tailed Student t test. (E) Representative photos of 
SA-β-gal activity showing the blue-stained senescent cells in Zmpste24−/− MEFs and 
wild-type littermate controls at passage 5. (F) Quantification of (E) showing the 
percentage of senescent cells. Data represent mean ± s.e.m., n = 3, ** P < 0.01, ***P < 
0.001, 2-tailed Student t test. 
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HP1α knockdown attenuates defective DNA damage response and cellular 
senescence 
DNA breaks in heterochromatin can be abrogated by knocking down HP1 or other 
heterochromatin components.28 To gain further insight into whether increased HP1α is 
the critical link between prelamin A and delayed DNA damage response and 
accelerated aging phenotypes in Zmpste24−/− MEFs, we explored if endogenous HP1α 
knockdown might alleviate the delayed DNA damage response and early onset of 
cellular senescence in Zmpste24−/− MEFs. In cells treated with short interfering RNAs 
(siRNAs) specifically targeting HP1α, although level of β-actin was quite stable for as 
long as 48 h, diminished HP1α expression was confirmed (Fig. S3). We next evaluated 
the effects of HP1α knockdown on γ-H2AX foci after CPT treatment. As shown in 
Figure 5A and B, a large number of γ-H2AX foci still persisted at 8 h in Zmpste24−/− 
MEFs, and this was significantly reduced in HP1α siRNA-treated Zmpste24−/− MEFs. 
Additionally, HP1α knockdown considerably reduced the expression of cellular 
senescence marker p16 expression (Fig. 5C and D). When cells were monitored for 
senescence-associated β-galactosidase (SA-β-gal) activity, the number of positively 
blue-stained cells dropped from more than 50% in scramble-treated to less than 25% in 
HP1α siRNA-treated Zmpste24−/− MEFs (Fig. 5E and F). Collectively, HP1α 
knockdown rescues defective DNA repair and attenuates the accelerated cellular 




In this report, we have shown that nuclear matrix-associated HP1α level was 
remarkably elevated in Zmpste24−/− MEFs. Upon DNA damage, a significantly 
compromised HP1α phosphorylation on Thr50 was observed in Zmpste24−/− MEFs, 
which correlates with the delayed γ-H2AX foci formation. Knocking down HP1α 
improved γ-H2AX foci formation and rescued cellular senescence in Zmpste24−/− 
MEFs. Our data suggest a critical role of HP1α in prelamin A-regulated genomic 
instability and premature aging. 
Heterochromatin perturbation and epigenetic mis-regulation are hallmarks of 
progeria.6,15,17 However, how various components functionally affect heterochromatin 
dynamics in the presence of prelamin A or progerin remains largely unknown. Here 
we found that prelamin A accumulation resulted in an increase of HP1α protein level, 
while the mRNA was hardly affected, suggesting a potential role for prelamin A in 
stabilizing HP1α protein. It has been shown that lamin A and prelamin A binds to 
HP1α in vitro, and farnesylated prelamin A showed reduced binding capacity to HP1α 
compared with the non-farnesylated form and wild-type lamin A.36 However, a 
comparable binding affinity of HP1α to prelaminA and lamin A was found in our 
study, although prelamin A is farnesylated in Zmpste24−/− MEFs. One possible 
interpretation of this seeming discordance is that ectopic farnesylated prelamin A 
might be functionally different from the endogenous one caused by Zmpste24 
deficiency. Consistent with this notion is the finding that different strategies in 
generating unfarnesylatable progerin may result in opposite phenotypes in knock-in 
mouse models.40-42 It has also been widely accepted that there is reduced of 
heterochromatin in HGPS cells, supported by decreased H3K9me3, H3K27me3, and 
 44│Chapter 2  
HP1α.15 However, we have previously shown that prelamin A might elicit functional 
difference with progerin in addition to the structural differences, i.e., loss of 50 amino 
acids, which may cause loss of function of lamin A.35 Interestingly, several reports 
found that lamin A regulates HP1 stability through inhibition of specific ubiquitin 
ligase activities, and loss of lamin A accelerates HP1α degradation in Lmna−/− 
MEFs.43,44 In this regard, the seemingly contradictory observation might be explained 
by the structural and functional difference between prelamin A in Zmpste24-null cells 
and progerin in human HGPS cells. The level of HP1α in the presence of progerin 
could be attributable to a combined gain of function of the partially processed C tail, 
which elevates the HP1α level, and loss of function of lamin A, which is due to 50-aa-
truncation and accelerates the degradation of HP1α. Nevertheless, the lack of 
difference between prelamin A and lamin A in their binding capacity to HP1α suggests 
that it is unlikely that prelamin A regulates HP1α stability in a similar manner as it 
does on Suv39h1. On the other front, HP1, H3K9me3, and its principal 
methyltransferase Suv39h1 are all enriched in the pericentric heterochromatin region, 
and it is considered that N-terminal upstream of Suv39h1 CD region possess 
interaction site with HP1 CSD region, recruiting HP1α to bind H3K9me3 within its 
CD region.45 Consistent with our previous report, we observed a remarkably increased 
level of H3K9me3 in Zmpste24-null cells and a significant increase of association of 
HP1α with the nuclear matrix fraction, wherein H3K9me3 is highly enriched. 
Therefore, it is also plausible to speculate that prelamin A might interfere with the 
correct positioning and stability of HP1α/Suv39h1/H3K9me3 heterochromatic 
complex, thus impairing the localization of pericentric heterochromatin domains at the 
nuclear periphery and finally resulting in disorganization of heterochromatin. 
Although initial studies revealed that HP1 plays a key role in heterochromatin 
formation and gene silencing, recent studies have highlighted the importance of HP1-
mediated chromatin remodeling and DNA damage response. In this study, we found 
that the level of pT50-HP1α, which co-localizes with γ-H2AX, is compromised in 
Zmpste24−/− MEFs after DNA damage, suggesting defective mobilization of HP1α and, 
thereafter, compromised chromatin remodeling. Another heterochromatin protein 
KAP-1, which promotes heterochromatic DSB repair by ATM-mediated 
phosphorylation and therefore facilitates the release of KAP-1 and CHD3 from 
heterochromatin and global chromatin relaxation, directly binds to HP1α CSD.27,28 We 
have previously shown that pS824-KAP-1 level is significantly reduced, preventing 
the release of CHD3 from heterochromatin and global chromatin relaxation in 
Zmpste24−/− MEFs.34 We therefore speculate that nuclear matrix fraction enrichment of 
HP1α in Zmpste24−/− MEFs might be also involved in the retention of KAP-1 on 
heterochromatin. Notably, the decreased level of pS824-KAP-1 in our previous study 
is not totally in accordance with the dynamic changes of chromatin relaxation in 
Zmpste24−/− MEFs. Although the level of pS824-KAP-1 was decreased, it peaked 30 
min after DNA damage, which is similar to wild-type cells. Interestingly, although 
delayed, the chromatin still underwent global relaxation at 2 h and, concomitantly, the 
recruitment of 53BP1 after irradiation in Zmpste24–/– MEFs, indicating a backup 
mechanism regulating the late-stage global chromatin relaxation. In this study, we 
found that the peak level of pT50-HP1α was postponed to 2 h, which correlates well 
with the delayed relaxation of chromatin in progeriod cells after DNA damage, 
HP1α mediates defective heterochromatin repair and accelerates senescence│45 
 
 
implicating that pT50-HP1α could be the backup mechanism mediating chromatin 
remodeling in progeroid cells. 
The rescue of cellular senescence by HP1α knockdown suggests potential links 
between chromatin remodeling, DNA repair, and premature aging. Interestingly, a 
recent report by Lattanzi and colleagues showed de-condensation of heterochromatin 
and enhanced DNA repair efficacy in centenarian fibroblasts and in normal cells 
treated with rapamycin, highlighting the pivotal roles of chromatin remodeling and 
DNA repair in aging/longevity.46 Rapamycin targets mTOR pathways, inhibits DNA 
damage response (or pseudo-DNA damage response), and therefore slows down 
cellular senescence.47-49 In this scenario, it would be interesting to examine whether 
rapamycin could rescue the defective chromatin remodeling and defective DNA repair 
in Zmpste24-null cells in future study. Nevertheless, our data shed new light into 
molecular basis of HP1α in heterochromatin mis-organization, delayed DNA damage 
response, and early senescence in Zmpste24-deficient progeria mouse model, 
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Figure S1. Histone H3K9 methylation profile in Zmpste24−/− MEFs. (A) 
Representative immunoblots showing H3K9me1, H3K9me2 and H3K9me3 levels in 
Zmpste24−/− MEFs and wild-type littermate controls at early passage 3. Histone H3 is 
internal control. (B) Relative levels of H3K9 methylation in Zmpste24−/− MEFs 
normalized to H3. Data, mean ± s.e.m., represent three independently derived lines of 



















Figure S2. Amino acid sequence surrounding H3K9me3 binding site of HP1α and 
anti HP1αT50P antibody specificity. (A) Sequence alignment of conserved residues 
surrounding Thr51 of HP1β and Thr50 of HP1α in human and mouse. (B) 
Representative immunoblots showing levels of pT50-HP1α and HP1α in Zmpste24−/− 
MEFs and wild-type controls treated with Shrimp Alkaline Phosphatase (SAP). 
 




Figure S3. Knocking down HP1α in wild-type control MEFs. (A) Representative 
immunoblot showing HP1α protein level in cells treated with HP1α siRNA. (B) 
Quantification of A. Data, mean ± s.e.m. represent three independently derived lines of 
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Cell-to-cell fusion can be quantified by endowing acceptor and donor cells with latent 
reporter genes/proteins and activators of these genes/proteins, respectively. One way 
to accomplish this goal is by using a bipartite lentivirus vector (LV)-based cell fusion 
assay system in which the cellular fusion partners are transduced with a flippase-
activatable Photinus pyralis luciferase (PpLuc) expression unit (acceptor cells) or with 
a ecombinant gene encoding FLPeNLS+, a nuclear-targeted and molecularly evolved 
version of lippase (donor cells). Fusion of both cell populations will lead to the FLPe-
dependent generation of a functional PpLuc gene. PpLuc activity is typically 
measured in cell lysates, precluding consecutive analysis of one cell culture. Therefore, 
in this study the PpLuc-coding sequence was replaced by that of Gaussia princeps 
luciferase (GpLuc), a secretory protein allowing repeated analysis of the same cell 
culture. In myotubes the spread of FLPeNLS+ may be limited due to its nuclear 
localization signal (NLS) causing low signal outputs. To test this hypothesis, 
myoblasts were transduced with LVs encoding either FLPeNLS+ or an NLS-less 
version of FLPe (FLPeNLS-) and subsequently co-cultured in different ratios with 
myoblasts containing the FLPe-activatable GpLuc expression cassette. At different 
times after induction of cell-to-cell fusion the GpLuc activity in the culture medium 
was determined. FLPeNLS+ and FLPeNLS- both activated the latent GpLuc gene but 
when the percentage of FLPe-expressing myoblasts was limiting, FLPeNLS+ generally 
yielded slightly higher signals than FLPeNLS- while at low acceptor-to-donor cell ratios 
FLPeNLS- was usually superior. The ability of FLPeNLS+ to spread through myofibers 
and to induce reporter gene expression is thus not limited by its NLS. However, at 
high FLPe concentrations the presence of the NLS negatively affected reporter gene 
expression. In summary, a rapid and simple chemiluminescence assay for quantifying 
cell-to-cell fusion progression based on GpLuc has been developed. 
 
  





During cell-to-cell fusion, plasma membranes of individual cells merge to form a 
multinucleated structure called a syncytium. Plasma membrane fusion is a crucial 
event during, for example, fertilization, syncytiotrophoblast production, skeletal 
muscle formation, bone remodeling, eye lens development and certain forms of tissue 
repair [1]. In general, cell fusion is a tightly regulated and highly selective process 
involving specific cell types. Inappropriate cell fusion has been implicated in tumor 
development and progression [2]. Cell fusion can be easily observed using 
microscopic techniques and in many studies the extent of cell fusion is expressed as 
fusion index, which either stands for the percentage of cells with two or more nuclei 
or the percentage of nuclei present in syncytia [3]. However, without continuous 
monitoring, it is impossible to decide by microscopy alone whether multinucleation is 
caused by cell fusion or the result of karyokinesis without cytokinesis. In addition, 
cells growing on top of each other can be mistaken for syncytia. Furthermore, as 
fusion index determinations are generally carried out manually, they are laborious, 
error-prone and often inaccurate. This has led to the development of methods for 
quantifying cell fusion independent of microscopic inspection. Nearly all these 
methods are based on systems of two components that interact to create a novel 
detectable signal only after cell fusion [3]. Mohler and Blau, for example, developed a 
quantitative cell fusion assay based on functional complementation between two 
biologically inactive β-galactosidase deletion mutants [4]. 
Another possibility to produce fusion-dependent signals is by applying site-
specific recombination systems such as Cre-loxP and FLP-FRT. In these systems, a 
latent reporter gene is activated by the action of the site-specific DNA recombinase 
Cre from bacteriophage P1 or flippase/FLP from Saccharomyces cerevisiae, which 
catalyze the excision and inversion of DNA flanked by 34-base pair (bp) recognition 
sequences (loxP for Cre and FRT for FLP) in a direct or inverted repeat configuration, 
respectively [5,6]. Gonçalves et al. previously developed a bipartite lentivirus vector 
(LV)-based cell fusion assay system in which the cellular fusion partners are endowed 
with a FLP-activatable Photinus pyralis luciferase (PpLuc) expression unit/’’gene 
switch’’ (acceptor cells) or with a recombinant gene encoding a molecularly evolved 
version of FLP (FLPe) with a nuclear localization signal (NLS) derived from the 
simian virus 40 large T antigen (donor cells) [7]. Fusion between acceptor and donor 
cells led to the FLPe-dependent generation of a functional episomal PpLuc expression 
module. This cell fusion monitoring system was successfully used to study the role of 
the p38 MAPK signaling pathway in myoblast fusion/myotube formation. However, 
since PpLuc is a cytoplasmic protein and its substrate D-luciferin is poorly membrane-
permeable, this assay requires lysis of the cells prior to luminometry and does not 
allow repeated analysis of the same cell culture. This prompted us to develop a 
nondestructive method to quantify cell fusion using the bipartite LV-based cell fusion 
assay system described by Gonc¸alves and colleagues as starting point.  
The key difference between the new and ‘‘old’’ version of the LV-based cell 
fusion assay system is the replacement of the PpLuc open reading frame (ORF) in the 
‘‘original’’ gene switch construct by the humanized coding sequence of Gaussia 




coelenterazine into coelenteramide plus light. GpLuc also displays a much higher 
specific luciferase activity than PpLuc and is exceptionally resistant to exposure to 
heat and strongly acidic and basic conditions [8]. In addition, we hypothesized that in 
myotubes the spread of nuclear-targeted FLPe (FLPeNLS+) beyond the direct 
surroundings of donor nuclei may be limited due to the presence of the NLS. This 
would result in the activation of only a fraction of the reporter genes especially in 
hybrid myotubes containing a relatively low percentage of FLPe gene-positive donor 
nuclei compared to GpLuc-encoding acceptor nuclei. To test this hypothesis, we 
generated an LV encoding an NLS-less version of FLPe (FLPeNLS-) and compared, in 
myogenic fusion assays, its ability to activate latent GpLuc genes with that of 
FLPeNLS+.  
 
Materials and Methods 
 
Plasmids 
DNA constructions were carried out with enzymes from Fermentas (Fisher Scientific, 
Landsmeer, the Netherlands) or from New England Biolabs (Bioké, Leiden, the 
Netherlands) by using established procedures [9] or following the instructions 
provided with specific reagents.  
To generate a bicistronic self-inactivating (SIN) human immunodeficiency 
virus type 1 (HIV1) vector shuttle plasmid coding for Streptomyces alboniger 
puromycin N-acetyl transferase (PurR) and FLPeNLS-, pLV.FLPe.PurR ([7]; 
GenBank accession number: GU253314; hereinafter referred to as pLV.hCMV-
IE.FLPeNLS+.IRES.PurR.hHBVPRE; Fig. 1A) was digested with BshT1 and Eco81I 
and the 9.6-kb DNA fragment containing the vector backbone was purified from 
agarose gel. The hybridization product of oligodeoxyribonucleotides 5’ 
CCGGTACCATGAGTCAATTTGATATATTATGTAAAAC-ACCACC 3’ and 5’ 
TTAGGTGGTGTTTTACATAATATATCAAATTGACTCATGGTA 3’ (both from 
Eurofins MWG Operon, Ebersberg, Germany) was combined with the 9.6-kb 
BshT16Eco81I fragment of pLV.hCMV-IE.FLPeNLS+.IRES.PurR.hHBVPRE by 
ligation with bacteriophage T4 DNA ligase producing pLV.hCMV IE.FLPeNLS-
.IRES.PurR.hHBVPRE (Fig. 1B).  
To generate a SIN-LV shuttle plasmid carrying a silent GpLuc gene that can be 
activated by FLP, cloning vector pR6K.MCS was digested with XmaJI and NotI, the 
2.2-kb DNA fragment containing the vector backbone was purified from agarose gel 
and combined with the 0.6-kb GpLuc-encoding XmaJI×NotI fragment of 
phGluc.dBamHI yielding construct pR6K.GpLuc. The cloning vector pR6K.MCS was 
derived from construct pA1.GFP.A2 ([10]; GenBank accession number: GQ380658) 
by combining its 2.0-kb SalI×Aflll fragment with the 0.3-kb SalI×Aflll fragment of 
pMOLUC ([11]; Addgene, Cambridge, MA; plasmid number: 12514). Plasmid 
phGluc.dBamHI was made from the mammalian expression vector phGluc ([12]; 
Addgene; plasmid number: 22522) by self-ligation of its 2.9-kb BamHI fragment. The 
GpLuc ORF was excised from pR6K.GpLuc by digestion with XmaJI and MluI and 
combined with the 7.2-kb BcuI×MluI fragment of pLV.GS.DsRed.dKpnI to generate 
pLV.GS.GpLuc.v1 (Fig. 1D). The LV shuttle plasmid pLV.GS.DsRed.dKpnI was 
derived from pLV.pA+.GS.DsRed ([7]; GenBank accession number: GU253312) by 
57│Development of a Lentivirus Vector-based Assay for Non-destructive Monitoring of Cell Fusion Activity 
 
 
self-ligation of its 7.9-kb KpnI fragment. The SIN-LV shuttle plasmid 
pLV.GS.GpLuc.v6 is a derivative of construct pLV.pA+.GS.Luc ([7], hereinafter 
referred to as pLV.GS.PpLuc), in which the sequences interspersed between the rabbit 
β-hemoglobin gene polyadenylation signal (rHBB pA) and the mouse metallothionein 
1 gene (mMT1) pA (i.e. the PpLuc ORF and an FRT sequence) are replaced by a 




Figure 1. Structure of the LV DNA in the LV shuttle plasmids. (A): pLV.hCMV-
IE.FLPeNLS+. IRES.PurR. hHBVPRE (B): pLV.hCMVIE. FLPeNLS-.IRES.PurR.hHBVPRE 
(C): pLV.hCMV-IE.IRES.PurR.hHBVPRE and (D): pLV.GS.GpLuc.v1. The start codons of 
the FLPeNLS+ and FLPeNLS- ORFs are shown in boldface. 5’ LTR, chimeric 5’ long terminal 
repeat containing the Rous sarcoma virus U3 region and the HIV1 R and U5 regions; Ψ, 
HIV1 packaging signal; RRE, HIV1 Rev-responsive element; cPPT, HIV1 central polypurine 
tract and termination site; hCMV-IE, human cytomegalovirus immediate early gene promoter; 
FLPeNLS+, molecularly evolved flippase with simian virus 40 (SV40) nuclear localization 
signal (NLS; black bar); FLPeNLS-, molecularly evolved flippase without NLS; EMCV IRES, 
encephalomyocarditis virus internal ribosomal entry site; PurR; Streptomyces alboniger 
puromycin N-acetyl transferase-coding sequence; hHBVPRE, human hepatitis B virus 
posttranscriptional regulatory element; black triangle/FRT, flippase recognition target 
sequence; hGAPDH, human glyceraldehyde 3-phosphate dehydrogenase gene promoter; 
rHBB2 pA, rabbit β-hemoglobin gene polyadenylation signal; GpLuc, Gaussia princeps 
luciferase-coding sequence; mMT1 pA, mouse metallothionein 1 gene polyadenylation signal; 







Figure 2. Improved design of the GpLuc gene switch cassette. (A–C): Detailed structure of 
the areas upstream of the Luc ORFs in pLV.GS.GpLuc.v1 (A), pLV.GS.GpLuc.v6 (B) and 
pLV.GS.PpLuc (C) starting at the HIV1 3’ LTR. U5, HIV1 LTR unique 5’ region; R, HIV1 
LTR repeat region; ΔU3, enhancer- and promoterless HIV1 LTR unique 3’ region; blue 
arrow, mouse metallothionein 1 gene polyadenylation signal (mMT1 pA); small black 
triangle, AATAAA motif in mMT1 pA; red diamonds, stop codons in frame with Luc ORFs; 
large black triangle, minimal FRT sequence; light yellow arrow, GpLuc ORF; green box, 5’ 
in-frame extension of the GpLuc ORF; white arrows, out-of-frame ORFs preceding Luc 
ORFs; red arrows, in-frame ORFs preceding Luc ORFs; dark yellow arrow, PpLuc ORF. 
 
More details about the genetic makeup of pLV.GS.GpLuc.v1, pLV.GS.GpLuc.v6 and 
pLV.GS.PpLuc and about the nucleotide sequences located in between the mMT1 pA 
and Luc ORFs of these three SIN-LV plasmids are provided in Figs. 2 and 3. The 
ligation mixtures were introduced in chemocompetent cells of Escherichia coli strain 
GeneHogs (Life Technologies Europe, Bleiswijk, the Netherlands) or GT115 
(InvivoGen, San Diego, CA). Large-scale plasmid purifications were performed using 




The culture and differentiation conditions of the murine Bmi1- and human TERT-
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Viral vectors  
The vesicular stomatitis virus G protein-pseudotyped SIN-LVs LV.FLPeNLS+.PurR, 
LV.FLPeNLS-.PurR, LV.PurR (negative control vector), LV.GS.GpLuc.v1, 
LV.GS.PpLuc and LV.GS.GpLuc.v6 were generated in 293T cells with the aid of the 
LV shuttle plasmids pLV.hCMV-IE.FLPeNLS+.IRES.PurR.hHBVPRE, pLV.hCMV-
IE.FLPeNLS-.IRES.PurR.hHBVPRE, pLV.CMV. IRES.PURO ([14], hereinafter 
referred to as pLV.hCMV-IE.IRES.PurR.hHBVPRE; Fig. 1C), pLV.GS.GpLuc.v1, 
pLV.GS.PpLuc and pLV.GS.GpLuc.v6, respectively. The 293T cells were transfected 
with one of the LV shuttle constructs and the packaging plasmids psPAX2 (Addgene; 
plasmid number: 12260) and pLP/VSVG (Life Technologies Europe) at a molar ratio 
of 2:1:1. To concentrate and purify the LV particles, producer cell supernatants were 
layered onto 5-ml cushions of 20% (wt/vol) sucrose in phosphate-buffered saline 
(PBS) and centrifuged at 15,000 rotations per minute for 2 h at 4°C in an SW32 rotor 
(Beckman Coulter Nederland, Woerden, the Netherlands). Prior to ultracentifugation, 
producer cell supernatants were clarified by low speed centrifugation and filtration 
through 0.45-mm pore-sized cellulose acetate filters (Pall Netherlands, Mijdrecht, the 
Netherlands). For more details about the SIN-LV production method, see [15]. The 
titers of the resulting LV stocks were determined using the RETROTEK HIV-1 p24 
Antigen ELISA kit (ZeptoMetrix, Franklin, MA) following the instructions provided 
by the manufacturer. To derive functional titers from these measurements a 





Figure 3. Alignment of the nucleotide sequences immediately upstream of the Luc ORFs 
in pLV.GS.GpLuc.v1, pLV.GS.PpLuc and pLV.GS.GpLuc.v6. Blue box, 3’ end of the 
mMT1 pA; underlined sequences, out-of-frame ORFs preceding Luc ORFs; boxed TAA 
sequences, in-frame stop codons preceding Luc ORFs; red letters, in-frame ORFs preceding 
Luc ORFs; green letters, 5’ in-frame extension of the GpLuc ORF in pLV.GS.GpLuc.v1; 
black box, minimal FRT sequence; boxed ATG sequences, Luc initiation codons; light yellow 






Cryopreserved LV.FLPeNLS+.PurR-transduced iDMD myoblasts ([7]; hereinafter 
referred to as myoblasts-FLPeNLS+) were thawed and cultured in the presence of 
puromycin (Life Technologies Europe) at a final concentration of 0.4 μg/ml to prevent 
transgene silencing. FLPeNLS-expressing iDMD myoblasts were generated by 
overnight (±20 h) exposure of 105 cells in a well of a 24-well cell culture plate 
(Greiner Bio-One, Alphen aan den Rijn, the Netherlands) to 30 TUs of LV.FLPeNLS-
.PurR per cell in 500 μl of growth medium in a humidified atmosphere of 5% CO2/95% 
air at 37°C. The next day, the cell monolayer was rinsed three times with 1 ml of PBS 
after which fresh culture medium was added. At 3 days post transduction, the culture 
of LV.FLPeNLS-.PurR-treated cells (hereinafter referred to as myoblasts-FLPeNLS-) as 
well as a control culture of untransduced iDMD myoblasts were given medium 
containing 0.8 μg/ml of puromycin. Within a week, all cells in the culture of 
untransduced iDMD myoblasts had died while the cells in the LV.FLPeNLS-.PurR-
treated culture were nicely expanding. The myoblasts-FLPeNLS- were passaged once a 
week (split ratio 1:3) in growth medium containing 0.4 μg/ml of puromycin. 
MyoblastsGS.GLuc, myoblastsGS.PLuc and myoblastsGS.GLuc+ were generated likewise by 
exposure of iDMD myoblasts to LV.GS.GpLuc.v1, LV.GS.PpLuc and 
LV.GS.GpLuc.v6, respectively. Before being used for co-culture experiments, the 
cells were passaged at least three times to rule out secondary transduction of the 
FLPe-expressing myoblasts in the co-cultures with luciferase-encoding SIN-LVs [16]. 
 
Co-culture establishment and maintenance 
Co-cultures containing a total number of 2×105 cells were established in wells of 24-
well culture plates by mixing myoblasts-FLPeNLS+ or myoblasts-FLPeNLS- with 
myoblastsGS.GLuc at the indicated ratios. Following an incubation period of about 72 h 
when the cell monolayers had reached 90–100% confluency, the growth medium was 
substituted by 400 μl of either differentiation medium or fresh growth medium. At 
specified time points thereafter, the culture medium (400 μl) was collected and stored 
at -80℃ for luciferase assay. The co-cultures were then either terminated or further 
incubated at 37℃ in a water-saturated atmosphere of 5% CO2/95% air.  
To compare the performance of the newly developed LV.GS.GpLuc.v1-based 
cell fusion assay system with that of the previously described LV.GS.PpLuc-based 
cell fusion quantification method [7], myoblastsGS.GLuc or myoblastsGS.PLuc were 
cocultured with myoblasts-FLPeNLS+ in different ratios in 24-well culture plates 
containing 2×105 cells per well. Samples (culture fluid for cultures containing 
myoblastsGS.GLuc and cell lysates for cultures containing myoblastsGS.PLuc) were 
harvested 96 h and 120 h after induction of myogenic differentiation. Exactly the same 
approach was used to compare the LV.GS.GpLuc.v1- and LV.GS.GpLuc.v6-based 
cell fusion assays. 
 
Immunocytology 
At different time points after the initiation of differentiation, 1:1 co-cultures of 
myoblasts-FLPeNLS- and myoblastsGS.GLuc were fixed by incubation for 30 minutes at 
room temperature (RT) in PBS containing 4% formaldehyde. To permeabilize the 
cells, they were exposed for 10 minutes at RT to 0.1% Triton X-100 in PBS. Next, 
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cells were incubated overnight at 4℃ with mouse antiskeletal muscle troponin I 
(skTnI) primary antibody (HyTest, Turku, Finland; clone 12F10) diluted 1:100 in PBS 
+0.1% donkey serum (Santa Cruz Biotechnology, Santa Cruz, CA) followed by a 2-h 
incubation at RT with Alexa Fluor 568-conjugated donkey anti-mouse IgG (H+L) 
secondary antibody (Life Technologies Europe) diluted 1:400 in PBS +0.1% donkey 
serum. Counterstaining of nuclei was performed with 10 μg/ml Hoechst 33342 (Life 
Technologies Europe) in PBS. Cells were washed three times with PBS after fixation, 
permeabilization and incubation with primary antibody, secondary antibody and 
DNA-binding fluorochrome. To minimize photobleaching, coverslips were mounted 
in Vectashield mounting medium (Vector Laboratories, Burlingame, CA). Pictures 
were taken with a fluorescence microscope equipped with a digital color camera 
(Nikon Eclipse 80i; Nikon Instruments Europe, Amstelveen, the Netherlands) using 
NIS Elements software (Nikon Instruments Europe).  
 
Subcellular fractionation and western blotting 
Myoblasts-FLPeNLS+ and myoblasts-FLPeNLS- were cultured separately in 24-well cell 
culture plates at a density of 2×105 cells per well. Following an incubation period of 
72 h when the cell monolayers had reached 90-100% confluency, the growth medium 
was substituted by 400 μl of either differentiation medium or fresh growth medium. 
Ninety-six h later, cell fractionation was carried out as described by Suzuki et al. [17] 
with the following modifications. Cell pellets were suspended in 97.5 μl of ice-cold 
0.1% NP40 in PBS. One-third of the lysate was removed as ‘‘whole cell lysate’’ and 
mixed with 5 μl of 10×NuPAGE Sample Reducing Agent and 12.5 μl of 4×NuPAGE 
LDS Sample Buffer (both from Life Technologies Europe). The rest of the lysate was 
briefly centrifuged at 4℃ after which 32.5 μl of the supernatant was removed as 
‘‘cytosolic fraction’’ and supplemented with 5 μl of 10×NuPAGE Sample Reducing 
Agent and 12.5 μl of 4×NuPAGE LDS Sample Buffer. The remaining supernatant was 
removed and the pellet was washed with and suspended in 30 μl PBS, after which 5 μl 
of 10×NuPAGE 
Sample Reducing Agent and 12.5 μl of 4×NuPAGE LDS Sample Buffer were 
added to produce the ‘‘nuclear fraction’’. Nuclear fractions and whole cell lysates 
were sonicated for 2 times 10 seconds at 200 Hz using a Soniprep 150 ultrasonic 
disintegrator (Measuring and Scientific Equipment, London, United Kingdom). After 
incubating the samples for 1 minute at 100℃, 10 μl of whole cell lysate, 10 μl of 
cytosolic fraction and 5 μl of nuclear fraction were applied to a NuPAGE Novex 12% 
Bis-Tris gel (Life Technologies Europe). Following electrophoretic separation, the 
proteins were transferred to a polyvinylidene difluoride membrane (Amersham 
Hybond P; GE Healthcare Europe, Diegem, Belgium) by wet electroblotting. Next, 
the membrane was incubated with 2% ECL AdvanceTM blocking agent (GE 
Healthcare Europe) in PBS-0.1% Tween 20 (PBST) for 1 h at RT and probed with 
rabbit anti-FLP (1:200; Diagenode, Seraing, Belgium; CS-169-100), mouse anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 1:10,000; Merck Millipore, 
Billerica, MA; clone 6C5) or rabbit anti-lamin A/C (1:10,000; Santa Cruz 
Biotechnology; sc-20681) primary antibodies overnight at 4℃, followed by a 1-h 
incubation with appropriate horseradish peroxidase-conjugated secondary antibodies 




A/C antibody was used as nuclear marker protein. Target protein signals were 
visualized using the SuperSignal West Femto Maximum Sensitivity Substrate Kit 
(Thermo Scientific, Rockford, IL) and chemiluminescence was measured with the 
ChemiDoc XRS imaging system (Bio-Rad Laboratories, Veenendaal, the Netherlands). 
 
FLPe functionality test 
To test the functionality of the FLPe molecules encoded by LV.FLPeNLS+.PurR and 
LV.FLPeNLS-.PurR, myoblastsGS.GLuc were transduced with LV.FLPeNLS+.PurR, 
LV.FLPeNLS-.PurR or LV.PurR. MyoblastsGS.GLuc were seeded in a 24-well cell culture 
plate at a density of 105 cells per well and exposed for 20 h to 75 μl per well of 
concentrated vector stock diluted in growth medium to a final volume of 500 μl. Next, 
the cell monolayers were rinsed three times with 1 ml of PBS after which 400 μl fresh 
growth medium was added. At 24 h after the removal of the inoculum, the culture 
medium was collected and transiently stored at -80℃ for subsequent analysis of 
luciferase activity. The cells were overlaid with 400 ml of fresh growth medium, 




After thawing the GpLuc-containing samples on ice, 50 μl of each sample was 
transferred to a well of a white opaque 96-well flat-bottom microtiter plate (OptiPlate-
96; PerkinElmer, Groningen, the Netherlands) for chemiluminescence measurements. 
The native coelenterazine (Promega Benelux, Leiden, the Netherlands) stock solution 
(5 mg/ml in acidified methanol) was diluted 1,000 times in phenol red-free 
Dulbecco’s modified Eagle’s medium (Life Technologies Europe) and equilibrated for 
1 h in the dark at RT before starting the measurements. The luciferase activity was 
measured at RT with the aid of a Wallace 1420 VICTOR 3 multilabel plate reader 
with automatic injection system (PerkinElmer). Immediately after automated addition 
of 20 ml of substrate to a well, substrate and sample were mixed by shaking for 1 
second (double orbital, 0.1 mm, normal speed). PpLuc activity was measured in cell 
lysates as previously described [7]. For each condition, three independent samples 
were measured in three series of measurements. 
 
Statistical analysis 
Different experimental groups were compared using the independent samples t-test. 
Differences among means were considered significant at P≤0.05. Graphs were 




Microscopic analysis of cell fusion kinetics 
Cultured myoblasts can be prompted to fuse with each other by withdrawing mitogens 
from the culture medium. This causes a time-dependent accumulation of nuclei in 
syncytial structures called myotubes or myosacs depending on whether these 
structures are elongated or rounded. To get a first impression of the cell-to-cell fusion 
kinetics of the genetically modified iDMD myoblasts, 1:1 co-cultures of myoblasts-
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FLPeNLS- and myoblastsGS.GLuc were exposed to myogenic differentiation conditions. 
As shown in the upper panel of Fig. 4, the myoblasts started to fuse 48 h after serum 
withdrawal resulting in the formation of myotubes/sacs. Both the percentage of nuclei 
present in myotubes/sacs as well as the size of the syncytia increased with time until 
120 h following serum removal, after which the cells started to detach from the 
surface of the culture plates. The fusion process was accompanied by the 
accumulation of sarcomeric proteins as evinced by the results of the skTnI-specific 
immunostaining depicted in the lower panel of Fig. 4. 
 
Figure 4. Microscopic analysis of cell fusion kinetics in 1:1 co-cultures of myoblasts-
FLPeNLS- and myoblastsGS.GLuc after maintenance for 72 h in growth medium and 
subsequent exposure to differentiation medium. At 24, 48, 72, 96 or 120 h after initiation 
of differentiation the cells were fixed and immunostained for skTnI (red fluorescence). The 
blue fluorescence corresponds to nuclei labeled with the karyophilic dye Hoechst 33342. The 
upper and lower row of pictures show phase-contrast images and fluoromicrographs, 
respectively. The first syncytia appeared at ±48 h after serum removal. The cell cultures 
displayed a time-dependent increase in frequency and size of myotubes/sacs until the cells 
started to detach from the surface of the culture plates. In parallel cultures of myoblasts kept 
in normal growth medium the cells remained firmly attached to their support and only few 
small syncytia were observed at late times after culture initiation (data no shown). 
 
Immunodetection of FLPe in LV.FLPeNLS+/-.PurR transduced iDMD myoblasts  
To compare FLPe protein level and intracellular distribution between myoblasts-
FLPeNLS+ and myoblasts-FLPeNLS-, western blot analysis was performed on whole cell 
lysates as well as on nuclear and cytosolic cell fractions (Fig. 5A). As expected from 
the presence at its amino terminus of the SV40 NLS, FLPeNLS+ (predicted molecular 
weight: 49.7 kilodaltons) had a slightly lower gel mobility than FLPeNLS- (predicted 
molecular weight: 48.6 kilodaltons). Both under growth and differentiation conditions, 
the steady-state level of FLPeNLS+ was considerably higher than that of FLPeNLS- 
even though the nucleotide sequences upstream of the FLPe start codon are very 
similar and both proteins contain a ‘‘destabilizing’’ amino acid residue (serine in 
FLPeNLS- versus alanine in FLPeNLS+; [18]) immediately downstream of the initiator 
methionine. Fig. 5A also reveals that a larger fraction of FLPeNLS+ molecules than of 
FLPeNLS- molecules also reveals that a larger fraction of FLPeNLS+ molecules than of 
FLPeNLS- molecules resides in the nucleus (nuclear-to-cytosolic ratios under 
differentiation conditions of 8.4 and 3.1, respectively) consistent with the presence in 





Figure 5. Analysis of FLPeNLS+/- level, intracellular localization and enzymatic activity. 
(A): Western blotting analysis of whole protein lysates, nuclear cell fractions and cytosolic 
cell fractions of myoblasts-FLPeNLS+ (+) and of myoblasts-FLPeNLS- (-) maintained in growth 
medium (no differentiation) or exposed to differentiation conditions for 96 h (differentiation). 
(B): Luciferase activity measurements in culture media of myoblastsGS.GLuc transduced with 
LV.FLPeNLS+.PurR, LV.FLPeNLS-.PurR or LV.PurR (negative control vector) representing 
different intervals (i.e. 0–24 h and 24–48 h) post transduction. Bars show mean 6 standard 
error of the mean (n = 3). (C): Fold change in luciferase activity calculated on the basis of the 
data presented in (B). The average light production by samples of LV.PurR-transduced 
myoblastsGS.GLuc was the denominator and the mean of the RLUs produced by 
LV.FLPeNLS+.PurR-transduced myoblastsGS.GLuc (NLS+) or by LV.FLPeNLS-.PurR-transduced 
myoblastsGS.GLuc (NLS-) was the numerator. NLS, nuclear localization signal; FLPe, 
molecularly evolved flippase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; RLUs, 
relative light units. 
 
Assessment of FLPeNLS+/- functionality 
To investigate the functionality of the FLPe molecules encoded by LV.FLPeNLS+.PurR 
and LV.FLPeNLS-.PurR, myoblastsGS.GLuc were transduced with either of these FLPe-
encoding SIN-LVs or with LV.PurR (negative control vector). Production of 
functional recombinases by the FLPe-encoding SIN-LVs should result in activation of 
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the GpLuc gene switch cassettes incorporated into the genomes of the myoblastsGS.GLuc 
and the secretion of active GpLuc molecules in their culture medium (Fig. 6). 
Analysis of the culture media harvested at 24 h after vector removal showed strong 
luciferase activity in the samples derived from the LV.FLPeNLS+.PurR- and 
LV.FLPeNLS-.PurR-transduced myoblastsGS.GLuc, while hardly any luciferase activity 
was detected in the culture medium of LV.PurR-transduced myoblastsGS.GLuc (Fig. 5B). 
During the next 24-h interval the luciferase activity in the culture media of 
LV.FLPeNLS+.PurR- and LV.FLPeNLS-.PurR-transduced myoblastsGS.GLuc further 
increased whereas the luciferase activity in the negative control samples remained 
very low. As a result, luciferase activity was 94/154- and 156/162-fold higher in 0-24 
h and 24-48 h culture medium of LV.FLPeNLS+.PurR- and LV.FLPeNLS-.PurR-
transduced myoblastsGS.GLuc, respectively, than in the corresponding culture media of 
LV.PurR-infected cells (Fig. 5C). These findings confirm the presence of FLP 
recombinase-activatable GpLuc expression units in myoblastsGS.GLuc and demonstrate 
that LV.FLPeNLS+.PurR and LV.FLPeNLS-.PurR both code for functional FLPe 
molecules.  
 
Validation of the LV.FLPeNLS+/-.PurR/LV.GS.GpLuc-based cell fusion assay 
system 
To compare the ability of FLPeNLS+ and FLPeNLS- to activate the GpLuc gene switch 
upon cell fusion, myoblastsGS.GLuc were cocultured with myoblasts-FLPeNLS+ or 
myoblasts-FLPeNLS- at different ratios (i.e. 95:5, 90:10, 75:25, 50:50, 25:75, 10:90 and 
5:95). Monocultures of myoblasts-FLPeNLS+, myoblasts-FLPeNLS- or myoblastsGS.GLuc 
exposed to growth or differentiation medium and co-cultures of FLPe-expressing 
myoblasts and myoblastsGS.GLuc maintained in growth medium served as negative 
controls. Based on the results of the microscopic analysis of cell fusion activity (Fig. 
4), the culture medium was harvested 96 h after induction of myogenic differentiation. 
It should be noted, however, that the kinetics of cell fusion progression slightly 
differed between individual experiments probably reflecting small differences in the 
myoblast populations used for different experiments. Luciferase activity in the 
medium of the fusogenic cell cultures depended on the ratio of myoblastsGS.GLuc and 
myoblasts-FLPe, showed a similar trend for myoblasts-FLPeNLS+ -and myoblasts-
FLPeNLS- containing co-cultures and was highest when co-cultures contained 50-95% 
myoblastsGS.GLuc (Fig. 7A). The peak of GpLuc activity was reached at 
myoblastGS.GLuc:myoblast-FLPe ratios of 90:10 and 75:25 for myoblasts-FLPeNLS+ and 
myoblasts-FLPeNLS-, respectively (Fig. 7A). Interestingly, at low 
myoblastGS.GLuc:myoblast-FLPe ratios (i.e. 10:90 and 5:95) the luciferase activity was 
significantly higher for myoblasts-FLPeNLS- than for myoblasts-FLPeNLS+ (Fig. 7A). 
Myoblast cultures kept under growth conditions and myoblast-FLPe monocultures 
maintained in differentiation medium yielded luminescence signals close to or at 
background levels. The monocultures of myoblastsGS.GLuc did, however, secrete 
detectable amounts of GpLuc under differentiation conditions although the signal 
intensity was much lower than that produced by serum-deprived co-cultures 
containing 50–90% myoblastsGS.GLuc. For the co-cultures containing 50-90% 
myoblastsGS.GLuc shifting from growth to differentiation medium resulted in a >100-






Figure 6. Schematic overview of the activation of the GpLuc gene switch cassette. 
Recognition of the FRT sites in chromosomally integrated copies of the LV.GS.GpLuc 
genome by FLPe leads to the activation of the latent GpLuc gene through the formation of 
circular episomes positioning the hGAPDH gene promoter upstream of the GpLuc ORF. 
Black triangle/FRT, flippase recognition target sequence; hGAPDH, human glyceraldehyde 
3-phosphate dehydrogenase gene promoter; rHBB2 pA, rabbit β-hemoglobin gene 
polyadenylation signal; GpLuc, Gaussia princeps luciferase-coding sequence; FLPe, 
molecularly evolved flippase.  




Figure 7. Validation of the LV.FLPeNLS+/-.PurR/LV.GS.GpLuc.v1-based cell fusion 
assay system. (A): Luminometric analysis of culture medium of myoblastsGS.GLuc co-cultured 
with myoblasts-FLPeNLS+ (+) or with myoblasts-FLPeNLS- (-) at the indicated ratios. At 72 h 
after cell seeding, the culture fluid in each well was replaced by fresh culture medium with 
(no differentiation) or without (differentiation conditions) serum. Nighty-six h later the 
culture media were collected and subjected to luciferase activity measurements. Bars 
represent mean ± standard error of the mean (n = 3). (B): Fold change in luciferase activity 
calculated on the basis of the data presented in (A). For each culture composition the average 
light production under growth conditions was the denominator and the mean of the RLUs 
produced under differentiation conditions was the numerator. RLUs, relative light units; 




Use of the LV.FLPeNLS+/-.PurR/LV.GS.GpLuc-based cell fusion assay system to 
analyse cell fusion progression 
To investigate the utility of the LV.FLPeNLS+/-.PurR/LV.GS.GpLuc-based cell fusion 
assay system to follow cell fusion progression, myoblastsGS.GLuc were mixed with 
myoblasts-FLPeNLS+ or with myoblasts-FLPeNLS- at a ratio of 50:50. After the cell 
cultures had become nearly confluent, they were either given fresh growth medium or 
exposed to differentiation medium. This was followed by the periodic collection of 
culture fluid for luciferase measurements using two different approaches. In one 
experiment, the culture medium was left on the cells for different time periods (i.e. 
from 0-24, 0-36, 0-48, 0-60, 0-72, 0-84, 0-96, 0-108 and 0-120 h) before being 
harvested for luminometry (‘‘cumulative assay’’; Fig. 8). In the other experiment, the 
culture fluid was refreshed every 24 h and the amount of biologically active luciferase 
that had been secreted between 0-24, 24-48, 48-72, 72-96 and 96-120 h after the start 
of the differentiation process was determined (‘‘kinetics assay’’; Fig. 9). As shown in 
Fig. 8A, following an initial slow increase, the luciferase activity in the culture 
medium of the serum-deprived co-cultures rose sharply at late times (>72 h) after 
initiation of differentiation. Co-cultures of myoblastsGS.GLuc and myoblasts-FLPeNLS- 
produced better results than the combination of myoblastsGS.GLuc and myoblasts-
FLPeNLS+ (Fig. 8A,B) in spite of the much higher FLPe concentration in myoblasts-
FLPeNLS+ than in myoblasts- FLPeNLS- (Fig. 5A). These findings were corroborated by 
the data derived from the ‘‘kinetics assay’’ (Fig. 9). 
On the basis of the previous results, another experiment was carried out in 
which we directly compared the performance of FLPeNLS+ and FLPeNLS- at different 
myoblastGS.GLuc:myoblast-FLPe ratios (i.e. 95:5, 75:25, 25:75 and 5:95) and different 
time points (i.e. 72, 96 and 120 h after serum withdrawal). The culture medium was 
refreshed just before the start of the first sampling interval (i.e. at 48 h after serum 
removal) and after each round of sample collection. This experiment confirmed that at 
high myoblastGS.GLuc:myoblast-FLPe ratios FLPeNLS- was nearly as efficient as 
FLPeNLS+ at inducing reporter gene expression while at low myoblastGS.GLuc:myoblast-
FLPe ratios FLPeNLS- gave rise to more RLUs (Fig. 10A) and to higher signal-to-noise 
ratios (Fig. 10B). In accordance with the experiment presented in Fig. 7, the co-
cultures consisting of 75% myoblastsGS.GLuc and 25% myoblasts-FLPe yielded the 
highest signals both in absolute (Fig. 10A) and relative (Fig. 10B) terms. Also in line 
with the previous experiments was the finding that most GpLuc accumulation takes 
place between 96 and 120 h after serum removal.  
 
Comparison of LV.GS.GpLuc.v1- and LV.GS.PpLuc-based cell fusion assay 
systems  
In the next experiment, a direct comparison was made between the previously 
described LV.GS.PpLuc-based quantitative cell fusion assay system [7] and the new 
LV.GS.GpLuc-based method to quantify cell-to-cell fusion. Consistent with the much 
higher light output of GpLuc than of PpLuc [8], LV.GS.GpLuc yielded up to 23-fold 
higher signals than LV.GS.PpLuc (Fig. 11A). However, the LV.GS.PpLuc-based cell 
fusion assay system appeared to be approximately twice as sensitive as its 
LV.GS.GpLuc-based counterpart at detecting myoblast-to-myoblast fusion at 120 h 
after initiation of differentiation (Fig. 11B). The difference in sensitivity between the 
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GS.GpLuc.v1- and LV.GS.PpLuc-based cell fusion assay systems was even bigger for 
the samples collected at 96 h after serum removal especially at the lowest two 
myoblastGS.Luc:myoblast-FLPeNLS+ ratios (i.e. when FLPe levels are highest). 
 
Figure 8. Analysis of GpLuc accumulation in proliferating and differentiating 1:1 co-
cultures of myoblastsGS.GLuc and either myoblasts-FLPeNLS+ or myoblasts-FLPeNLS-. (A): 
Luminometric analysis of culture medium of co-cultures of 50% myoblastsGS.GLuc and 50% 
myoblasts-FLPeNLS+ (+) or 50% myoblasts-FLPeNLS- (2). At 72 h after cell seeding, the 
culture fluid was replaced by fresh culture medium with (growth conditions, no 
differentiation) or without (differentiation conditions) serum, which was left on the cells for 
the indicated periods of time. Bars represent mean ± standard error of the mean (n = 3). (B): 
Fold change in luciferase activity calculated on the basis of the data presented in (A). For 
each sampling time the average light production under growth conditions was the 
denominator and the mean of the RLUs produced under differentiation conditions was the 





Figure 9. Analysis of GpLuc secretion in proliferating and differentiating 1:1 co-
cultures of myoblastsGS.GLuc and either myoblasts-FLPeNLS+ or myoblasts-FLPeNLS-. (A): 
Luminometric analysis of culture medium of co-cultures of 50% myoblastsGS.GLuc and 50% 
myoblasts-FLPeNLS+ (+) or 50% myoblasts-FLPeNLS- (2). At 72 h after cell seeding, the 
culture fluid was replaced by fresh culture medium with (growth conditions, no 
differentiation) or without (differentiation conditions) serum, which was left on the cells for 
the indicated 24-h time intervals. Bars represent mean ± standard error of the mean (n = 3). 
(B): Fold change in luciferase activity calculated on the basis of the data presented in (A). For 
each sampling time the average light production under differentiation conditions was the 
numerator. RLUs, relative light units; NLS, nuclear localization signal. 
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Improvement of the GS.GpLuc-based cell fusion assay system 
The results presented in Figs. 7 and 11 identify the FLP-independent increase in 
GpLuc production when shifting from growth to differentiation medium as the main 
contributor to the reduced signal-to-noise ratio of the LV.GS.GpLuc-based cell fusion 
assay system as compared to its LV.GS.PpLuc-based counterpart. In search for a 
possible explanation for the high background signal produced by LV.GS.GpLuc.v1 in 
comparison to LV.GS.PpLuc, we compared their genetic organization upstream of the 
Luc start codon. As shown in Figs. 2 A,B and 3 the PpLuc ORF in LV.GS.PpLuc is 
preceded by an out-of-frame ORF (uORF) starting with 2 ATG codons in a favourable 
context for translational initiation [19] and ending with a highly efficient stop codon 
[20] separated by only 7 nucleotides from the PpLuc initiation codon. This specific 
genetic makeup will be effective in supressing any PpLuc expression directed by 
mRNAs with 5’ ends located upstream of the second ATG codon in the uORF. 
Oppositely, in LV.GS.GpLuc.v1 the previously mentioned tandem of ATG codons are 
in-frame with the GpLuc initiation codon allowing the synthesis of an N-terminally 
extended GpLuc fusion protein. Located further upstream of the GpLuc ORF in 
LV.GS.GpLuc.v1 is an out-of-frame ORF with suboptimal start and stop codons. 
LV.GS.GpLuc.v1 thus offers much more possibilities for ‘‘leaky’’ Luc expression 
than LV.GS.PpLuc. To solve this problem, we designed LV.GS.GpLuc.v6. In this 
construct, the distance between the mMT1 pA and GpLuc ORF is kept very short to 
minimize the chance of creating transcriptional start sites in the intervening region. As 
an additional measure to limit leaky GpLuc expression, LV.GS.GpLuc.v6 contains a 
21-bp uORF starting immediately upstream of the FRT sequence and ending with an 
efficient stop codon provided by the FRT sequence. Between the stop codon of the 
uORF and the PpLuc initiation codon only 20 nucleotides are present comprising the 
remainder of the FRT sequence and an optimal start site for GpLuc translation.  
LV.GS.GpLuc.v6 was used to generate myoblastsGS.GLuc+ carrying the 
optimized GpLuc gene switch cassette. Next, the performance of the 
LV.GS.GpLuc.v1- and LV.GS.GpLuc.v6- based cell fusion assay systems was 
compared in an experiment with the same setup as used for the comparison of 
LV.GS.GpLuc.v1 with LV.GS.PpLuc except for the omission of the 1:1 
myoblastGS.GLuc(+):myoblast-FLPeNLS+ ratio. Luciferase activity in 0-96 h and 0-120 h 
culture medium of serum-deprived myoblastGS.GLuc+ monocultures was ±3-fold lower 
than in culture medium of differentiating myoblastGS.GLuc monocultures (Fig. 12), 
demonstrating the effectiveness of the new gene switch design to inhibit leaky GpLuc 
expression. However, since the improved gene switch design also reduced FLPe-
dependent signal output the fold increase in GpLuc activity during myogenic 
differentiation of myoblastGS.GLuc(+):myoblast-FLPeNLS+ co-cultures was quite similar 
for LV.GS.GpLuc.v1 and LV.GS.GpLuc.v6 (Fig. 12B). Still, in comparison to 
LV.GS.GpLuc.v1 for LV.GS.GpLuc.v6 a much larger part of the increase in GpLuc 
activity observed in differentiating myoblastGS.GLuc(+):myoblast-FLPeNLS+ co-cultures 





Figure 10. Performance of FLPeNLS+ and FLPeNLS- at different acceptor-to-donor cell 
ratios and time points. (A): GpLuc release by proliferating or differentiating co-cultures of 
myoblastsGS.GLuc and myoblasts-FLPeNLS+ (+) or myoblasts-FLPeNLS- (-) at different time 
intervals after culture initiation. MyoblastsGS.GLuc and myoblasts-FLPe were seeded in 
different ratios (i.e. 95:5%, 75:25%, 25:75% and 5:95%). At 72 h after cell seeding, the 
culture fluid was replaced by fresh culture medium with (growth conditions, no 
differentiation) or without (differentiation conditions) serum. Fourthy-eight h later the culture 
medium was refreshed once again. Twenty-four h later the culture fluid was harvested for 
luciferase activity measurement and replaced by the same volume of fresh culture medium. 
This procedure was repeated every 24 h until 120 h after the first medium change. Bars 
represent mean ± standard error of the mean (n = 3). (B): Fold change in luciferase activity 
calculated on the basis of the data presented in (A). For each experimental condition the 
average light production under growth conditions was the denominator and the mean of the 
RLUs produced under differentiation conditions was the numerator. RLUs, relative light units; 
MBsGS.GLuc, myoblastsGS.GLuc; MBs-FLPe, myoblasts-FLPe; NLS, nuclear localization signal. 





Figure 11. Comparison of LV.GS.GpLuc.v1- and LV.GS.PpLuc-based cell fusion assay 
systems. (A): GpLuc and PpLuc production by proliferating or differentiating co-cultures of 
myoblastsGS.GLuc or myoblastsGS.PLuc with myoblasts-FLPeNLS+ at different times after culture 
initiation. Cells were seeded in different ratios (i.e. 100:0%, 90:10%, 75:25% and 50:50%). 
At 72 h after cell seeding the culture fluid was replaced by fresh culture medium with 
(growth conditions, no differentiation) or without (differentiation conditions) serum. Ninety-
six h and 120 h later samples (culture fluid for cultures containing myoblastsGS.GLuc and cell 
lysates for cultures containing myoblastsGS.PLuc) were harvested for luciferase activity 
measurements. Bars represent mean 6 standard error of the mean (n = 3). (B): Fold change in 
luciferase activity calculated on the basis of the data presented in (A). For each experimental 
condition the average light production under growth conditions was the denominator and the 
mean of the RLUs produced under differentiation conditions was the numerator. RLUs, 
relative light units; G, LV.GS.GpLuc.v1-based cell fusion assay; P, LV.GS.PpLuc-based cell 







Figure 12. Comparison of LV.GS.GpLuc.v1- and LV.GS.GpLuc.v6-based cell fusion 
assay systems. (A): GpLuc production by proliferating or differentiating co-cultures of 
myoblastsGS.GLuc or myoblastsGS.GLuc+ with myoblasts-FLPeNLS+ at different times after culture 
initiation. Cells were seeded in different ratios (i.e. 100:0%, 90:10% and 75:25%). At 72 h 
after cell seeding the culture fluid was replaced by fresh culture medium with (growth 
conditions, no differentiation) or without (differentiation conditions) serum. Ninety-six h and 
120 h later culture medium collected for luciferase activity measurement. Bars represent 
mean ± standard error of the mean (n = 3). (B): Fold change in luciferase activity calculated 
on the basis of the data presented in (A). For each experimental condition the average light 
production under growth conditions was the denominator and the mean of the RLUs 
produced under differentiation conditions was the numerator. RLUs, relative light units; G1, 
LV.GS.GpLuc.v1-based cell fusion assay; G6, LV.GS.GpLuc.v6-based cell fusion assay; 
MBsGS.GLuc(+), myoblastsGS.GLuc or myoblastsGS.GLuc+; MBs-FLPeNLS+, myoblasts-FLPeNLS+. 
 
  





Apart from being involved in the formation and maintenance of skeletal muscles, 
bones and the placenta, cell-to-cell fusion plays an important role in numerous other 
biological processes like fertilization. It has also been implicated in the initiation and 
progression of cancer [2] and as a driving force in evolution [21]. Moreover, cell-to-
cell fusion has been of great value to establish the chromosomal location of specific 
genes [22], can be used to induce cellular reprogramming [23,24] and is indispensable 
for generating hybridomas [25]. The involvement of cell-to-cell fusion in a large 
variety of biological processes and its diverse biotechnological applications have 
prompted investigations into the mechanisms of cell fusion and the contribution of 
specific factors to this process. Instrumental to this research is the availability of 
robust assays to determine cell fusion kinetics and extent. However, most of the 
existing quantitative cell fusion assays do not allow consecutive analysis of the same 
cells/tissue. Accordingly, in this paper a new quantitative assay is presented to 
monitor cell-to-cell fusion. This assay is based on the activation of a latent GpLuc 
gene after fusion of cells containing this latent reporter gene with cells encoding a 
recombinase that activates the dormant GpLuc gene. The extent of cell-to-cell fusion 
is subsequently quantified by simply measuring the enzymatic activity of the 
luciferase molecules secreted by the cellular fusion products. To the best of our 
knowledge this is the first assay that allows quantification of cell fusion activity by 
medium sampling.  
To validate the new cell fusion assay it was used to monitor the formation of 
myotubes/sacs in cultures of serum-deprived human myoblasts. In these experiments, 
several parameters were varied including the acceptor-to-donor cell ratio and the 
sample regimen(s) of the cell culture medium. In general, transgene expression 
increased with increasing fractions of myoblastsGS.GLuc up to the point at which the 
number of active/nuclear FLPe molecules became limiting (i.e. at 
myoblastGS.GLuc:myoblast-FLPe ratios of 90:10 for FLPeNLS- and of 95:5 for FLPeNLS+; 
Fig. 7).  
At high myoblastGS.GLuc:myoblast-FLPe ratios LV.FLPeNLS+ was slightly more 
effective than LV.FLPeNLS- in activating the latent GpLuc gene most likely due to fact 
that under differentiation conditions myoblasts-FLPeNLS+ contain ±5-fold more 
nuclear FLPe molecules than myoblasts-FLPeNLS- (Fig. 5A). In contrast, at low 
myoblastGS.GLuc:myoblast-FLPe ratios (i.e. when FLPe is no longer limiting) 
LV.FLPeNLS- consistently outperformed LV.FLPeNLS+ (Figs. 7 and 10). Collectively, 
these findings suggest that its NLS does not noticeably hamper the spreading of 
FLPeNLS+ through myofibers/sacs but that high nuclear FLPe levels may somehow 
limit reporter gene expression. A possible explanation for the higher GpLuc 
expression in differentiating cocultures containing large percentages of myoblasts-
FLPeNLS- in comparison to those with large fractions of myoblasts-FLPeNLS+ may be 
the more frequent occurrence of secondary recombination events in the latter co-
cultures leading to the deactivation of functional GpLuc expression modules.  
While monocultures of myoblastsGS.GLuc maintained in growth medium 
displayed very little if any leaky GpLuc expression, considerable amounts of GpLuc 




There are several possible explanations for this finding. Firstly, growth and 
differentiation medium may differently affect light output e.g. by (i) causing different 
levels of coelenterazine “auto-oxidation”, (ii) containing different concentrations of 
chemiluminescence inhibi- tors or (iii) absorbing blue light to a different extent. 
Possibilities (i) and (iii) can be ruled out since mixing of coelenterazine substrate 
solution with fresh or myoblasts-FLPeNLS+-conditioned growth or differentiation 
medium produced very similar signals (data not shown). This leaves us with the 
possibility that transcription termination by the mMT1 pA incorporated into the gene 
switch constructs is not very efficient or that differentiation conditions somehow 
stimulate transcription initiation in the region located in between the mMT1 pA and 
the Luc ORFs. For LV.GS.PpLuc and LV.GS.GpLuc.v6 the resulting transcripts may 
not lead to substantial luciferase production due to the presence of “decoy” ORFs 
immediately upstream of the Luc initiation codons (Figs. 2 and 3). A similar favorable 
situation does not exist for LV.GS.GpLuc.v1, which may explain the high background 
signals produced by this construct under differentiation conditions. Even though the 
luciferase activity in culture medium of differentiating myoblastGS.GLuc+ monocultures 
is ±3-fold lower than in culture medium of differentiating myoblastGS.GLuc 
monocultures LV.GS.GpLuc.v6 still gives rise to a higher background signal under 
differentiation conditions than LV.GS.PpLuc (compare Fig. 11 with 12). Considering 
that the sequences in between the mMT1 pA and the Luc start codon in LV.GS.PpLuc 
and LV.GS.GpLuc.v1 are nearly identical this may suggest that the GpLuc-coding 
sequence itself is the source of the relatively high luciferase activity detected in 
medium of differentiating LV.GS.GpLuc monocultures. If so, the problem could be 
overcome by switching to another secretory luciferase (e.g. Vargula hilgendorfii 
luciferase [26], Lucia luciferase (InvivoGen Europe, Toulouse, France) or secretory 
NanoLuc [27]). Also the fact that GpLuc is a secretory protein with a long half-life 
(66 days in culture medium) [28] while Ppluc has a relatively short half-life (±2 hours 
in cells) [29] may contribute to the higher background signals associated with 
LV.GS.GpLuc.v1 and LV.GS.GpLuc.v6 than with LV.GS.PpLuc.  
Taken together, in this paper a new assay to quantify (the progression of) cell-
to-cell fusion activity is described. Due to its nondestructive nature allowing repeated 
sampling of the same specimen, this assay will be an attractive alternative to existing 
quantitative cell fusion assays based on (i) light microscopic assessment of 
multinucleation, (ii) fluorescence dequenching, (iii) fluorescence resonance energy 
transfer, (iv) biochemical complementation or (v) activation of reporter genes 
different from GpLuc including LacZ and PpLuc [3]. Other advantages of the 
LV.FLPeNLS+/-.PurR/LV.GS.GpLuc-based cell fusion assay include the simplicity and 
speed of the analytical procedures and the ability to combine it with 
(immuno)cytology, real-time microscopy, cell function assays and other methods to 
study cell behavior.  
The sensitivity of the current assay could be improved by changing the human 
glyceraldehyde 3-phosphate dehydrogenase (hGAPDH) gene promoter driving GpLuc 
expression for a promoter with higher activity in the cell type(s) under investigation. 
In addition, the sequences interspersed between the 39 long terminal repeat (LTR) and 
the GpLuc initiation codon of LV.GS.GpLuc.v6 may be further optimized to minimize 
leaky GpLuc expression. 
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Aims: The generation of homogeneous cardiomyocyte populations from fresh tissue 
or stem cells is laborious and costly. A potential solution to this problem would be to 
establish lines of immortalized cardiomyocytes. However, as proliferation and 
(terminal) differentiation of cardiomyocytes are mutually exclusively processes, their 
permanent immortalization causes loss of electrical and mechanical functions. We 
therefore aimed at developing conditionally immortalized atrial myocyte (iAM) lines 
allowing toggling between proliferative and contractile phenotypes by a single-
component change in culture medium composition.  
 
Methods and results: Freshly isolated neonatal rat atrial cardiomyocytes (AMs) were 
transduced with a lentiviral vector conferring doxycycline-controlled expression of 
simian virus 40 large T antigen. Under proliferative conditions (i.e. in the presence of 
doxycycline), the resulting cells lost most cardiomyocyte traits and doubled every 38 
hours. Under differentiation conditions (i.e. in the absence of doxycycline), the cells 
stopped dividing and spontaneously reacquired a phenotype very similar to that of 
primary AMs in gene expression profile, sarcomeric organization, contractile 
behaviour, electrical properties and response to ion channel-modulating compounds 
(as assessed by patch-clamp and optical voltage mapping). Moreover, differentiated 
iAMs had much narrower action potentials and propagated them at >10-fold higher 
speeds than the widely used murine atrial HL-1 cells. High-frequency electrical 
stimulation of confluent monolayers of differentiated iAMs resulted in reentrant 
conduction resembling atrial fibrillation, which could be terminated by tertiapin 
treatment, just like in monolayers of primary AMs.  
 
Conclusion: Through controlled expansion and differentiation of AMs, large numbers 
of functional cardiomyocytes were generated with properties far superior to the 
differentiated progeny of existing cardiomyocyte lines. iAMs provide an attractive 
new model system for studying cardiomyocyte proliferation, differentiation, 
metabolism and (electro)physiology and to investigate cardiac diseases, regeneration 
and drug responses, without using animals. 
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Nonstandard abbreviations and acronyms  
 
AMs neonatal rat atrial cardiomyocytes 
AF atrial fibrillation 
ANP atrial natriuretic peptide 
AP action potential 
APD action potential duration 
CV conduction velocity 
Cx43 connexin 43 
dox doxycycline 
eGFP enhanced green fluorescent protein 
iAMs conditionally immortalized AMs 




Leiden University Medical Center 
LV lentiviral vector  
Mlc2a atrial regulatory myosin light chain 
Mlc2v ventricular regulatory myosin light chain 
pAMs primary AMs 
pVMs primary neonatal rat ventricular cardiomyocytes 
PSC-CMCs cardiomyocytes derived from pluripotent stem cells 
RMP resting membrane potential 
RT-qPCR reverse transcription-quantitative polymerase chain reaction 












Due to the limited availability of human heart tissue and the low mitotic activity of 
postnatal human cardiomyocytes, cardiac research has strongly relied on experiments 
in animals1,2 or with primary cardiomyocytes of animal origin3,4. The increasing 
opposition to the use of animals for biomedical research has fuelled the search for 
alternative models of human cardiac disease. 
Recently, cardiomyocytes derived from pluripotent stem cells (PSC-CMCs) 
have emerged as new models for studying different aspects of cardiac disease. Despite 
the great potential of PSC-CMCs as cardiac model systems, they have some serious 
drawbacks that need to be overcome before becoming a practical alternative to the use 
of laboratory animals. Both the generation of PSCs and the production of 
homogeneous populations of cardiomyocytes from these cells is a laborious, time-
consuming and costly endeavour of varying efficiency, which requires properly timed 
treatment of the starting material with different cocktails of expensive growth factors 
and small molecules5. Moreover, PSCs greatly differ in their ability to differentiate 
into cardiomyocytes and typically yield phenotypically heterogeneous populations of 
immature cardiac muscle cells6,7. The latter feature is limiting the use of PSC-CMCs 
in studying cardiac physiology and pathology, e.g. it has been proven difficult to 
establish homogeneous (confluent) monolayers of these cells for cardiac arrhythmia 
research by high-resolution optical mapping8. 
As another approach to reduce laboratory animal use in cardiac research, 
cardiomyocyte lines have been generated using cardiac muscle cells from rodents and 
humans as starting material and the simian virus 40 (SV40) large T (LT) antigen to 
induce cell proliferation9-15. Unfortunately, all cardiomyocyte lines generated thus far, 
including the widely used HL-1 cell line, display large structural and functional 
deficits in comparison to the primary cells from which they were derived. 
In an attempt to overcome the paucity of cell lines with robust cardiomyogenic 
differentiation capacity, we developed a new strategy to selectively and conditionally 
immortalize cardiomyocytes. Given our special interest in atrial fibrillation (AF) as 
the most common heart rhythm disorder in clinical practice16, the recent discovery by 
members of our research group that neonatal rat atrial cardiomyocytes (AMs) possess 
a constitutively active acetylcholine-dependent K+ current playing an important role in 
the development of AF17 and the relatively low cell yields obtained from 
enzymatically dissociated neonatal rat atria, AMs were chosen as starting material. 
These cells were transduced with a single lentiviral vector (LV) allowing myocyte-
restricted doxycycline (dox)/tetracycline-dependent LT expression followed by their 
clonal expansion in the presence of dox. The resulting monoclonal cell lines were 
characterized by cell proliferation assays, reverse transcription-quantitative 
polymerase chain reaction (RT-qPCR) analysis, phase-contrast and 
immunofluorescence microscopy (IFM), western blotting, optical voltage mapping 
The response of the cells to cardiac ion channel inhibitors and their ability to integrate 
with pAMs were also investigated. Altogether, our data show that we have generated 
cardiomyocyte lines that (i) outperform all existing lines of cardiac muscle cells in 
terms of cardiomyogenic differentiation ability, (ii) have great potential as models for 
fundamental and applied cardiac research and (iii) depending on the specific 
85│Genesis of the iAM-1 Cell Line  
 
 
application, may provide easy-to-use and cost-effective alternatives for PSC-CMCs 
and for cardiomyocytes freshly isolated from animals. 
 
Methods 
Detailed methods are available in Supplementary material online. 
 
Animal experiments 
All animal experiments were approved by the Animal Experiments Committee of 
Leiden University Medical Center (LUMC) and conformed to the Guide for the Care 
and Use of Laboratory Animals as stated by the US National Institutes of Health. 
 
Cardiac cell culture 
Neonatal rat cardiomyocytes were isolated and cultured essentially as described18. 
 
LV production 
LV particles were produced using a previously published method18. The molecular 
structure of the shuttle plasmid used for the production of the LT-encoding LV is 
depicted in Figure 1A. 
 
Molecular analyses 
The primer pairs used for transcriptome analysis by RT-qPCR are shown in Table S1 
(see Supplementary material online). 
Details about the antibodies used for western blotting and immunostaining of 
formaldehyde-fixed cells are presented in Table S2 (see Supplementary material 
online). 
Apoptosis was studied using Alexa Fluor-568-conjugated annexin V. 
 
Electrophysiological studies 
Optical voltage mapping using di-4-ANEPPS as fluorescent voltage indicator was 
performed essentially as described previously19. A detailed description of the whole-
cell patch-clamp studies can be found in the Supplementary material online. 
 
Statistical analyses 
Data were derived from a specified number (N) of observations from 3 different cell 
cultures. Unless otherwise stated, data were expressed as mean±standard deviation 
(SD) and SDs were represented by error bars. All data were analysed with the nested 
ANOVA test using the Real Statistics Resource Pack software (release 5.1, copyright 
2013 – 2017, Charles Zaiontz, www.real-statistics.com). For comparisons 
involving >2 experimental groups, this test was followed by Bonferroni post-hoc 
analysis. Results were considered statistically significant at P values <0.05. Statistical 









Conditional immortalization of AMs 
Low-density cardiomyocyte-enriched cultures of primary cells isolated from the atria 
of 2-day-old Wistar rats were transduced with LV particles containing a dox-inducible 
LT expression unit based on the monopartite lentiviral Tet-on system developed by 
Szulc et al.20. LT expression in this LV system was driven by the strong hybrid 
striated muscle-specific MHCK7 promoter21 (Figure 1A) to minimize the likelihood of 
inadvertently immortalizing the ±12% non-cardiomyocytes present in the primary 
atrial cell cultures17 (data not shown). 
In the presence of dox, cells started to divide forming clearly discernible 
colonies at 1-3 weeks post-transduction (Figure 1B). Nine of >80 cell clones were 
randomly selected for testing the dox dependency of their proliferation ability. Cells 
of all 9 clones were actively dividing in the presence of dox and stopped doing so in 
its absence. To investigate whether these clones contained excitable cells, confluent 
monolayers were established, maintained in dox-free culture medium for 9 days and 
examined by optical voltage mapping. Following 1-Hz electrical stimulation, 7 of the 
9 clones produced excitatory waves spreading from the pacing electrode to the 
opposite site of the culture dishes. Of these 7 clones, clone #5 showed the shortest 
action potential (AP) duration (APD) and highest conduction velocity (CV) and was 
therefore picked for further investigation. Western blot analysis and IFM showed 
expression of LT in this clone to be tightly and effectively controlled by dox (Figure 
1C-E). 
Comparison of the light microscopic morphology of the conditionally 
immortalized AMs (iAMs) with those of primary AMs (pAMs) revealed that the 
surface area of proliferating iAMs did not significantly differ from that of pAMs at 
culture day 1 (Figure 2A and E). Also, in near-confluent monolayers, iAMs that were 
kept for 9 days in dox-free medium closely resembled pAMs at culture day 9 in both 
size and appearance (Figure 2A). 
In the presence of dox, 72.2±8.1% of iAMs stained positive for the 
proliferation marker Ki-67, which percentage dramatically decreased upon dox 
removal (Figure 2B and F). Consistently, in the presence of dox, iAMs proliferated 
with an average doubling time of 38 h, whereas under differentiation conditions (i.e. 
in the absence of dox), the cell number slightly decreased with time (Figure 2G). As 
expected, in primary atrial cell cultures, the percentage of α-actinin+ cells expressing 
Ki-67 was very low indicating that the large majority of proliferating Ki-67+ cells in 
these cultures are non-cardiomyocytes (Figure 2C and F). Probing iAM cultures with 
fluorescently labelled annexin V for the presence of surface-exposed 
phosphatidylserine as marker of apoptosis revealed low signals in proliferating 
cultures, which slightly increased under differentiation conditions (Figure 2D and H) 
but did not noticeably differ from those in 9-day-old pAM cultures (Figure 2D and H). 
 




Figure 1. Conditional immortalization of pAMs. (A) Scheme of the procedure used for the 
reversible immortalization, amplification and subsequent redifferentiation of pAMs. A, 
atrium. Ori, bacterial origin of replication. AmpR, Escherichia coli ß-lactamase gene. LTR, 
human immunodeficiency virus type 1 (HIV1) long terminal repeat. Ψ, HIV1 packaging 
signal. RRE, HIV1 Rev-responsive element. cPPT, HIV1 central polypurine tract and 
termination site. MHCK7, chimeric striated muscle-specific promoter21. LT, coding sequence 
of the temperature-sensitive mutant LT protein tsA5833. IRES, encephalomyocarditis virus 
internal ribosome entry site. tTS, coding sequence of the hybrid tetracycline-controlled 
transcriptional repressor TetR-KRAB34. WHVPRE, woodchuck hepatitis virus 
posttranscriptional regulatory element. TRE, tetracycline-responsive promoter element 
consisting of 7 repeats of a 19 nucleotide tetracycline operator (tetO) sequence. (B) Bright-
field images of a single cell in a pAM culture showing dox-dependent clonal expansion. (C-E) 
Analysis by western blotting (C, D) and immunocytology (E) of LT protein expression in 





Figure 2. Morphology, proliferative activity and apoptosis analysis of iAMs. (A) Bright-
field images of proliferating iAMs (i.e. iAM-d0) and iAM-d9 and of pAMs at culture day 1 
(pAM-d1) and 9 (pAM-d9). (B) Fluorescence images of proliferating iAMs and of iAMs at 
different days after dox removal immunostained for the proliferation marker Ki-67. The 
arrow is pointing at the nucleus shown at a higher magnification in the inset. (C) 
Fluoromicrograph of a 3-day-old pAM (pAM-d3) culture that was not subjected to 
mitomycin C treatment following double immunostaining for Ki-67 and sarcomeric α-actinin. 
The Ki-67+/α-actinin- cells observed in this culture mainly result from uninhibited 
proliferation of cardiac fibroblasts (data not shown). Arrows are pointing at the nuclei shown 
at a higher magnification in the insets. (D) Fluorescence images of proliferating iAMs, of 
iAMs at different days after dox removal and of a 9-day-old, mitomycin C-treated pAM 
(pAM-d9) culture labelled with Alexa Fluor-568-conjugated annexin V to assess 
externalization of phosphatidylserine as indicator of apoptosis. (E) Quantification of cell 
surface area of iAM-d0 and of pAM-d1. Data are presented as mean±SD, N=30 cells per 
experimental group, each consisting of 3 cell preparations. For statistical analysis, the nested 
ANOVA test was used. (F) Graph showing the percentage of Ki-67+ nuclei in proliferating 
iAM cultures, in iAM cultures at different days after dox removal and among the 
cardiomyocytes (i.e. α-actinin+ cells) in pAM-d3 cultures. Data are presented as mean±SD, 
N=12 cell cultures per experimental group from 3 individual preparations. Statistics was done 
89│Genesis of the iAM-1 Cell Line  
 
 
using the nested ANOVA test with Bonferroni post-hoc correction. (G) Quantification of cell 
numbers in iAM cultures with or without dox. Data are presented as mean±SD, N=3. (H) 
Quantification of cell surface-bound annexin V in proliferating iAM cultures, in iAM cultures 
at different days after dox removal and in mitomycin C-treated pAM-d9 cultures. Data are 
presented as mean±SD, N=12 cell cultures per experimental group from 3 individual 
preparations. Statistics was done using the nested ANOVA test with Bonferroni post-hoc 
correction. AUs, arbitrary units. **P<0.01 vs pAM cultures. 
 
Figure 3. Cardiomyogenic differentiation potential of iAMs. (A, C) Analysis by RT-qPCR 
of the expression of the cardiac transcription factor genes Nkx2.5, Gata4 and Mef2c, the 
cardiac sarcomeric protein genes Actn2 and Myh6 (A), the “atrial” genes Nppa, Myl4 and 
Myl7 and the “ventricular” genes Myl2, Myl3 and Myh7 (C) in pAMs and pVMs at day 9 of 
culture and in iAMs on the indicated days of differentiation. mRNA levels are expressed 
relative to those in 9-day-old pAM (pAM-d9) cultures, which were set at 1. Data are 
presented as mean±SD, N=3. The low abundance of “atrial” transcripts in pAM samples is 
most likely due to the presence of some ventricular myocytes in these samples. Similarly, the 
pVM cultures may have contained low numbers of atrial myocytes. Alternatively, pAMs may 
express “ventricular” genes at low levels and pVMs may display low-level expression of 
“atrial” genes. (B, D) Fluorescence images of proliferating iAMs and of iAMs at different 
days after dox removal immunostained for sarcomeric α-actinin (red, B) or the atrial 
regulatory myosin light chain MLC2a (green, D). pAMs and pVMs at culture day 9 served as 
positive and negative control for the MLC2a immunostaining, respectively. Cell nuclei have 




Cardiomyogenic differentiation potential of iAMs 
The expression of cardiac marker genes in proliferating and differentiating iAM 
cultures was assessed by RT-qPCR analysis and compared with that of pAMs and of 
primary neonatal rat ventricular cardiomyocytes (pVMs) at culture day 9. Previous 
experience has shown that at this particular time point, the primary cardiomyocytes 
are optimally adapted to the in vitro environment and still in an advanced state of 
differentiation17-19,22,23. Expression of the Nkx2.5, Gata4 and Mef2c genes, which 
encode early cardiac transcriptional regulators, was higher in proliferating (i.e. day 0) 
iAMs than in pAMs and pVMs and rapidly increased soon after dox removal (Figure 
2A). Expression of the sarcomeric protein-encoding Actn2 and Myh6 genes, on the 
other hand, was lower in day 0 iAMs than in pAMs and s. Transcription of these genes 
also showed a rapid increase under differentiation conditions to very similar levels as 
in pAMs and pVMs (Figure 3A). 
To study myofibrillogenesis, cells were immunostained for sarcomeric α-
actinin (Figure 3B). At the immortalized stage, α-actinin expression in iAMs was low 
and in most cells the protein was diffusely spread throughout the cytoplasm. However, 
in a few cells, α-actinin showed a punctate staining pattern with the protein clustering 
in spherical or short elongated structures. At day 3 of differentiation, α-actinin formed 
longer structures with a dot-like appearance reminiscent of immature myofibrils. 
Myofibril assembly nearly reached completion at day 6 after dox removal, with most 
of the α-actinin displaying the Z-line staining pattern typical of cardiomyocytes. At 
the later stages of differentiation (i.e. at days 9 and 12 after dox removal), myofibrils 
underwent further maturation resulting in cells with highly organized sarcomeres. 
After dox removal, mRNA levels of the atrial natriuretic peptide (ANP)-
encoding Nppa gene, the atrial essential myosin light chain-encoding Myl4 gene and 
the atrial regulatory myosin light chain (i.e. Mlc2a)-encoding Myl7 gene were 
moderately (Myl4) to strongly (Nppa and Myl7) upregulated in iAMs (Figure 3C). 
Moreover, neither in the absence nor in the presence of dox, iAMs expressed 
detectable amounts of transcripts encoding ventricular regulatory myosin light chain 
(i.e. Mlc2v; Myl2 gene), ventricular essential myosin light chain (Myl3 gene) or β-
myosin heavy chain (Myh7 gene; Figure 3C). The RNA samples of 9-day-old pAM 
cultures contained high amounts of ‘’atrial” mRNA while ”ventricular” transcripts 
were barely detectable in these samples (Figure 3C). For the RNA samples from the 
9-day-old pVM cultures the opposite was true, i.e. they contained high amounts of 
Myl2, Myl3 and Myh7 transcripts but hardly any Nppa, Myl4 or Myl7 mRNA (Figure 
3C). Collectively, these data indicate that iAMs reacquire properties of atrial rather 
than ventricular cardiomyocytes when cultured in dox-free medium (Figure 3C). 
Mlc2a immunostaining confirmed these findings and showed gradual incorporation of 
this protein into sarcomeres indiscernible from those in pAMs that had been cultured 
for 9 days (Figure 3D). iAMs started to exhibit spontaneous contractions from day 6 
of differentiation (Supplementary material online, Movie I) demonstrating sarcomere 
functionality. The immunostainings for α-actinin and Mlc2a also revealed that the 
spontaneous differentiation of iAMs in the absence of dox is a highly synchronous 
event occurring in essentially all cells at approximately the same time. 
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Electrophysiological properties of iAMs 
RT-qPCRs targeting genes encoding cardiac ion channels showed an increase in the 
mRNA levels of Scn5a/Nav1.5, Cacna1c/Cav1.2, Kcnj3/Kir3.1, Kcnj5/Kir3.4 and 
Kcnj11/Kir6.2 during the early stages of iAM differentiation, which, later in the 
differentiation process, dropped to approximately equal levels as in pAMs at culture 
day 9 (Supplementary material online, Figure S1A-E). A similar differentiation-
dependent trend in expression levels was observed for Kcnd3/Kv4.3 and Kcnh2/Kv11.1 
but in these cases transcript levels at the late stages of iAM differentiation were higher 
than those in day 9 pAMs (Supplementary material online, Figure S1F and G). The 
iAMs did not express detectable amounts of Kcnj2/Kir2.1 at any stage in the 
differentiation process in contrast to pAMs that had been cultured for 9 days 
(Supplementary material online, Figure S1H). However, Kcnj2 expression in pAMs 
was much lower than in pVMs at culture day 9. Transcript levels of the pacemaker 
channel genes Hcn2 and Hcn4 showed dynamic changes during the cardiomyogenic 
differentiation of iAMs (Supplementary material online, Figure S1I and J). 
Proliferating iAMs expressed more Hcn2 mRNA than pAMs at day 9 of culture but 
this difference largely disappeared following 12 days of cardiomyogenic 
differentiation of the iAMs. The Hcn4 mRNA level in proliferating iAMs was lower 
than in pAMs at culture day 9 but showed a gradual increase during the first 9 days of 
iAM differentiation to suddenly drop afterwards. RT-qPCR analysis of Ryr2 and 
Atp2a2/Serca2 transcripts showed an increase in the expression of these Ca2+-handling 
protein genes early during iAM differentiation. From day 3 of differentiation onwards, 
Ryr2 and Atp2a2 mRNA levels in iAMs remained constant and were very similar 
(Ryr2) or 2- to 3-fold higher (Atp2a2) than in pAMs at culture day 9 (Supplementary 
material online, Figure S1K and L). 
Since spreading of APs through cardiac tissue critically depends on the 
presence of intercellular conduits, iAM cultures at different stages of differentiation 
were immunostained for the gap junction protein connexin 43 (Cx43). As shown in 
Figure 4A, Cx43 was first observed in iAMs at 3 days after dox removal and its 
amounts gradually increased as the cells further differentiated. Initially, Cx43 was 
mainly detected in the perinuclear region (i.e. at the site of biosynthesis) but at days 9 
of differentiation, most Cx43 was found in punctate patterns at the interfaces between 
iAMs. To investigate the functionality of these gap junctional plaques, confluent 
monolayers of differentiated iAMs were subjected to 1-Hz electrical point stimulation, 
which caused the cells to contract at the pacing frequency (Supplementary material 
online, Movie II). This result was corroborated by optical voltage mapping, which 
showed uniform radial spreading of excitatory waves from the site of electrical point 
stimulation in iAM cultures at day 9 of differentiation (Supplementary material online, 
Movie III). Additional optical voltage mapping experiments revealed a gradual 
increase in CV (Figure 4B and D; Supplementary material online, Movie III) and 
decrease in APD (Figure 4C, E and F) with ongoing iAM differentiation. As a matter 
of fact, CV and APD at 30 and 80% repolarization (APD30 and APD80, respectively) 
did not significantly differ between iAM cultures at differentiation days 9 and 12 and 
9-day-old pAM cultures. These data suggest that upon dox removal, iAMs 
differentiate into AMs with electrophysiological properties strongly resembling those 




To investigate the ionic basis of the similar electrophysiological properties of 
pAMs and cardiomyogenically differentiated iAMs as measured by optical voltage, 
we conducted patch-clamp experiments on these cardiomyocytes. The resting 
membrane potentials (RMP) of pAMs and iAMs in monolayer culture did not 
significantly differ (-64.5±1.2 mV, N=15 vs -67.5±1.6 mV, N=13), while single-cell 
recordings showed pAMs to have a more negative RMP (-62.8±1.8 mV, N=14) than 
iAMs (-46.0±1.9 mV, N=27; Supplementary material online, Figure S2A). In spite of 
the measured difference in RMP between single pAMs and single iAMs, both cell 
types were excitable and produced APs with very similar characteristics under the 
same stimulation conditions (Supplementary material online, Figure S2B and Table 
S3). Of all the AP parameters assessed only the upstroke velocity and the overshoot 
were somewhat smaller for the iAMs in comparison to the pAMs (Supplementary 
material online, Table S3). In voltage-clamp experiments, we found that the main 
membrane current responsible for the excitability of both cell types is a fast voltage-
activated transient Na+ current (consistent with the expression of Scn5a in these cells, 
Supplementary material online, Figure S1A), which occurred in these cells as a 
dominant current component (see Supplementary material online, Figure S2B, D and 
E). Although these patch-clamp results fit with the optical mapping data, we were 
puzzled by the similar RMPs for pAM and iAM monolayers, given the undetectable 
Kcnj2 expression in cardiomyogenically differentiated iAMs (Supplementary material 
online, Figure S1H) and the presumed difference in the inward rectifier current 
between pAMs and iAMs (IK1; Supplementary material online, Figure S2B). This 
apparent discrepancy was resolved by showing, with the aid of ouabain, that the 
electrogenic Na+/K+ ATPase plays a vital role in generating hyperpolarized RMPs in 
both pAMs and iAMs (Supplementary material online, Figure S3). 
To investigate their ability to form a functional cardiac syncytium with pAMs, 
iAMs were labelled with enhanced green fluorescent protein (eGFP) by lentiviral 
transduction. Next, 1:1 co-cultures of pAMs treated at day 1 of culture with 
mitomycin C and eGFP-labelled iAMs were established and subsequently kept for 8 
days in dox-free culture medium. The co-cultures were compared with iAM 
monocultures at day 9 of differentiation and with 9-day-old, mitomycin C-treated 
pAM cultures. (Supplementary material online, Figure S4A). Cx43 immunostaining of 
the co-cultures revealed the presence of gap junctions between iAMs and pAMs 
(Supplementary material online, Figure S4B). Optical voltage mapping showed 
uniform radial spreading of APs from the pacing electrode at roughly the same speed 
in all 3 culture types (Supplementary material online, Figure S4C and D) suggesting 
proper electrical integration of differentiated iAMs in co-cultures with pAMs. 
 





Figure 4. Electrophysiological properties of iAMs. (A) Fluorescence images of 
proliferating iAMs and of iAMs at different days after dox removal immunostained for Cx43 
(green) showing its differentiation-dependent accumulation at the sarcolemma in gap 
junctional plaques. As positive controls for the Cx43 immunostaining, 9-day-old pAM and 
pVM cultures were included. Hoechst 33342 (blue) staining shows cell nuclei. (B-F) Optical 
voltage mapping of confluent iAM and 9-day-old pAM (pAM-d9) monolayers following 1-
Hz electrical point stimulation. (B, C) Typical activation maps (B; isochrones are separated 
by 6 ms) and optical signal traces (C) of iAM cultures at different days after dox removal 
showing an increase in CV and a decrease in APD with advancing iAM differentiation. (D-F) 
Quantification of CV (D), APD30 (E) and APD80 (F) in pAM-d9 cultures and in iAM cultures 
at 3, 6, 9 and 12 days of differentiation. Data are presented as mean±SD, N=12 cell cultures 
per experimental group from 3 individual preparations. Statistics was done using the nested 
ANOVA test with Bonferroni post-hoc correction. AUs, arbitrary units. **P<0.01 and 





Comparison of the electrophysiological properties of iAMs and HL-1 cells 
The electrophysiological properties of iAM clone #5 were compared with those of the 
widely used HL-1 cell line, which was derived from the AT-1 mouse atrial myocyte 
tumour lineage11. To this end, confluent monolayers of iAMs at day 9 of 
differentiation and optimally maintained confluent cultures of HL-1 cells were 
subjected to optical voltage mapping following 1-Hz pacing. The CV in the HL-1 
cultures was ±20-fold lower than in the iAM cultures (Figure 5A and B; Movie III) 
and HL-1 cells displayed greatly prolonged APs as compared to differentiated iAMs 
(Figure 5C) characterized by a very slow upstroke. These data clearly demonstrate 




Figure 6. Comparison by optical voltage mapping and 1-Hz electrical point stimulation 
of the electrophysiological properties of confluent monolayers of iAMs at day 9 of 
differentiation (iAM-d9) with those of HL-1 cells. Typical activation maps (A, 6-ms 
isochrone spacing) showing a much slower CV (B) and optical signal traces (C) showing a 
much longer APD for the HL-1 cells as compared to the iAM-d9. Data are presented as 
mean±SD, N=9 cell cultures per group from 3 individual preparations. For statistical analysis, 
the nested ANOVA test was used. AUs, arbitrary units. ****P<0.001. 
 
iAMs as in vitro model of AF 
Our research group previously developed an in vitro model of AF based on high-
frequency electrical stimulation of confluent pAM cultures. The resulting reentrant 
circuits, or so-called rotors, could be terminated by prolonging APD of the pAMs 
using the Kir3.x-specific inhibitor tertiapin17. To determine whether confluent cultures 
of iAMs at different stages of differentiation would display similar behaviour, they 
were burst paced in the absence or presence of 100 nM tertiapin. While rotors could 
be readily induced in iAM cultures from differentiation day 6 onwards (Figure 6A-C; 
Supplementary material online, Movie IV), reentry could not be established in iAM 
cultures at day 3 of differentiation (Figure 6C). Reentry inducibility, the number of 
rotors per culture and rotor frequency increased with the time after dox removal 
95│Genesis of the iAM-1 Cell Line  
 
 
(Figure 6C-E). After treatment with tertiapin, iAMs that had been cultured for 9 days 
without dox showed a strong increase in APD (Figure 6F-H). Moreover, in the 
presence of tertiapin it was no longer possible to induce reentry in confluent 
monolayers of iAMs at day 6, 9 or 12 of differentiation by burst pacing (Figure 6C-F). 
The fact that tertiapin treatment only slightly reduced the CV in confluent monolayers 
of iAMs at day 9 of differentiation (from 20.5 to 19.8 cm/s; Figure 6I) suggests that 





Figure 5. Suitability of iAMs as in vitro AF model assessed by optical voltage mapping. 
(A, F) Typical optical signal traces of mock- (A) and tertiapin (F)-treated iAMs at day 9 of 
differentiation (iAM-d9) after high-frequency (10-50 Hz) electrical point stimulation. (B) 
Activation maps (6-ms isochrone spacing) of iAM-d9 cultures showing 1 (left) or 2 (right) 
reentrant circuits. (C-E) Inducibility of reentry (C), arrhythmia complexity (D) and 
quantification of rotor frequency (E) in iAM cultures at 3, 6, 9 and 12 days of differentiation. 
(G) Typical optical AP records of mock- (black) and tertiapin (red)-treated iAM-d9 following 
1-Hz pacing. (H-I) Quantification of APD30, APD80 (H) and CV (I) of mock- and tertiapin-
treated iAM-d9. Data are presented as mean±SD, N=9 cell cultures per experimental group 
from 3 individual preparations. Statistics was done using the nested ANOVA test with 







Until now, all attempts to generate lines of cardiomyocytes that can give rise to cells 
with electrical and contractile properties approaching those of the starting material 
have failed. Indeed, all cardiomyocyte lines reported to date display large structural 
and functional deficits compared to the primary cardiomyocytes from which they were 
derived11,13,15,24. In this study, we have solved this problem and describe the generation 
of monoclonal lines of conditionally immortalized neonatal rat atrial myocytes with 
preserved cardiomyogenic differentiation capacity. This was accomplished by 
transducing pAMs with an LV directing myocyte-selective and dox-dependent 
expression of the SV40 LT antigen. Culturing of the resulting cells in medium with 
dox caused their rapid expansion, while in dox-free culture medium, the amplified 
cells spontaneously and synchronously differentiated into fully functional (i.e. 
excitable and contractile) AMs that were successfully used to develop a monolayer 
model of AF, for investigating the APD-prolonging effects of toxins (tertiapin, Figure 
6). To provide our iAMs with a unique and easy-to-remember identifier, we have 
dubbed the progeny of iAM clone #5 the iAM-1 cell line. 
 
Properties of iAMs 
RT-qPCR analysis of iAMs in different stages of differentiation (Figure 3 and 
Supplementary material online, Figure S1) shows a rapid increase in mRNA levels of 
cardiac transcription factors, ion channels, Ca2+-handling proteins and sarcomeric 
proteins shortly after dox removal. At later stages of differentiation, these mRNA 
levels generally either stay fairly constant (as for the genes encoding cardiac 
transcription factors, sarcomeric and Ca2+-handling proteins and ANP) or decline 
again to the approximate mRNA levels of pAMs (Scn5a, Cacna1c, Hcn2, Kcnj3, 
Kcnj11) and/or proliferating iAMs (Scn5a, Cacna1c, Kcnd3, Kcnh2, Kcnj3). These 
findings are consistent with the notion that upon dox removal iAMs rapidly engage in 
a cardiomyogenic differentiation program with the concomitant upregulation of genes 
needed to build a functional cardiomyocyte. To complement the RT-qPCR data, we 
recently initiated an RNA-seq study focussing on transcriptomes of iAMs at different 
stages of cardiomyogenic differentiation and subsequent dedifferentiation. The results 
of this study will be presented elsewhere. 
Following their differentiation in the absence of dox, iAMs acquire properties 
of atrial rather than ventricular myocytes as evinced by the high-level expression in 
differentiated iAMs of “atrial” genes including Nppa, Myl4, Myl7, Kcnj3 and Kcnj517 
and the lack of expression of the “ventricular” Myl2, Myl3 and Myh7 genes25. 
Moreover, following 1-Hz pacing, differentiated iAMs display rapid contractions that 
strongly resemble those of pAMs but are quite different from the slower contractions 
of pVMs (Supplementary material online, Movie II and data not shown). Consistently, 
the average APD30 and APD80 of differentiated iAMs do not significantly differ from 
those of pAMs (Figure 4E and F, respectively; Supplementary material online, Table 
S3) but are much shorter than the average APD30 and APD80 of pVMs (Supplementary 
material online, Figure S5). Collectively, these findings indicate that although LT 
expression results in the dedifferentiation and proliferation of AMs, the cells retain 
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some kind of epigenetic memory causing them to spontaneously differentiate into 
atrial myocytes upon dox removal. 
 
RMPs of iAMs and pAMs 
pAM and iAM monolayers had similar RMPs (Figure S2A). Although RMP 
measurements of single cells are less reliable than those of cell clusters, because the 
voltage is measured from a high-resistance source (Rm>100 MΩ) after establishing 
gigaseal, the RMPs of single pAMs and pAM monolayers did not significantly differ 
(Figure S2A). However, the RMP of single iAMs was significantly depolarized 
compared to that of iAM monolayers (Figure S2A). Further experiments as part of a 
dedicated patch-clamp study are needed to determine the precise cause for this 
difference, which may, however, relate to the lack of Kcnj2 expression in 
cardiomyogenically differentiated iAMs (Figure S1H) together with technical 
difficulties to perform meaningful RMP measurements in neonatal/immature (atrial) 
cardiomyocytes due to their high plasma membrane resistance26,27.  
Our finding that the electrogenic Na+/K+ ATPase plays an important role in the 
generation of the RMP of AMs is of particular interest, because it ensures a 
sufficiently negative RMP for the maintenance of excitability of iAMs in monolayer 
cultures, in the absence of Kcnj2 expression. The great importance of the Na+/K+ 
pump for establishing physiological Na+ and K+ gradients is widely recognized in the 
electrophysiology of adult cardiomyocytes. Decreased activity of the Na+/K+ pump 
under ischaemic conditions causes the loss of physiological K+ and Na+ gradients with 
consequent RMP depolarization and other effects favouring arrhythmogenesis28. 
However, as stated in many physiology textbooks, a direct contribution of the 
electrogenic action of the Na+/K+ pump to the RMP of adult cardiomyocytes is often 
considered as relatively small compared to the pump’s indirect electrogenic effect, i.e. 
its ability to create transmembrane K+ and Na+ gradients. This may be understood by 
considering the Na+/K+ pumps in the plasma membrane as a low conductance pathway 
with a negative reversal potential determined by their ATP-driven action29,30. This 
implies that the direct electrogenic effects of pump currents will, at the same current 
densities, be more prominent in high-resistance (~1 GΩ) cardiomyocytes like the AMs 
than in lower-resistance (~100 MΩ) cardiomyocytes like adult rat ventricular 
cardiomyocytes31. Possibly, no/low expression of inward rectifier K+ channels in 
iAMs and an important role for the Na+/K+ ATPase activity in setting the RMP is 
characteristic for young (atrial) myocytes or a sign of incomplete differentiation of 
these cells. Developmental increases in IK1 are not uncommon and have previously 
been reported for ventricular cardiomyocytes of various rodent species32. 
Because of the dominance of voltage-activated Na+ channels in the voltage-
clamp recordings of both pAMs and iAMs, we ascribed the excitability of iAMs 
mainly to those channels. However, AMs also express, though at much lower levels, 
voltage-activated Ca2+ channels33 (Supplementary material online, Figure S1B), which 
may be expected to contribute to pAM and iAM excitability. How these Ca2+ channels 
compare in their contribution to excitability in pAMs and iAMs deserves further 
experimental work. The same applies to the contributions of outward rectifier K+ 
currents to the excitability of pAMs and iAMs, and to the realisation of the RMP of 




Possible applications of iAMs 
Long-term culture of iAMs did not significantly reduce their proliferation rate in the 
presence of dox and the sarcomeric organization and contractile behaviour of iAMs 
from different passages at day 9 of differentiation were indistinguishable (data not 
shown). Moreover, no progressive cell flattening, nuclear enlargement, development 
of senescence-associated heterochromatin foci or other signs of senescence were 
observed during the first 55 population doublings of the cells. Assessment of the 
electrophysiological properties of confluent monolayers of differentiated iAMs by 
optical voltage mapping after 25, 40 and 55 population doublings revealed no 
significant differences in APD or CV (see Supplementary material online, Figure S6). 
Also, differentiated iAMs resume cell division following addition of dox to the culture 
medium and redifferentiate again into atrial myocytes following subsequent dox 
removal (data not shown). iAMs therefore provide a virtually unlimited supply of 
cardiomyocytes for fundamental research but may also prove very useful for: (i) the 
development of acquired disease models, (ii) identifying new therapeutic targets, (iii) 
screening of drugs and toxins, (iv) testing of new treatment modalities (e.g. gene and 
cell therapy), (v) production of biopharmaceuticals in bioreactors or encapsulated 
cell/tissue grafts and (vi) the improvement of tissue engineering approaches. The 
recent rapid progress in genome editing technologies34 will further expand the 
applicability of iAMs allowing them to be used as models for studying key aspects of 
inherited cardiomyopathies. 
A highly attractive feature of the iAMs is that they spontaneously undergo 
cardiomyogenic differentiation in a synchronous and near quantitative manner in 
standard culture medium without dox. Contrarily, generation of cardiomyocytes from 
embryonic or induced PSCs requires their properly timed treatment with various 
cocktails of growth factors and small molecules5. This typically yields phenotypically 
heterogeneous populations of mostly immature cardiomyocytes contaminated with 
variable percentages of non-cardiomyocytes. Consequently, to obtain relatively pure 
populations of PSC-CMCs various different enrichment procedures have been 
developed35. Production of more or less homogeneous populations of cardiomyocytes 
from PSCs thus is a laborious, time-consuming and costly endeavour as compared to 
the straightforward generation of atrial myocytes from iAMs. This may explain why 
there are very few reports on the use of PSC-CMCs to investigate cardiac arrhythmias 
in monolayer cultures by optical mapping8, while such experiments are easily 
performed with differentiated iAM monolayers (Figure 4-6 and Supplementary 
material online, Figure S3-9). Also, in contrast to PSC-CMCs, iAMs offer the 
possibility to study the molecular mechanisms involved in the transition of a 
differentiated cardiomyocyte that is no longer able to undergo cytokinesis into an 
actively dividing cell. This is particularly relevant given the growing interest in the 
regeneration of mammalian hearts from within by stimulating cardiomyocytes 
surrounding the site(s) of cardiac injury to multiply themselves through cell 
division36,37. Current findings regarding the molecular changes accompanying the 
reactivation of cardiomyocyte proliferation should be interpreted with caution due to 
the presence of other cell types (e.g. cardiac fibroblasts and inflammatory cells) in 
most test materials. iAMs do not suffer from this drawback making them a potentially 
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highly useful model system to study the mechanisms underlying cell cycle reentry and 
progression of cardiomyocytes.  
Optical voltage mapping of other clones of excitable iAMs yielded very similar 
results although not all of them reached the same maximum CV and minimum APD as 
clone #5 (e.g. clone #1 and #6; Supplementary material online, Figure S7A-C and D-F, 
respectively). An intriguing finding of this study is the difference in 
electrophysiological properties between the differentiated progeny of different iAM 
clones, which extends to iAM clones not presented in this study. The cause(s) of this 
heterogeneity is/are unclear given the fact that cardiomyogenically differentiated cells 
with a similarly high level of sarcomeric organization still differed in 
electrophysiological behaviour (data not shown). Therefore, besides a different 
propensity to mature, other factors might explain the electrophysiological differences 
between individual iAM clones. Different iAM clones may, for instance, be derived 
from different parts of the atria (e.g. left or right atrium, epi- or endocardial atrium) or 
represent different subtypes of atrial myocytes (i.e. nodal, bundle and working cells). 
Also, the number and location of the chromosomal insertion sites of the LV genomes 
and the cell’s epigenetic status at the moment of immortalization may have 
contributed to the observed heterogeneity in electrophysiological properties between 
different iAM clones. 
Although single-cell patch-clamp analysis can yield a wealth of information 
about the electrophysiological behaviour of individual cells and has been widely used 
to estimate the risk of drug-induced proarrhythmia, the technique does not directly 
assess proarrhythmic potential and is of limited use for studying arrhythmia 
mechanisms. Optical mapping, on the other hand, allows investigation of normal and 
disturbed cardiac electrical impulse propagation in a direct manner with high spatial 
and temporal resolution38,39. As demonstrated by the experiments described in Figure 
4-6 and Figure S4, S7-9 (see Supplementary material online), confluent iAM cultures 
are well-suited for optical mapping studies. In combination with their large 
proliferation capacity, this opens perspectives for developing high-throughput 
analyses based on the iAM lines and/or future lines of other cardiomyocytes generated 
with our conditional immortalization method.  
 
Comparison between HL-1 and iAM-1 cells 
Of all AM lines generated to date, the murine AM line HL-1 has the most 
differentiated phenotype and is therefore most widely used. Side-by-side comparison 
of the electrophysiological properties of confluent monolayers of differentiated iAM-1 
cells and HL-1 cells by optical voltage mapping (Figure 5 and Movie III) showed an 
average CV for the HL-1 cultures of 1 cm/s, which is about 20-fold lower than that of 
differentiated iAM-1 cell cultures and in line with previous reports24. Since Ma et al40. 
reported a resting membrane potential of −77.7±0.4 mV for HL-1 cells at an 
extracellular K+ concentration of 4 mM, the low CV in confluent HL-1 cell 
monolayers does not seem to result from a high percentage of cardiac fast Na+ 
channels being in an inactivated state. The large difference in CV between both cell 
types thus conceivably relates to the fact that confluent HL-1 monolayers are a blend 
of proliferating cells without cardiomyocyte functionality, which are electrically 




in the iAM cultures at 9 days of differentiation virtually all cells are in a similar 
advanced stage of differentiation forming a highly conductive cardiac syncytium 
(Figure 4, 5 and Supplementary material online, Figure S4, S5, S7-9). Gap junctional 
coupling between undifferentiated and differentiated cells may also explain the 
apparent discrepancy between the broad optical voltage traces of HL-1 cells in 
monolayer cultures versus the short APDs recorded for single HL-1 cells following 




By employing a monopartite LV system allowing inducible expression of the SV40 
LT antigen in cardiomyocytes, we have generated lines of iAMs with (functional) 
properties superior to those of all existing cardiomyocyte lines, none of which yields 
cells that approach the structural and functional maturity of dox-deprived iAMs. This 
is especially true for differentiated iAM-1 monolayers, which show homogeneous AP 
propagation at much higher speeds than obtained with other lines of cardiac muscle 
cells. The broad applicability of the iAMs was illustrated by their use (i) to study the 
cardiac ion channel-modulatory activity of toxins and drugs and (ii) as AF model. 
Since iAMs undergo a highly coordinated and precisely timed cardiomyogenic 
differentiation process, they might also be ideally suited to study specific aspects of 
cardiac muscle cell formation and maturation. Finally, because differentiation of iAMs 
into electrically and mechanically active cardiomyocytes that phenotypically resemble 
atrial myocytes of newborn rats occurs spontaneously (i.e. without the need for 
complex treatment regimens with expensive [bio]chemicals), iAMs may provide an 
easy-to-use and cost-effective system to address specific fundamental and applied 
cardiac research.  
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Construction of plasmids 
DNA constructions were carried out with enzymes from Fermentas (Thermo Fisher 
Scientific, Breda, the Netherlands) or from New England Biolabs (Bioke´, Leiden, the 
Netherlands) and with oligodeoxyribonucleotides from Eurofins MWG Operon 
(Ebersberg, Germany) using established procedures or following the instructions 
provided with specific reagents. 
To generate a thermosensitive version of the oncogenic simian virus 40 (SV40) 
large T (LT) antigen (mutant tsA58 also known as tsA438A-V1), plasmid 
pAT153.SV40ori(-)2 was incubated with PvuII and the 4.3-kb digestion product was 
recircularized with bacteriophage T4 DNA ligase to generate pAT153.SV40ori(-
).dPvuII. pAT153.SV40ori(-).dPvuII was subsequently cut with HindIII and PvuII and 
the large digestion product of 4.3 kb was combined with the hybridization product of 
oligodeoxyribonucleotides 5’ CTGTGCTTCTAGAATTATGTGGGGGGAA 3’ and 5’ 
AGCTTTCCCCCCACATAATTCTAGAAGCACAG 3’ (underlined nucleotides 
represent the mutant LT codon and its complement) producing pAT153.SV40ori(-
).dPvuII.LT-tsA58. Next, pAT153.SV40ori(-)dPvuII.LT-tsA58 was linearized with 
PvuII and the 4.3-kb digestion product was ligated to the 2.0-kb PvuII fragment of 
pAT153.SV40ori(-) to generate pAT153.SV40ori(-).LT-tsA58. pAT153.SV40ori(-
).LT-tsA58 was used as template in a polymerase chain reaction (PCR) with 
VELOCITY DNA polymerase (GC Biotech, Alphen aan den Rijn, the Netherlands) 
and primers 5’ 
AGGTTTAAACTACGGGATCCGTGCACCATGGATAAAGTTTTAAACAGAGA
GGA 3’ and 5’ CCGAATTCTTTATGTTTCAGGTTCAGGG 3’ (underlined 
nucleotides represent the LT initiation codon and the complement of its termination 
codon) to amplify the LT-coding sequence. The resulting PCR fragment was inserted 
into plasmid pJET1.2/blunt using the CloneJET PCR cloning kit (Thermo Fisher 
Scientific) to generate pJet1.2.LT-tsA58. pJet1.2.LT-tsA58 was incubated with MssI 
and EcoRI and the 2.5-kb digestion product was combined with the 11.0-kb 
MssI×EcoRI fragment of lentiviral vector (LV) shuttle plasmid pLV.iMHCK7 to 
generate pLV.iMHCK7.LT-tsA58 (Figure 1A). pLV.iMHCK7 is a derivative of 
pLVET-tTR-KRAB3 (Addgene, Cambridge, MA; plasmid number: 116444) in which 
the human EEF1A1 gene promoter and the Aequorea victoria enhanced green 
fluorescent protein (eGFP)-coding sequence were replaced by the striated muscle-
specific MHCK7 promoter4 and a small polylinker containing unique SpeI, MssI, PstI 
and EcoRI restriction enzyme recognition sequences. 
LV shuttle plasmid pLV.MHCK7.eGFP is a derivative of construct 
pLV.MHCK7.eYFP.WHVPRE5, in which the coding sequence for the Aequorea 
victoria enhanced yellow fluorescent protein and the woodchuck hepatitis virus 
posttranscriptional regulatory element (WHVPRE) are replaced by the eGFP open 






To generate vesicular stomatitis virus G protein-pseudotyped particles of 
LV.iMHCK7.LT-tsA58, subconfluent monolayers of 293T cells were transfected with 
LV shuttle construct pLV.iMHCK7.LT-tsA58 and the packaging plasmids psPAX2 
(Addgene; plasmid number: 12260) and pLP/VSVG (Thermo Fisher Scientific) at a 
molar ratio of 2:1:1. The 293T cells were cultured in high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM; Life Technologies Europe, Bleiswijk, the 
Netherlands, catalogue number: 41966) with 10% foetal bovine serum (FBS; Life 
Technologies Europe). The transfection mixture, which consisted of 35 µg of plasmid 
DNA and 105 µg of polyethyleneimine (Polysciences Europe, Eppelheim, Germany) 
in 2 ml of 150 mM NaCl per 175-cm2 cell culture flask (Greiner Bio-One, Alphen aan 
den Rijn, the Netherlands), was directly added to the culture medium. The next 
morning, the transfection medium was replaced by 15 ml of fresh high-glucose 
DMEM supplemented with 5% FBS and 25 mM HEPES-NaOH (pH 7.4). At ±48 
hours after the start of the transfection procedure, the culture supernatants were 
harvested and cleared from cellular debris by centrifugation at room temperature (RT) 
for 10 minutes at 3,750×g and subsequent filtration through 0.45-µm pore-sized, 33-
mm diameter polyethersulfone Millex-HP syringe filters (Millipore, Amsterdam, the 
Netherlands). To concentrate and purify the LV particles, 30 ml of vector suspension 
in a 38.5-ml polypropylene ultracentrifuge tube (Beckman Coulter Nederland, 
Woerden, the Netherlands) was underlayed with 5 ml of 20% (wt/vol) sucrose in 
phosphate-buffered saline (PBS) and centrifuged for 120 minutes at 4°C with slow 
acceleration and without braking at 15,000 revolutions per minutes in an SW32 rotor 
(Beckman Coulter Nederland). Next, the supernatants were discarded and the pellets 
were suspended in PBS-1% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, 
MO) by overnight incubation with gentle shaking at 4°C. The concentrated vector 
suspension was divided on ice in 50 µl aliquots for storage at -80°C. 
LV.MHCK7.eGFP particles were generated using the same procedure except for the 
use of pLV.MHCK7.eGFP instead of pLV.iMHCK7.LT-tsA58 as LV shuttle plasmid. 
 
Animal experiments 
All animal experiments were approved by the Animal Experiments Committee of 
Leiden University Medical Center and conformed to the Guide for the Care and Use 
of Laboratory Animals as stated by the US National Institutes of Health. 
 
Isolation and culture of cardiomyocytes 
Cardiomyocytes were isolated from neonatal Wistar rat hearts and cultured as detailed 
elsewhere7. Briefly, rats were anaesthetized with 4-5% isoflurane inhalation. After 
adequate anaesthesia had been confirmed by the absence of pain reflexes, hearts were 
excised. Atria and ventricles were separated from the hearts, minced and dissociated 
by 2 subsequent 30-minute treatments with collagenase type I (Worthington 
Biochemical, Lakewood, NJ) and DNase I (Sigma-Aldrich). Cells were pelleted by 
centrifugation for 10 minutes at RT and 160×g and suspended in Ham’s F10 medium 
(Life Technologies Europe, catalogue number: 11550) supplemented with 100 
units/mL of penicillin and 100 µg/mL of streptomycin (Life Technologies Europe) 
and with 10% heat-inactivated FBS and 10% heat-inactivated horse serum (HS; Life 
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Technologies Europe). Next, cell suspensions were transferred to Primaria culture 
dishes (Corning Life Sciences, Amsterdam, the Netherlands) and incubated for 120 
minutes at 37°C in a humidified atmosphere of 5% CO2 to allow preferential 
attachment of non-cardiomyocytes. The unattached cells (mainly atrial myocytes AMs 
or ventricle myocytes VMs) were collected, passed through a cell strainer (70-μm 
mesh pore size; BD Biosciences, Breda, the Netherlands) and seeded at a density of 
2×103 cells/cm2 in a 6-well cell culture plate (Corning Life Sciences) coated with 
fibronectin from bovine plasma (Sigma-Aldrich) for immortalization purposes or on 
bovine fibronectin-coated glass coverslips in 24-well cell culture plates (Greiner Bio-
One) at a density between 2×104 and 8×105 cells/well for comparative studies. 
LV.iMHCK7.LT-tsA58-transduced cells and primary AMs (pAMs) were 
subsequently maintained in a 1:1 mixture of low-glucose DMEM (Life Technologies 
Europe, catalogue number: 22320) and Ham’s F10 medium (DMEM/F10) 
supplemented with 5% heat-inactivated HS, 1× penicillin-streptomycin, 2% BSA and 
sodium ascorbate to a final concentration of 0.4 mM and in DMEM/F10 with 10% 
heat-inactivated FBS and 100 ng/ml doxycycline (dox) or no dox as indicated, 
respectively. Culture medium was replaced daily (pAMs and pVMs) or every 2-3 days 
(immortalized AMs). 
For the isolation and culture of neonatal rat ventricular cardiomyocytes (pVMs) 
the same method was used as for pAMs except that ventricular instead of atrial tissue 
of newborn rats served as starting material. 
HL-1 cells were cultured in 25-cm2 cell culture flasks (Corning Life Sciences) 
for regular passaging and on round glass coverslips (diameter of 15 mm) for optical 
mapping purposes essentially as described in the MEA Application Note: HL-1 
Cardiac Cell Line of Multi Channel Systems (Reutlingen,Germany; 
http://www.multichannelsystems.com/sites/multichannelsystems.com/files/ 
documents/applications/MEA-Application%20Note_HL-1.pdf). 
The best performing line of conditionally immortalized AMs (iAMs) has been 
designated iAM-1. Inquiries about this cell line and other iAM lines can be send to 
iAM-1@hartlongcentrum.nl. 
 
Transduction of pAMs and generation of iAM clones 
At day 1 of culture, pAMs were transduced with LV.iMHCK7.LT-tsA58. The next 
day, the inoculum was replaced by culture medium containing 100 ng/ml dox to 
induce LT expression. The cells were given fresh culture medium every other day. 
After 1 week of culture, the transduced cells were trypsinized and plated at a low 
density of 10~20 cells/cm2 in a 100-mm diameter cell culture dish (Greiner Bio-One) 
to generate single-cell clones. After 2-3 weeks, individual cell colonies were picked 
and expanded in the presence of dox. To investigate their spontaneous 
cardiomyogenic differentiation ability, iAMs were cultured in the absence of dox for 3, 
6, 9 and 12 days and characterized by a combination of molecular biological, cell 
biological, immunological and electrophysiological techniques. 
To facilitate their identification in co-cultures with pAMs, iAM-1 cells were 
eGFP-labelled using the LV designated LV.MHCK7.eGFP and passaged multiple 






Western blotting was carried out as detailed before9. After blocking, the membranes 
were incubated overnight at 4°C with primary mouse monoclonal antibodies directed 
against LT (1:2,000; Santa Cruz Biotechnology, Dallas, TX, catalogue number: sc-147) 
or glyceraldehyde 3-phosphate dehydrogenase (GAPDH; loading control; 1:100,000; 
Millipore, catalogue number: MAB374) and then probed with goat anti-mouse IgG 
secondary antibodies linked to horseradish peroxidase (1:15,000; Santa Cruz 
Biotechnology) for 1 hour at RT. Chemiluminescence was produced using the 
SuperSignal West Femto maximum sensitivity substrate (Thermo Fisher Scientific), 
captured by a ChemiDoc XRS imaging system (Bio-Rad Laboratories, Veenendaal, 
the Netherlands) and analysed by Quantity One software (Bio-Rad Laboratories) using 
the GAPDH signals for normalization purposes. 
 
Immunocytology 
Immunostaining of cultured cells was performed as previously described10 using the 
following primary antibodies at a dilution of 1:200 in PBS containing 0.1% normal 
donkey serum (NDS; Sigma-Aldrich): mouse anti-LT (Santa Cruz Biotechnology, 
catalogue number: sc-147), rabbit anti-Ki-67 (Abcam, Cambridge, United Kingdom, 
catalogue number: ab15580), mouse anti-α-actinin (Sigma-Aldrich, catalogue number: 
A7811), rabbit anti-atrial myosin light chain 2 (MLC2a)11 and rabbit anti-connexin 43 
(Cx43; Sigma-Aldrich, catalogue number: C6219). Bound antigens were detected 
using Alexa 488-conjugated donkey anti-rabbit IgG (H+L) (Thermo Fisher Scientific, 
catalogue number: A21206) and Alexa 568-coupled donkey anti-mouse IgG (H+L) 
(Thermo Fisher Scientific, catalogue number: A10037). These secondary antibodies 
were diluted 1:400 in PBS. Hoechst 33342 (10 µg/µl; Thermo Fisher Scientific) was 
used to counterstain nuclei. Stained cells were visualized using a digital colour 
camera-equipped fluorescence microscope (Nikon Eclipse 80i; Nikon Instruments 
Europe, Amstelveen, the Netherlands). 
 
Analysis of cell proliferation and programmed cell death 
To assess their proliferation rate, iAMs were cultured at low density in medium with 
or without 100 ng/ml dox. At different days after culture initiation, cells were 
collected in PBS, mixed at a ratio of 1:1 with 0.4% Trypan Blue (VWR International, 
Amsterdam, the Netherlands) in PBS and briefly incubated at RT after which viable 
cells were counted using a haemocytometer. To distinguish proliferating from non-
proliferating cells, monolayer cultures of AMs were immunostained with Ki-67-
specific antibodies. 
To study apoptosis, cells were incubated with Alexa Fluor-568-conjugated 
annexin V (Thermo Fisher Scientific, catalogue number: A13202) as described 
before10. pAMs treated for 24 hours with 1 µM of the chemotherapeutic agent 
doxorubicin (Sigma-Aldrich) served as positive control for the apoptosis assay.  
Quantitative analyses of cell surface area, the percentage of Ki-67+ 
cardiomyocytes and cell surface-bound annexin V were performed with the Java-
based image processing program Image J (version 1.50i, National Institutes of Health, 
Bethesda, MD). 
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Reverse transcription-quantitative PCR (RT-qPCR) 
RT-qPCR was performed as previously reported10. Briefly, iAMs were seeded at a 
density of 8×105 cells/well in 24-well cell culture plates and cultured for 1 day in 
medium containing 100 ng/ml dox. The next day, cells were either lysed in TRIzol 
Reagent (Thermo Fisher Scientific) and total RNA was isolated using the RNeasy 
Mini kit (QIAGEN Benelux, Venlo, the Netherlands) or kept for 3, 6, 9 or 12 days in 
culture medium without dox prior to cell lysis and RNA extraction. The RNA was 
reverse transcribed with the iScript cDNA synthesis kit (Bio-Rad Laboratories) and 
gene expression levels were determined by PCR using the Bioline SensiFAST SYBR 
No-ROX kit (GC biotech) and intron-spanning primer pairs (Table S1). Due to the 
high nucleotide sequence identity of the pacemaker channel genes, Hcn2 and Hcn4 
mRNA levels were determined using TaqMan primer/probe sets Rn01408572_mH 
andRn00572232_m1), respectively, together with TaqMan Universal Master Mix II 
(all from Thermo Fisher Scientific). PCR amplifications were performed in a CFX96 
Touch Real-Time PCR Detection System (Bio-Rad Laboratories) or in a QuantStudio 
5 Real-Time PCR System (Thermo Fisher Scientific). Per target gene 3 independent 
experiments were performed consisting of 3 samples per experiment. Quantitative 
analyses were based on the 2-ΔΔCT method using CFX Manager software (Bio-Rad 
Laboratories). PCR amplifications of the rat 18S rRNA gene (Rn18s) were included 
for normalization purposes.  
 
Optical voltage mapping 
For studying action potential (AP) propagation in confluent monolayer cultures, cells 
were seeded at a density of 8×105 cells/well in 24-well cell culture plates onto bovine 
fibronectin-coated round glass coverslips (diameter of 15 mm) and subjected to 
optical voltage mapping using di-4-ANEPPS (Thermo Fisher Scientific) as fluorescent 
voltage indicator as described previously5. The measurements were carried out at 
37°C on 9-day-old pAM and pVM cultures and on iAMs that had been maintained for 
0, 3, 6, 9 and 12 days in dox-free medium. Optical signals were captured using a 
MiCAM ULTIMA-L imaging system (SciMedia, Costa Mesa, CA). Optical traces 
were analysed using Brain Vision Analyzer 1208 software (Brainvision, Tokyo, 
Japan). To minimize noise artefacts, calculations were based on the average of the 
signals at a selected pixel and its eight nearest neighbours. Conduction velocity (CV) 
and AP duration (APD) at different percentages of repolarization were determined 
using cardiomyocyte cultures showing uniform AP propagation and 1:1 capture after 
1-Hz local electrical stimulation with an epoxy-coated bipolar platinum electrode 
delivering square 10-ms, 8-V suprathreshold electrical impulses via a STG 2004 
stimulus generator and MC Stimulus II software (both from Multi Channel Systems). 
Burst pacing with a cycle length of 20-100 ms was used to induce reentry. The effects 
of tertiapin (100 nM, Alomone Labs), astemizole (100 nM, a gift of Zhiyi Yu), 
carbachol (2 μM, Alcon, Gorinchem, the Netherlands) and ouabain (100 -400 μM, 
Sigma-Aldrich) were investigated by pipetting them directly into the medium and 
dispersing them by gentle shaking, followed by optical mapping. To facilitate APD 
comparison, the amplitude of the optical signal traces was normalized for all samples 






Whole-cell patch-clamp recordings were conducted on single iAMs and pAMs 
(2.5×104 cells/2-cm2 well) and on iAM and pAM monolayers (8×105 cells/2-cm2 well) 
seeded on fibronectin-coated glass coverslips. The monolayer measurements were 
carried out using 9-day-old cultures of freshly isolated pAMs or iAMs that were 
cultured for 9 days in the absence of dox. For single-cell measurements, freshly 
isolated pAMs were cultured for 2-3 days before patch-clamping. Single-cell patch-
clamping of iAMs was done 1-3 days after low-density replating of monolayer cells 
that had been maintained for 8-9 days without dox unless indicated otherwise. For 
patch-clamp experiments, pAMs and iAMs were submerged in a Tyrode bath solution 
containing (in mM): 126 NaCl, 11 glucose, 10 HEPES, 5.4 KCl, 1 MgCl2, and 1.8 
CaCl2 (adjusted to pH 7.40 with NaOH). Patch recordings were conducted 15-60 
minutes later at 20-23°C. Data acquisition was done using an inverted Zeiss Axiovert 
35 microscope (Carl Zeiss, Oberkochen, Germany), an MPC-200 multi-
micromanipulator system (Sutter Instrument, Novato, CA) and a conventional patch-
clamp rig consisting of a CV-7B head stage, MultiClamp 700B amplifier and a 
Digidata 1440A A/D converter (Axon CNS, Molecular Devices, Sunnyvale, CA). 
Patch pipettes were fabricated from borosilicate glass capillaries with an inner and 
outer diameter of 1.17 and 1.5 mm, respectively (Harvard Apparatus, Kent, United 
Kingdom), using a vertical puller (P-30; Sutter Instrument). Pipette tips were fire-
polished and had typical tip resistances for single cell and monolayer measurements of 
2-4 and 4-7 MΩ, respectively, when filled with a solution containing (in mM): 80 
potassium DL-aspartate, 40 KCl, 8 NaCl, 5.5 glucose, 5 HEPES, 5 EGTA, 1 MgCl2, 4 
Mg-ATP, and 0.1 Na3-GTP (adjusted to pH 7.20 with KOH). The plasma membrane 
resistance (Rm) of single pAMs and iAMs at their resting membrane potential (RMP) 
was approximately 1.1 and 0.9 GΩ, respectively. The effects of carbachol (2 μM) and 
ouabain (100 and 300 μM) were investigated via local drug perfusion while 
continuously monitoring the RMP. For fast Na+ current analysis, signals induced by 
50-ms depolarizing pulses in 10-mV increments starting from a holding potential of -
80 mV in the absence and presence of 10 µM tetrodotoxin (TTX, Alomone Labs, 
Jerusalem, Israel) were digitally subtracted. Voltage clamp recordings were ≥75% 
compensated for pipette series resistance and capacitive transients. Throughout the 
experiments, the current and voltage outputs of the amplifier were continuously 
sampled at 10 kHz after low-pass filtered at 4 kHz with a four-pole Bessel filter. Data 
acquisition was carried out using pCLAMP 10.7 software (Axon CNS, Molecular 
Devices).  
Current densities were determined by normalizing peak current amplitudes to 
cell capacitance. Voltage dependence of activation was analysed by fitting the data 






), where V is the variable 
test potential, V1/2 the voltage of half-maximum activation, k the slope factor, and Imax 
the normalized maximum amplitude of the Na+ current. All data were corrected for 
liquid junction potentials. Data analysis was done using Clampfit 10.7 (Axon CNS, 
Molecular Devices), Excel (version 2010, Microsoft, Redmond, WA) and Prism 7 
(Graphpad Software, La Jolla, CA). 
 
Atrial tissue culture and iAM injection in cultured atrial tissue 
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Atrial tissue from neonatal rats was used as graft recipient of iAMs. Two-day-old 
Wistar rats were anaesthetized by 4-5% isoflurane inhalation and adequate anaesthesia 
was confirmed by the absence of reflexes. After the chest was opened and the inferior 
vena cava was cut off with scissors, the right atrium was punctured with a 19-gauge 
needle. The heart was perfused through this needle with pre-warmed and oxygenated 
PBS containing 10 IU/ml heparin (LEO Pharma, Amsterdam, the Netherlands) to 
flush out the blood. Two and a half μl of growth factor-reduced Matrigel (BD 
Biosciences) was mixed with 2.5 μl cell suspension containing 5×104 iAMs and 
injected into the bilateral atrial free walls using a 25-μl syringe equipped with a 33-
gauge needle (Hamilton Robotics, Reno, NV). 
Subsequently, the atrial tissue including the injected area was excised and 
cultured with the following modifications. The atrial tissue was placed with the 
endocardial surface down onto the semi-porous polytetrafluoroethylene membrane 
(0.4 µm pore size) of a PICM0RG50 cell culture insert (Millipore) in a 35-mm 
diameter Petri dish containing 1 ml sterilized Tyrode’s solution (TS; 136 mM NaCl, 
5.4 mM KCl, 10 mM MgH2PO4, 1 mM MgH2PO4, 10 mM glucose, 0.9 mM CaCl2) of 
RT and gradually warmed to 37°C. Next, the TS was replaced with 1 ml pre-warmed 
low-glucose DMEM supplemented with 1% heat-inactivated FBS, 1× penicillin-
streptomycin, 1× B-27 supplement minus antioxidants (Life Technologies Europe) 
and 5 μM Z-Asp-2,6-dichlorobenzoyloxymethylketone (Santa Cruz Biotechnology) 
and the tissue was kept at 37°C in humidified 95% air-5% CO2 (culture conditions) 
until histological examination. Culture medium was replaced every 2 days. 
 
Whole tissue staining and confocal microscopy 
Neonatal rat atrial tissue was quickly washed 3 times with PBS and fixed by 
incubation for 30 minutes at 4°C in buffered 4% formaldehyde (Added Pharma, Oss, 
the Netherlands) followed by 3 quick washes with PBS and a 5-minute wash with 
PBST (0.1% Triton X-100 Sigma-Aldrich in PBS). Next, aspecific binding sites were 
blocked by incubation for 1 hour at RT with 10% NDS in PBST. After two 10-minute 
washes with PBST, samples were incubated overnight at 4°C with primary antibodies 
directed against sarcomeric α-actinin to detect cardiomyocytes (mouse IgG1, clone 
EA-53; Sigma-Aldrich) or against eGFP to detect iAMs (rabbit IgG, polyclonal; 
Thermo Fisher Scientific, catalogue number: A11122) and diluted 1:200 in PBS-1% 
FBS. After 3 quick and four 15-minute washes with PBS, the tissues were incubated 
with appropriate Alexa Fluor 488/568-conjugated secondary antibodies of donkey 
origin (1:200 dilution in PBS containing 1% FBS) for 4 hours at 4°C followed by 
another sequence of 3 short and 4 long washes with PBS. Nuclear counterstaining was 
performed by incubating the cells for 10 minutes at RT with 10 µg/ml Hoechst 33342 
followed by 3 washes with PBS. Coverslips were mounted in Vectashield mounting 
medium (Vector Laboratories, Burlingame, CA). Images were acquired with a Leica 
TCS SP8 confocal laser scanning microscope (Leica Microsystems, Rijswijk, the 
Netherlands). For Z plane reconstruction, we acquired confocal stacks with a step size 
of 0.3 µm and analysed the resulting images using Leica Application Suite AF Lite 
software (Leica Microsystems). 
 




For monitoring the transfection efficiency of iAMs with plasmid DNA, we used the 
eGFP-encoding mammalian expression plasmid pU.CAG.eGFP. One day before 
transfection, iAMs were seeded at a density of 4.8×105 cells per well in a 24-well cell 
culture plate and maintained in iAM culture medium with dox. The next day, the cells 
were transfected with Lipofectamine 3000 reagent (Thermo Fisher Scientific) 
according to the manufacturer’s instructions. To this end, 50 μl of plasmid DNA-lipid 
complexes containing 500 ng of pU.CAG.eGFP DNA, 1 μl of P3000 reagent and 1.5 
μl of Lipofectamine 3000 reagent diluted in Opti-MEM I reduced serum medium 
(Thermo Fisher Scientific) were added per well to 500 µl of iAM culture medium 
without dox. At the indicated times after the start of the transfection procedure, the 
cells were processed for flow cytometry using a BD Accuri flow cytometer (BD 
Biosciences), (immuno)fluorescence microscopy and optical voltage mapping. For the 
cells that were analysed at day 9 post-transfection, the transfection medium was 




Data were derived from a specified number (N) of observations from 3 different cell 
cultures. Unless otherwise stated, data were expressed as mean±standard deviation 
(SD) and SDs were represented by error bars. All data were analysed with the nested 
ANOVA test using the Real Statistics Resource Pack software (release 5.1, copyright 
2013 – 2017, Charles Zaiontz, www.real-statistics.com). For comparisons 
involving >2 experimental groups, this test was followed by Bonferroni post-hoc 
analysis. Results were considered statistically significant at P values <0.05. Statistical 





Excitability of iAMs 
Short depolarizing current-clamp stimulations of single cells (10-20 ms, 100-300 pA, 
holding potential: -80 mV) were sufficient to evoke APs in pAMs (Figure S2B, left 
panel) and in a fraction of iAMs (Figure S2B, right panel). The fraction of these so-
called excitable iAMs gradually increased from ±35% at day 3 of culture in the 
absence of dox to ±90% at day 9 and 12 after the initiation of the differentiation 
process by dox removal (Figure S2C).  
The shapes of the pAM and iAM APs were similar based on the nearly 
identical APDs at 30 and 80% repolarization (APD30 and APD80, respectively). Also, 
the while the AP amplitudes of iAMs did not significantly differ from those of pAMs 
although iAMs had a smaller upstroke velocity and overshoot than pAMs (Table S3). 
Thus, overall, the excitability properties of pAMs and cardiomyogenically 
differentiated iAMs were rather similar. 
To investigate the ionic basic of the APs generated by iAMs, whole-cell 
membrane current was recorded using voltage steps applied from a holding potential 
of -90 mV to test potentials ranging from -130 through +70 mV. In pAMs (Figure 
S2B, left panel), the whole-cell current evoked by hyperpolarizing potentials was 
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inward and stationary and had the properties of an inward rectifier K+ current12. The 
magnitude of this current gradually declined to zero when increasing the potentials 
from -130 to -70 mV. Depolarization beyond a holding potential of -70 mV elicited a 
large, fast transient inward current with a time course typical of a fast voltage-
activated Na+ current, as in Ramos-Mondragon et al.13, and consistent with mRNA 
expression of Scn5a (Figure S1A). Upon further depolarization, the fast inward 
current became smaller and gradually gave way to a tiny outward current which, based 
on its electrophysiological characteristics and the RT-qPCR data, likely represents an 
outward rectifier K+ current. As shown in the right panel of Figure S2B, excitable 
iAMs displayed a similar total inward current as pAMs but a much stronger total 
outward current and no obvious inwardly rectifying K+ current (i.e. IK1), consistent 
with the absence of detectable Kcnj2 expression in iAMs (Figure S1H). Since IK1 is 
important for maintaining a stable negative RMP12, optical voltage mapping and 
patch-clamp studies were conducted to determine the role of the atrium-specific 
acetylcholine-activated K+ channels (i.e. Kir3.1 and Kir3.4) and the electrogenic 
Na+/K+ pump in regulating the RMP of cardiomyogenically differentiated iAMs 
(Figure S3).  
First, we applied the muscarinic receptor agonist carbachol to maximize IK,ACh 
currents in confluent pAM and cardiomyogenically differentiated iAM monolayers. 
Carbachol had no effect on the CV (Figure S3A and D) or RMP of the iAM (-67.5±2.5 
mV vs -67.1±2.6 mV in control cultures, N=8) and pAM (-64.5±1.9 mV vs -64.3±1.7 
mV, N=7) monolayers (Figure S3B and E). Also, no carbachol effect was measured in 
single pAMs (Figure S3F). However, iAMs dissociated from cardiomyogenically 
differentiated monolayers and subsequently cultured as single cells for 1-3 days 
showed a hyperpolarizing shift of -16.9±2.6 mV in the RMP after carbachol 
administration (Figure S3C), thereby approaching the RMP of pAMs. 
To determine the role of the Na+/K+ ATPase in maintaining a hyperpolarized 
RMP, its activity was inhibited in a graded manner by exposing pAM and 
cardiomyogenically differentiated iAM monolayers to increasing concentrations of 
ouabain. After ouabain administration, the CV decreased dose-dependently in both the 
pAM and iAM monolayers, although the iAM cultures seemed somewhat more 
sensitive to ouabain than the pAM cultures. Also, monolayers subjected to 300 and 
400 µM ouabain showed partial or full conduction block in optical mapping 
experiments (Figure S3G and J). These findings are consistent with the patch-clamp 
results, which showed a dose-dependent depolarizing effect of ouabain on the RMP of 
the monolayers (Figure S3H, I, K and L) due to both electrogenic effects and changes 
in the intracellular ion concentrations. To specifically investigate the electrogenic 
effects of the Na+/K+ pump, we performed single-cell patch-clamp measurements, 
because in these experiments the intra- and extracellular ion concentrations are fixed 
by the composition of the pipette and bath solutions, respectively. Since this gave a 
similar depolarizing effect of ouabain on the RMPs of pAMs and iAMs as found in 
the monolayer studies, we conclude that the Na+/K+ pump plays an important 
electrogenic role in maintaining a negative RMP in iAMs as well as pAMs. This result 
explains why iAM monolayers despite the lack of detectable Kcnj2 expression (Figure 
S1H) are able to generate a stable hyperpolarized RMP to maintain excitability. 




measurement conditions of the whole-cell patch-clamp (Figure S2A)14, but are easily 
repolarized by (full) activation of Kir3.x channels. 
In conclusion, the electrogenic contribution of the Na+/K+ pump to their RMP 
allows iAMs to display similar excitability properties as pAMs linked to the presence 
of similarly strong voltage-activated Na+ currents. 
 
iAMs as in vitro model for studying ion channel-drug interactions 
Drug-induced ventricular arrhythmias due to inadvertent blockade of the Kv11.1 
channel represents a major safety concern in drug development15. RT-qPCR analysis 
showed that the Kcnh2/Kv11.1 gene is highly expressed in iAMs peaking at 6 days 
after the initiation of differentiation. At this time, Kcnh2 transcripts were 16-fold more 
abundant in iAMs than in pAMs at culture day 9 (N=3, P<0.01; Figure S1G). Double 
immunostaining of these cells for Kv11.1 and sarcomeric α-actinin showed that both 
cell types expressed the Kv11.1 protein and that it was concentrated around the 
nucleus and at the sarcolemma (Figure S8A). To test whether iAMs could be used to 
identify unintended Kv11.1 blockers, the effect of exposing iAMs at day 6 of 
differentiation to 100 nM of the antihistamine astemizole, which was previously 
shown to efficiently and selectively block the Kv11.1 channel16, was studied by optical 
voltage mapping. Astemizole significantly increased APD at 40 and 90% 
repolarization (APD40 and APD90, respectively) from 21.5±1.0 and 88.7±5.4 ms in 
vehicle-treated cultures to 30.2±2.1 and 110.9±4.2 ms in cultures containing 100 nM 
astemizole (N=6, P<0.01; Figure S8B and C) without affecting CV (14.8±2.8 cm/s vs 
14.5±1.1 cm/s in control cultures; N=6, P=0.57; Figure S8D and E). These data 
demonstrate the presence of a detectable IKr in differentiating iAMs and show the 
utility of AM cultures as in vitro model to investigate the AP-prolonging effects of 
Kv11.1 blockers. 
 
Plasmid DNA transfection of iAMs 
The practical applicability of iAMs would benefit greatly from them being well 
transfectable with plasmid DNA. We hence tested whether iAMs would be amenable 
to plasmid DNA transfection with Lipofectamine 3000. Near-confluent cultures of 
proliferating iAMs were lipofected with the eGFP-encoding mammalian expression 
plasmid pU.CAG.eGFP in dox-free medium and transgene expression was assessed by 
direct fluorescence microscopy and flow cytometry at 2 and 9 days after dox removal 
(Figure S9A and B). At 2 days post-transfection, approximately 50% of the iAMs 
were eGFP+, which percentage did not decrease following incubation of the cells in 
dox-free medium for 7 more days. Importantly, transfected cells differentiated equally 
well into functional cardiomyocytes as their non-transduced counterparts judged from 
the results of α-actinin immunostaining (Figure S9C) and optical voltage mapping 
(Figure S9D) of the iAM cultures at 9 day after transfection. 
 
Engraftment of iAMs into viable neonatal rat atrium 
To investigate their ability of engraftment, we developed a transplantation model to 
study the engraftment of iAMs in neonatal rat atrium (Figure S10A). eGFP-labelled 
iAMs were cultured for 2 days in dox-free medium to initiate cardiomyogenic 
differentiation and subsequently injected into the atrium. Following iAM injection, the 
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atrium was excised and kept in culture for 6 days. The presence of spontaneous 
contractions at the end of the culture period demonstrated that the atrial tissue was still 
viable after 6 days of culture (Supplementary material online, Movie V). Confocal 
laser scanning microscopy of the tissue after fixation at the end of the culture period 
revealed the presence of eGFP+ cells throughout the atrium (Figure S10B). 
Immunostaining for α-actinin showed that many of the eGFP+ cells possessed highly 
organized sarcomeres (Figure S10B), whose length (i.e. distance between 2 Z-lines) 
did not significantly differ from that of pAMs (Figure S10C). Collectively, these data 
provide evidence for the cardiomyogenic differentiation and structural integration of 




Figure S1. Analysis by RT-qPCR of the expression of the cardiac ion channel genes 
Scn5a (A), Cacna1c (B), Kcnj3 (C), Kcnj5 (D), Kcnj11 (E), Kcnd3 (F), Kcnh2 (G), Kcnj2 
(H), Hcn2 (I) and Hcn4 (J) and the cardiac Ca2+-handling protein genes Ryr2 (K) and 
Atp2a2 (L) in pAMs and pVMs at day 9 of culture and in iAMs on the indicated days of 
differentiation. mRNA levels are expressed relative to those in 9-day-old pAM (pAM-d9) 







Figure S2. Single-cell patch-clamp analysis of pAMs and cardiomyogenically 
differentiated iAMs. (A) RMP of pAM monolayers (-64.5±1.2 mV, N=15), iAM monolayers 
(-67.5±1.6 mV, N=18 ), single pAMs (-63.9±1.5 mV, N=13) and single iAMs (-45.7±2.9 mV, 
N=12). (B) Whole-cell membrane current traces and APs of a pAM at culture day 3 (left) and 
an iAM kept in the absence of dox for 12 days (right). Before starting the measurement, the 
cells were clamped at a holding potential of -80 mV. (C) Graph showing the percentage of 
excitable iaCMCs at 3, 6, 9 and 12 days of differentiation. N=9, 9, 7 and 8 for iaCMC-d3, 
iaCMC-d6, iaCMC-d9 and iaCMC-d12, respectively. (D) Nav1.5 I-V relationship and INa 
current (i.e. TTX-sensitive current) densities in single pAMs and iAMs. Current density was 
obtained by normalizing peak Na+ currents to cell capacitance. (E) Steady-state of Nav1.5 
activation. pAM V½=-48.2±2.4 mV, slope factor=6.8±1.0 (N=5); iAM V½=-51.7±2.5 mV, 
slope factor=9.1±1.1 (N=6). Peak current densities and steady-state activation of single pAMs 
and iAMs were similar. Data are presented as mean±SEM. Statistics was done using the 
nested ANOVA test. *P<0.05. 
  




Figure S3. Electrophysiological analyses of pAM and iAM monolayers and single cells 
using optical voltage mapping and whole-cell patch-clamp recordings. Administration of 
2 μM of carbachol to 9-day-old pAM monolayers and cardiomyogenically differentiated iAM 
monolayers did not affect the CV of (A) iAM (N=10) and (D) pAM monolayers (N=7). 
Consistently, patch-clamp recordings showed no shift in the RMP of (B) iAM (N=9) and (E) 
pAM (N=7) monolayers after carbachol treatment. Also carbachol had no effect on the RMP 
of single 2-3 day-old pAMs (N=8). However, iAMs dissociated from monolayers that had 
maintained for 9 days in the absence of dox showed a significant shift in the RMP (-16.9±2.6 
mV, N=6) towards more negative potentials upon exposure to 2 µM carbachol. Statistics was 
done using the nested ANOVA test. Analysis by optical voltage mapping and whole-cell 
patch-clamp of cardiomyogenically differentiated iAM monolayers (G, N=6; and H, N=9) 
and single cells (I, N=6), as well as pAM monolayers (J, N=8; and K, N=8) and single cells 
(L, N=5) subjected to increasing concentrations of ouabain showed a significant dose-
dependent decrease in CV and a depolarization of the RMP. Thus, the Na+/K+ ATPase plays a 
crucial role in maintaining a stable negative RMP in both pAMs and iAMs. Statistics was 
done using the nested ANOVA test with Bonferroni post-hoc correction. Optical voltage 
mapping data are presented as mean±SD, patch-clamp data as mean±SEM. *P<0.05, 





Figure S4. Comparison by optical voltage mapping and 1-Hz electrical point stimulation 
of the electrophysiological properties of confluent 9-day-old cultures of pAMs, dox-
deprived eGFP-labelled iAMs (eGFP-iAMs) and 50% pAMs-50% eGFP-iAMs. (A) 
Bright field images (upper panel) and fluorescence images (lower panel) of each culture type. 
(B) Fluorescence image of 9-day-old pAM/eGFP-iAM co-culture immunostained for Cx43 
(red) showing its presence at interfaces between iAMs (green) and pAMs. Cell nuclei have 
been visualized by staining with Hoechst 33342 (blue). (C, D) Activation maps (C; 
isochrones are separated by 6 ms) and CV quantification (D) reveal no significant different in 
the speed of AP propagation between the 3 culture types. Data are presented as mean±SD, 
N=6 cell cultures per group from 3 individual preparations. Statistics was done using the 
nested ANOVA test with Bonferroni post-hoc correction. 





Figure S5. Comparison by optical voltage mapping and 1-Hz electrical point stimulation 
of APD30 and APD80 of pAMs and pVMs in 9-day-old cultures with those of iAMs at day 
9 of differentiation showing that the pVMs have much longer APDs than the atrial 







Figure S6. Comparison by optical voltage mapping and 1-Hz electrical point stimulation 
of the electrophysiological properties of iAMs at day 9 of differentiation (iAM-d9) that, 
after being cryopreserved, went through 25, 40 or 55 passage doublings (PDs) prior to 
dox removal. CV (A), APD30 (B) and APD80 (C) did not significantly differ between iAM-d9 
of different PD. Data are presented as mean±SD, N=12 cell cultures per group from 4 








Figure S7. Characterization by optical voltage mapping and 1-Hz electrical point 
stimulation of confluent monolayers of iAM clones #1 (A-C) and #6 (D-F). Typical 
activation maps (A, D; isochrones are separated by 6 ms) and optical signal traces (B, E) 
acquired at different days after dox removal showing an increase in CV and a decrease in 
APD with advancing iAM differentiation. (C, F) Quantification of CV, APD30 and APD80 at 
3, 6 and 9 days of iAM differentiation. Data are presented as mean±SD, N=12 cell cultures 
per group from 3 individual preparations. AUs, arbitrary units. 
  





Figure S8. Suitability of iAMs as in vitro model to assess the IKr-blocking potential of 
drugs by optical voltage mapping. (A) Immunofluorescence analysis of Kv11.1 protein 
expression in iAM-d6 cultures and in 9-day-old pAM cultures. (B-E) Optical signal traces (B), 
quantitative analyses of APD40 and APD90 (C), activation maps (D) and CV (E) following 1-
Hz pacing of iAM-d6 cultures exposed for 30 minutes to 100 nM astemizole or vehicle 
(control). Data are presented as mean±SD, N=6 cell cultures per group from 3 individual 
preparations. For statistical analysis, the nested ANOVA test was used. AUs, arbitrary units. 







Figure S9. Transient transfection of iAMs with plasmid DNA. (A) Direct fluorescent 
images of iAMs immediately prior to lipofection (day 0) with the eGFP-encoding mammalian 
expression plasmid pU.CAG.eGFP (left panel) and following maintenance, after transfection, 
for 2 or 9 days in culture medium without dox (middle and right panel, respectively). (B) 
Quantification, by flow cytometry, of the percentage of eGFP+ cells in the cultures shown in 
(A). (C) Fluoromicrograph of an iAM culture that was transfected with pU.CAG.eGFP, 
subsequently maintained for 9 days in dox-free culture medium and finally immunostained 
for sarcomeric α-actinin. (D) Activation maps (6-ms isochrone spacing) of untransfected (-
pU.CAG.eGFP) and pU.CAG.eGFP-transfected (+pU.CAG.eGFP) iAM cultures kept for 9 
days in dox-free culture medium. 





Figure S10. Structural integration of iAMs into neonatal rat atrium. (A) Experimental 
design to assess the engraftment and cardiomyogenic differentiation potential of iAMs 
following their injection into neonatal rat atrium. A, atrium. (B) Analysis by confocal laser 
scanning fluorescence microscopy of the presence and phenotype of eGFP-labelled iAMs 
following double immunostaining for eGFP (green) and sarcomeric α-actinin (red) and 
labelling of cell nuclei with Hoechst 33342 (blue). The 2 small panels in the middle row 
represent higher magnifications of the upper 2 eGFP+ cells in the adjacent larger panel. A 
series of YZ reconstructions of the eGFP+ cell-rich zone in this panel (area demarcated by 
white lines) is shown in the bottom panel. (C) Sarcomere lengths of endogenous pAMs and of 
iAMs that underwent cardiomyogenic differentiation following intra-atrial injection. Data are 
presented as mean±SD, N=15 cells per experimental group from 3 individual preparations. 





Figure S11. Activity of the MHCK7 promoter in proliferating iAMs and in iAMs at 
different days after initiation of cardiomyogenic differentiation. (A) Map of LV shuttle 
plasmid pLV.MHCK7.eGFP eGFP, eGFP-coding sequence. WHVoPRE, optimized version 
of the WHVPRE6, SIN-LTR, 3’ long terminal repeat containing a 400-bp deletion in unique 
region 3 rendering the corresponding LV self-inactivating17. For an explanation of the other 
abbreviations, see Figure 1A. (B) Fluoromicrographs of LV.MHCK7.eGFP-transduced iAMs 
showing an increase in MHCK7 promoter activity, as evinced by an increase in eGFP 




Movie I. iAM culture at 6 days after dox removal showing spontaneously contracting 
cells. 
 
Movie II. iAM culture at 9 days after dox removal showing rhythmic contractions 
evoked by 1-Hz electrical point stimulation. 
 
Movie III. Optical voltage recordings showing spreading of action potentials in a 9-
day-old pAM culture, iAM cultures at 3 and 9 days after dox removal and an HL-1 
culture following 1-Hz electrical point stimulation. The movie is played at 1/8th of the 
normal speed. 
 
Movie IV. iAM culture at 9 days after dox removal showing reentrant conduction 
provoked by high-frequency electrical point stimulation. The movie is played at 1/8th 
of the normal speed. 
 
Movie V. Neonatal rat atrial tissue injected with eGFP-labelled iAMs and kept in 
culture for 6 days showing spontaneous contractions. 
  





For most parenchymal cell types including cardiomyocytes, proliferation and 
(terminal) differentiation are mutually exclusive processes. Permanent LT expression, 
as occurs in the AT-118, HL-119 and AC20 lines therefore does not allow the generation 
of homogeneous populations of differentiated cells. For HL-1 cells, this problem was 
partially overcome by culturing them in a highly specialized medium promoting their 
cardiomyogenic differentiation21. In order to control LT activity, Jahn et al. 22 and 
Goldman et al.23 relied on a temperature-sensitive version of the LT antigen (i.e. LT 
mutant tsA58) to immortalize neonatal rat and human foetal cardiomyocytes, 
respectively. Culturing of the neonatal rat cardiomyocytes at the non-permissive 
temperature of 39°C promoted their cardiomyogenic differentiation but still didn’t 
yield excitable cells with well-developed sarcomeres whereas the human foetal 
cardiomyocytes failed to express cardiac differentiation markers at both the restrictive 
and permissive temperature. As an alternative method to control LT activity, Rybkin 
et al. generated transgenic mice containing an LT expression cassette under the 
control of cardiac-specific transcriptional regulatory elements of the murine Nkx2.5 
gene from which the LT-coding sequence could be excised using Cre recombinase. 
Cells isolated from the subendocardial tumor-like structures in the hearts of these 
animals could be serially passaged >50 times without showing obvious signs of 
senescence. Following removal of the LT-coding sequence by transduction with an 
adenovirus vector expressing Cre recombinase, the cells developed sarcomeres and 
some of them produced weak and slow Ca2+ transients after electrical stimulation. 
This, however, only occurred in low-serum medium containing insulin, transferrin and 
selenium or after ectopic expression of cardiomyogenic factors and did not result in 
the generation of contractile cells. Zhang et al.24 also relied on the Cre-LoxP site-
specific recombination system to generate lines of conditionally immortalized pVMs. 
Cre-mediated removal of the LT expression module and exposure to cardiomyogenic 
differentiation conditions did, however, not give rise to excitable or contractile cells. 
The aforementioned immortalization strategy in which the immortalization 
gene is flanked with recombinase recognition sites to allow its excision following cell 
amplification thereby facilitating redifferentiation of the cells has some inherent 
disadvantages. Firstly, immortalization and subsequent deimmortalization of the cells 
requires two consecutive genetic manipulations. Secondly, due to the specific nature 
of the recombinase-mediated excision reaction, repeated switching between 
proliferative and differentiated cell states is impractical making deimmortalization 
essentially an irreversible process. Thirdly, recombinase-mediated excision reactions 
are never complete. Consequently, after recombinase treatment of a cell population 
there will always be a small fraction of cells that have retained the immortalization 
gene. As these cells will have a proliferative advantage, they will gradually “overgrow” 
the deimmortalized cells in the culture. 
These drawbacks and the poor cardiomyogenic differentiation capacity of the 
deimmortalized cardiac muscle cell lines generated by Rybkin et al.25 and Zhang et 
al.24 prompted us to test another conditional immortalization strategy in an attempt to 
generate (fully) differentiation-competent cardiomyocyte lines. By transducing pAMs 




LT antigen, we succeeded to establish lines of cardiomyocytes showing rapid 
expansion in the presence of dox, while in its absence, the cells spontaneously and 
synchronously differentiated into fully functional (i.e. excitable and contractile) AMs. 
As primary cultures of pAMs inevitably contain some non-cardiomyocytes 
(mainly cardiac fibroblasts), the myocyte-specific MHCK7 promoter4,5 was chosen to 
drive LT expression to avoid the fortuitous generation of non-cardiomyocyte clones. 
The success of this strategy critically depended on the MHCK7 promoter remaining 
active following the dedifferentiation of the AMs. Comparison of MHCK7 promoter 
activity in proliferating and differentiating AMs (Figure S11) showed that this was 
indeed the case. Cardiomyogenic differentiation led to an increase in the 
transcriptional activity of this promoter, consistent with the upregulation of cardiac 
transcription factor gene expression (Figure 3A). Nonetheless, LT expression was not 
detectable in differentiated iAMs either by western blotting or by IFM (Figure 1C-E). 
Concordantly, expression of the proliferation marker Ki-67 quickly ceased in the 
absence of dox (Figure 2B and F) indicating that soon after dox removal LT levels 
became too low to stimulate cell division.  
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Table S1 Primer pairs used for gene expression analysis  
Gene Forward primer Reverse primer 
Actn2 GGCTATGAGGAATGGCTATTGA AAGTAGGGCTCGAACTTCC 
Atp2a2 TGACCCACGAGCTGTTAATC GGTGTTCTCTCCTGTTCTGT 
Cacna1c CAAGGTGGTACACGAAGCTCA ACAGTGCTGCCCCTGGAGTA 
Gata4 GGCTCTCTGGGAAACTGG GAGGTGCCTAGTCCTTGC 
Kcnd3 CAACTTTAGCAGGATCTACCATC AGAGCTTCATTGAGGAGTCCA 
Kcnh2 TAGCCTCCTCAACATCCC CCATGTCTGCACTTAGCC 
Kcnj2 GGATCTTACATGCTTCTGTAACC CAGAGAACTTGTCCTGTTGC 
Kcnj3 ACAGCCACATGGTCTCC CCAGTTCAAGTTGGTCAAGG 
Kcnj5 GGTTGTGGTCATACTAGAAGGG GCAGTCATATCTGCCTTGGG 
Kncj11 GGAAGACCCGGAGGTAATAAG CTCCACTCAGCTATCCTTCAC 
Mef2c GATTCAGATCACGAGGATTATGG GTGCTGTTGAAGATGATCAGG 
Myh6 CTACCAGATCCTGTCCAACAA GCACATCAAAGGCGCTATC 
Myh7 CACCAAGAGGGTCATCCAATA CCAAATCGGGAGGAGTTATCA 
Myl2 TTTGAGCAGACCCAGATCC ACGTGTCCCTTAGGTCATTC 
Myl3 GCTCTGGGACAGAATCCTAC TCTTGGAGTTGAGCTCTTCC 
Myl4 TCAGGGACTCTGCCTTTG CCTCTTTGAATTCTTCGATCTGG 
Myl7 TCAATGTTCGAGCAAGCC CTGACTTGCAGATGATTCCG 
Nkx2.5 CTCCCACCTTTAGGAGAAGG CGAGGCATCAGGTTAGGTC 
Nppa CCAAGGGCTTCTTCCTCTTC CTCATCTTCTACCGGCATCTTC 
Rn18s GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
Ryr2 AACTGGCCTTTGATGTTGGC AATATGAGGTCGTCTCCAACCC 






Table S2 Antibodies 













Ki-67 rabbit 1:200 (IC) Abcam Ab15580 
Sarcomeric α-
actinin 
mouse 1:200 (IC) Sigma-Aldrich A7811 




Cx43 rabbit 1:200 (IC) Sigma-Aldrich C6219 
Kv11.1 rabbit 1:200 (IC) Millipore AB5930 




Antigen Host  Supplier Conjugate 













WB, western blotting; IC, immunocytology. 
 
 
Table S3 AP properties of pAMs and iAMs 
 pAM (N=13) iAM (N=15) 
Upstroke velocity (mV/ms) 19.1±1.9 11.4±1.2** 
AP amplitude (mV) 108.3±4.0 94.4±2.3 
Overshoot (mV) 23.8±3.7 13.9±2.4* 
APD30 (ms) 20.5±2.6 19.5±1.3 
APD80 (ms) 74.2±9.5 70.0±6.9 
Data represent mean±standard error of the mean (SEM). Statistical analysis was done 
using the nested ANOVA test. *P<0.05; **P<0.01 
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Brown adipose tissue (BAT) is regarded as a potential target to treat obesity and 
associated metabolic disorders because of its capacity to take up and combust glucose 
and fatty acids for thermoregulation. However, its cellular and molecular investigation 
has been hampered due to high cellular heterogeneity and a limited availability of cell 
material. In this study, monoclonal lines of conditionally immortalized brown 
preadipocytes (iBPAs) were generated, using mouse BAT as starting material. These 
cell lines retain long-term proliferation as well as adipogenic capacity. RT-qPCR 
analyses showed that brown fat markers including uncoupling protein 1 (Ucp1) were 
highly expressed in brown fat cells differentiated from iBPAs. Furthermore, the 
differentiated cells responded to β3-adrenergic stimulation by increasing glycerol 
release and Ucp1 expression. iBPA-derived brown fat cells may represent an easy-to-
use model system for fundamental and applied research into BAT. 
  






Obesity results from energy intake exceeding expenditure and is a major risk factor 
for metabolic disorders. A positive energy balance leads to storage of excess energy 
mainly in adipose tissue1,2. In mammals, two major types of functionally distinct 
adipose tissue exist, i.e. white adipose tissue (WAT) and brown adipose tissue (BAT)3. 
WAT is specialized in storing energy in the form of triglycerides4-6, while brown 
adipocytes dissipate energy for heat production by uncoupling the electron transport 
chain from ATP synthesis through expression of uncoupling protein 1 (UCP1)4,7-11. As 
a result, BAT represents a therapeutic target to enhance energy expenditure and 
combat obesity and related metabolic disorders2,12,13. 
The development of therapeutic strategies based on BAT is hampered by the 
lack of proper brown adipocyte cell culture models. As mature adipocytes are post-
mitotic and thus unable to multiply themselves in vitro, the formation of sufficient 
brown adipocytes for experiments requires proliferation and differentiation of 
adipocyte precursors. Over the last years, a number of different murine brown 
preadipocyte (BPA) lines have been generated such as BFC-114, HB215, HIB 1B16,17 
and T37i18. Although these cell lines have been helpful in increasing the 
understanding of adipocyte biology, they all possess some inherent disadvantages 
limiting their usefulness as model systems to study the properties of brown fat. BCF-1 
cells are spontaneously immortalized cells derived from interscapular BAT but do not 
express detectable amounts of Ucp1 following differentiation even after adrenergic 
stimulation with isoproterenol19. HB2 cells are brown preadipocytes isolated from the 
interscapular BAT of p53 knockout mice, while HIB 1B and T37i cells were derived 
from transgenic mice expressing the simian virus 40 (SV40) large T (LT) antigen 
using constitutively active, lineage-restricted promoters to drive transgene expression. 
While these transgenic cells all express Ucp1 following adipogenic differentiation and 
proper stimulation, their gene expression profiles may not accurately recapitulate that 
of native brown fat cells as both p53 and LT have been shown to affect formation of 
brown adipocytes20,21. Moreover, continuous proliferation pressure due to permanent 
immortalization may alter the differentiation capacity of BPAs causing their 
differentiated progeny to functionally differ from primary brown fat cells. Indeed, 
HB2 cells display a passage number-dependent decrease in the ability to express Ucp1 
following adipogenic differentiation and adrenergic stimulation15. These drawbacks 
prompted us to generate conditionally immortalized monoclonal BPA (iBPA) lines of 
mice by using a lentiviral vector (LV) expressing LT in a doxycycline 
(dox)/tetracycline-dependent manner to control cell proliferation22. The resulting 
monoclonal cell lines were characterized in terms of their dox-dependent LT 
expression level and proliferation capacity and their ability to undergo adipogenic 
differentiation in the presence of insulin and rosiglitazone using multilocular lipid 
droplet formation and expression of brown fat marker genes as read-out systems. 
Finally, the effects of adrenergic stimulation on the glycerol secretion and Ucp1 
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Materials and Methods 
 
Construction of plasmids 
DNA constructions were carried out with enzymes from Fermentas (Thermo Fisher 
Scientific, Breda, the Netherlands) or from New England Biolabs (Bioke´, Leiden, the 
Netherlands) and with oligodeoxyribonucleotides from Sigma-Aldrich (Zwijndrecht, 
the Netherlands) using established procedures or following the instructions provided 
with specific reagents. 
Plasmid pAT153.SV40ori(-)tsA58, which codes for the temperature-sensitive 
mutant of the oncogenic SV40 LT antigen designated tsA5823, was used as template in 
a polymerase chain reaction (PCR) with VELOCITY DNA polymerase (GC Biotech, 
Alphen aan den Rijn, the Netherlands) and primers 5’ 
AAGGATCCGTGCACCATGGATAAAGTTTTAAACAGAGAGGA 3’ and 5’ 
CCGAATTCTTTATGTTTCAGGTTCAGGG 3’ (the LT initiation codon and the 
complement of its termination codon are underlined). The resulting PCR fragment was 
inserted into plasmid pJET1.2/blunt using the CloneJET PCR cloning kit (Thermo 
Fisher Scientific) to generate pJet1.2.LT-tsA58. pJet1.2.LT-tsA58 was incubated with 
BamHI and EcoRI and the 2.5-kb digestion product was combined with the 11.5-kb 
BamHI×EcoRI fragment of SIN-LV shuttle plasmid pLVET.tTS.dEcoRI to generate 
pLV.ihEEF1A1.LT-tsA58. pLVET.tTS.dEcoRI is a derivative of pLVET-tTR-
KRAB22 (Addgene, Cambridge, MA; plasmid number: 116444). It was made by 
digestion of pLVET-tTR-KRAB with EcoRI and NheI and ligation of the resulting 
1.6-kb fragment encoding the encephalomyocarditis virus internal ribosomal entry site 
and the tetracycline-controlled transrepressor protein TetR-KRAB24 to the 10.8-kb 
EcoRI×BcuI fragment of pLVET-tTR-KRAB. 
  
LV production 
LV production was carried out as detailed before25. To generate vesicular stomatitis 
virus G protein-pseudotyped particles of LV.ihEEF1A1.LT-tsA58, subconfluent 
monolayers of 293T cells were transfected with LV shuttle construct 
pLV.ihEEF1A1.LT-tsA58 and the packaging plasmids psPAX2 (Addgene; plasmid 
number: 12260) and pLP/VSVG (Thermo Fisher Scientific) at a molar ratio of 2:1:1. 
The 293T cells were cultured in high-glucose Dulbecco’s modified Eagle’s medium 
(DMEM; Life Technologies Europe, Bleiswijk, the Netherlands; catalogue number: 
41966) with 10% fetal bovine serum (FBS; Life Technologies Europe). The 
transfection mixture consisted of 35 µg of plasmid DNA and 105 µg of 
polyethyleneimine (Polysciences Europe, Eppelheim, Germany) in 2 ml of 150 mM 
NaCl per 175-cm2 cell culture flask (Greiner Bio-One, Alphen aan den Rijn, the 
Netherlands) and was directly added to the culture medium. The next morning, the 
transfection medium was replaced by 15 ml of fresh high-glucose DMEM 
supplemented with 5% FBS and 25 mM HEPES-NaOH (pH 7.4). At ± 48 hours after 
the addition of plasmid DNA to the producer cells , the culture supernatants were 
harvested and cleared from cellular debris by centrifugation at room temperature (RT) 
for 10 min at 3,750×g and subsequent filtration through 0.45-µm pore-sized, 33-mm 
diameter polyethersulfone Millex-HP syringe filters (Millipore, Amsterdam, the 
Netherlands). To concentrate and purify the LV particles, 30 ml of vector suspension 




in a 38.5-ml polypropylene ultracentrifuge tube (Beckman Coulter Nederland, 
Woerden, the Netherlands) was underlayed with 5 ml of 20% (wt/vol) sucrose in 
phosphate-buffered saline (PBS) and spun for 120 min at 4°C with slow acceleration 
and without braking at 15,000 revolutions per min in an SW32 rotor (Beckman 
Coulter Nederland). Next, the supernatants were removed and the pellets were 
suspended in PBS-1% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO) 
by overnight incubation with gentle shaking at 4°C. The concentrated vector 
suspension was divided on ice in 50 µl aliquots for storage at -80°C. 
 
Isolation and culture of primary murine BPAs  
Primary murine BPAs were isolated from the interscapular BAT depot of 4-week-old 
male C57Bl/6J mice (Charles River Laboratories International, Wilmington, MA). 
Isolated tissue was minced with scissor into 3- to 4-mm pieces, washed once with 
DMEM/F-12 GlutaMAX (Thermo Fisher Scientific; catalogue number: 10565018) 
and incubated in DMEM/F-12 GlutaMAX containing 1 mg/mL collagenase type I 
(Thermo Fisher Scientific; catalog number: 17018029) at 37°C for 45 min. After 
centrifugation and resuspension in growth medium (DMEM/F-12 GlutaMAX 
supplemented with 10% heat-inactivated FBS, 100 U/mL penicillin and 100 µg/mL 
streptomycin), cells were filtered through a 200-µm pore-sized nylon filter (Sefar, 
Lochem, the Netherlands; catalogue number: 03-200/39) and seeded into a culture 
flask. Growth medium was replaced the following day and then every other day.  
 
Transduction of primary murine BPAs and generation of lines of conditionally 
immortalized mouse BPAs 
At passage two, i.e. after approximately 8 population doublings (PDs), the primary 
murine BPAs were transduced with LV.ihEEF1a1.SV40-LT-tsA58. The next day, the 
inoculum was replaced by growth medium containing 100 ng/ml dox (Sigma-Aldrich) 
to induce LT expression. The cells were subsequently given fresh growth medium 
with dox every other day. After 1 week of culture, the transduced cells were 
trypsinized and plated at a low density of 10~20 cells/cm2 to allow formation of 
single-cell clones. Two to 3 weeks later, individual cell colonies were picked and 
separately expanded in the presence of dox.  
 
Culture, differentiation and adrenergic stimulation of murine iBPAs 
Murine BPA clones were cultured in growth medium supplemented with 100 ng/mL 
dox. Growth medium was replaced every other day and cells were split 1:8 after 
reaching approximately 70% confluency. For differentiation, cells were allowed to 
grow confluent and 2 days later exposed to growth medium containing 5.6 nM bovine 
insulin (Sigma-Aldrich; catalogue number: I0305000), 25 µg/mL sodium ascorbate 
(Sigma-Aldrich; catalogue number: A-7631) and 1 µM of the peroxisome proliferator-
activated receptor γ agonist rosiglitazone (Sigma-Aldrich; catalogue number: R2408), 
10 mM HEPES (adjusted to pH 7.40 with NaOH). This so-called adipogenic 
differentiation medium was replaced every other day and the various clones were 
screened for their adipogenic capacity, i.e. their ability to develop multilocular lipid 
droplets and to express the brown fat marker gene Ucp1. Next, differentiated BPAs 
were stimulated with 1 µM of the broad-spectrum adrenoreceptor agonist noradrenalin 
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(NA), 10 µM of the highly selective β3 adrenoreceptor agonist CL316243 or vehicle 
(PBS) for 8 hours. Subsequently, supernatant was collected for colorimetric 
determination of glycerol production (INstruchemie, Delfzijl, the Netherlands) and 
cells were lysed in TriPure (Roche Life Science, Almere, the Netherlands) for RNA 
and protein analysis as described below.  
 
Analysis of cell proliferation  
To draw growth curves, the primary murine BPAs and conditionally immortalized 
cells were subcultured 1:4 and 1:8 on reaching confluency so that each passage 
corresponded to 2 and 3 PDs, respectively. To assess their proliferation rate and 
dependence on the activity of SV40 LT antigen, the murine iBPAs were cultured at 
low density in medium with or without 100 ng/ml dox. At different days after culture 
initiation, cells were collected in medium and counted using an Accuri flow cytometer 
(BD Biosciences, Breda, the Netherlands). 
 
Western blotting 
Western blotting was carried out as detailed before26. After blocking, the membranes 
were incubated overnight at 4°C with primary mouse monoclonal antibodies directed 
against LT (1:2,000; Santa Cruz Biotechnology, Dallas, TX; catalogue number: sc-
147) or glyceraldehyde 3-phosphate dehydrogenase (GAPDH; loading control; 
1:100,000; Millipore; catalogue number: MAB374) and then probed with goat anti-
mouse IgG secondary antibodies linked to horseradish peroxidase (1:15,000; Santa 
Cruz Biotechnology) for 1 hour at RT. Chemiluminescence was produced using the 
SuperSignal West Femto maximum sensitivity substrate (Thermo Fisher Scientific), 
captured by a ChemiDoc XRS imaging system (Bio-Rad Laboratories, Veenendaal, 
the Netherlands) and analysed by Quantity One software (Bio-Rad Laboratories) using 
the GAPDH signals for normalization purposes.  
 
Immunocytology 
Cells were processed for immunostaining as previously described27. Detection of LT 
was done with the same primary antibody as used for the analysis of LT expression by 
western blotting. Actively replicating were detected using polyclonal rabbit anti-Ki-67 
antibodies (Abcam, Cambridge, United Kingdom; catalogue number: ab15580), The 
primary antibodies were diluted 1:200 in PBS containing 0.1% normal donkey serum 
(Sigma-Aldrich) and left on the cells overnight at 4°C. Bound antigens were detected 
using Alexa 488-conjugated donkey anti-rabbit IgG (H+L) (Thermo Fisher Scientific; 
catalogue number: A21206) and Alexa 568-coupled donkey anti-mouse IgG (H+L) 
(Thermo Fisher Scientific; catalogue number: A10037). These secondary antibodies 
were diluted 1:400 in PBS. Hoechst 33342 (10 µg/µl; Thermo Fisher Scientific) was 
used to counterstain nuclei. Stained cells were visualized using a digital color camera-
equipped fluorescence microscope (Nikon Eclipse 80i; Nikon Instruments Europe, 
Amstelveen, the Netherlands). 
 
RNA isolation, cDNA synthesis and reverse transcription-quantitative PCR (RT-
qPCR) analysis 




Every other day, starting from day 0 to day 14 of differentiation, cells (n=4 cultures 
per time point and experimental group) were lysed in TriPure. After RNA extraction, 
cDNA synthesis was performed using M-MLV reverse transcriptase (Promega 
Benelux, Leiden, the Netherlands; catalogue number: M1705), random primers, 
dNTPs and RNasin ribonuclease inhibitor (all from Promega Benelux) and 1 µg of 
input RNA. Real-time PCR was carried out on a CFX96 PCR machine (Bio-Rad 
Laboratories, Veenendaal, the Netherlands) using GoTaq qPCR master mix (Promega 
Benelux; catalogue number: A6002). mRNA expression was normalized to that of the 
ribosomal protein-encoding housekeeping gene Rplp0, also known as 36b4. Data was 
expressed as means ± standard error of the mean (SEM) of arbitrary units determined 
using the 2-ΔCT method. The intron-spanning primer pairs used are listed in Table 1.  
 
Table 1 – List of primer sequences for RT-qPCR 

















Prdm16 ACTTTGGATGGGAGCAGATG CTCCAGGCTCGATGTCCTTA 
Ucp1 TCAGGATTGGCCTCTACGAC TGCATTCTGACCTTCACGAC 
 
Statistical analysis 
Data are represented as mean ± SEM. Effect of adrenergic stimuli on BPAs was 
analysed by two-way ANOVA with Dunnet’s post hoc test. GraphPad Prism version 
6.0 (GraphPad Software, La Jolla, CA) was used for all calculations. Differences at P 




Generation of iBPAs 
Since primary BPAs gradually become senescent and stop proliferating at about PD18 
(Figure 1B), the cells were transduced with an LV conferring dox-dependent 
expression of the betapolyomavirus oncoprotein LT (Figure 1A) and kept in dox-
containing culture medium. In contrast to untransduced control cells (nBPAs) , the 
LT-expressing BPAs kept proliferating at the same speed for at least 60 PDs without 
showing any conspicuous signs of senescence (Figure 1B). To directly compare their 
proliferation rate and morphology, equal numbers of nBPAs and transduced BPAs 
(tBPAs) from PD18 were plated at a cell density corresponding to a confluency of 20% 
and cultured in medium without (nBPAs, tBPAs) or with (tBPAs) dox. Four days later 
microscopic images were taken. Whereas the cell density of the nBPAs remained 
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constant, the confluency of the dox-treated tBPA cultures increased to approximately 
40 and 90% in the absence and presence of dox, respectively (Figure 1C). Moreover, 
after transduction, the cells maintained a fibroblast-like morphology (Figure 1C). 
Western blot analysis and immunofluorescence microscopy confirmed LT expression 
in tBPAs but not in nBPAs (Figure 1D and E). Taken together, the expression of LT 
enabled BPAs to continuously proliferate and bypass senescence, therefore, we named 
these cells immortalized BPAs (iBPAs).  
 
iBPAs are clonogenic and possess long-term inducible expansion capacity 
From over 50 rapidly growing cell clones, clone #6 was picked to further study the 
long-term dox-dependent proliferation capacity of iBPAs since it was one of the most 
adipogenic clones (see below). First, LT expression of clone #6 cells of PD40 and 
PD100 before (day 0) and after (day 2, 4, 6 and 8) dox removal were compared by 
western blotting and immunofluorescence staining. Both PD40 and PD100 cells 
displayed dox-inducible LT expression, i.e. LT was highly expressed in the presence 
of dox, and LT levels gradually dropped in its absence, being no longer detectable at 6 
days after dox removal (Figure 2A, B and C). Moreover, quantitative analysis of the 
western blot data showed no statistically significant difference in LT levels between 
PD40 and PD100 iBPAs cultured in the presence, or for different days, in the absence 
of dox (Figure 2B and C). Consistently, iBPAs of PD40 and PD100 possessed very 
similar dox-inducible proliferation capacity as shown by immunostaining for the 
cellular proliferation marker Ki-67 (Supplementary Figure 1). In the presence of dox, 
cells proliferated with an average doubling time of 19 hours, whereas in the absence 
of dox, the cell number slightly increased up to day 4 and then stayed constant in both 
PD40 as well as PD100 iBPAs (Figure 2D). The small increase in the number of 
iBPAs during the first 4 days after dox removal, which is also evident in Fig. 1C, is 
likely due to the slow decline of the LT level following transgene silencing. To sum 
up, iBPAs maintain a high proliferation rate for at least 100 PDs. 





Figure 1. Conditional immortalization of BPAs 
(A) Schematic representation of LV shuttle plasmid and protocol to generate conditionally 
immortalized BPAs. Ori, bacterial origin of replication. AmpR, Escherichia coli ß-lactamase 
gene. LTR, human immunodeficiency virus type 1 (HIV1) long terminal repeat. Ψ, HIV1 
packaging signal. RRE, HIV1 Rev-responsive element. cPPT, HIV1 central polypurine tract 
and termination site. hEEF1α1, human eukaryotic translation elongation factor 1A1 gene 
promoter. LT, coding sequence of the temperature-sensitive mutant LT protein tsA5834. IRES, 
encephalomyocarditis virus internal ribosome entry site. tTS, coding sequence of the hybrid 
tetracycline-controlled transcriptional repressor TetR-KRAB24. WHVPRE, woodchuck 
hepatitis virus posttranscriptional regulatory element. TRE, tetracycline-responsive promoter 
element consisting of 7 repeats of a 19-nucleotide tetracycline operator (tetO) sequence. (B) 
Growth curves of nBPAs and tBPAs. The tBPAs continued to expand after the nBPAs had 
become senescent. Cells were cultured in the presence of dox. (C) Microscopic images 
showing the cell density and morphology at PD18 of nBPAs cultured with dox and of tBPAs 
cultured with or without dox. (D, E) Confirmation of LT expression in dox-exposed tBPAs 
(PD 18) by western blot and immunofluorescence staining. In both cases, dox-treated nBPAs 
of PD 18 served as negative controls.  




Figure 2. Dox-dependent LT expression and proliferation of iBPAs. 
(A) Fluorographs of clone #6 iBPAs of PB40 and PD100 stained with the DNA binding dye 
Hoechst 33342 (blue) and for the SV40 LT protein (red) before (0) and at 2, 4, 6 and 8 days 
after dox removal. (B, C) Western blot analysis of LT expression of clone #6 iBPAs at PD40 
and PD100 before (0) and at 2, 4, 6 and 8 days after dox removal. (D) Quantification of cell 
numbers in PD40 and PD100 cultures of clone #6 iBPAs exposed for the indicated days to 
medium with or without dox. 




iBPAs possess adipogenic capacity  
In order to assess the adipogenic capacity, cells from each clone were cultured in 
growth medium and when these clonal preadipocyte cell lines reached 100% 
confluence, dox was removed from the culture at which time point the cells were 
induced to differentiate to brown adipocytes under adipogenic culture conditions for 
14 days (Figure 3A). Clone #6 and #7 cells were most adipogenic based on the extent 
of lipid droplet formation and Ucp1 expression level (Supplementary Figure 2). To 
better characterize the adipogenic potential of these two clones, microscopic images of 
cell cultures subjected to adipogenic differentiation conditions were taken every two 
days. The cells of both clones gradually accumulated small lipid droplets acquiring the 
multilocular typical for brown fat cells and after 14 days of adipogenic differentiation > 
90% of the cells was lipid-laden (Figure 3B). PD40 iBPAs were further analysed by 
RT-qPCR to assess the expression of brown adipocyte markers in the time course of 
differentiation. The unique brown fat marker Ucp1 showed a robust induction at the 
RNA level starting at day 4 of adipogenic differentiation for both clones (Figure 3C). 
Ucp1 peaked at differentiation day 12 for clone #6 and at differentiation day 10 for 
clone #7 (Figure 3C). The transcriptional coactivators PR domain containing 16 
(Prdm16, Figure 3D) and peroxisome proliferator-activated receptor gamma 
coactivator 1-α (Ppargc1a, Figure 3E), the peroxisome proliferator-activated receptor 
γ (Pparg, Figure 3F), fatty acid binding protein 4 (Fabp4, Figure 3G) and lipoprotein 
lipase (Lpl, Figure 3H) followed similar patterns of expression, i.e. expression of all 
these markers was induced from the start of adipogenic differentiation and, except for 
Lpl, peaked at differentiation day 12. Based on these data, we conclude that following 
conditional immortalization primary murine BPAs retain their adipogenic capacity 
and that optimal differentiation of iBPAs is reached at 12-14 days after initiation of 
adipogenesis. 
 
Extensive proliferation reduces the adipogenic capacity of iBPAs 
There is no reduction in the adipogenic capacity of iBPAs at least until PD64 (data not 
shown). To study what would happen afterwards, clone #6 and #7 cells at PD100 were 
exposed to adipogenic differentiation medium and the expression patterns of the 
brown fat marker genes were assessed. After 100 doublings, only approximately 30% 
of the cells contained multiple lipid droplets at differentiation day 14 (Supplementary 
Figure 3) indicating incompletely preservation of adipogenic capacity. Moreover, the 
expression of Ucp1 in clone #6 cells was up to 50-fold lower at PD100 than at PD40. 
However, exposure to adipogenic differentiation medium still resulted in an 
approximately 1000-fold upregulation of Ucp1 expression at differentiation day 12 
(Figure 4A). In contrast, clone #7 cells of PD100 showed hardly any increase in Ucp1 
expression following adipogenic stimulation (Figure 4A). Both clone #6 and #7 cells 
showed a clear increase in the expression of the other brown fat marker genes after 
exposure to adipogenic differentiation conditions (Figure 4B-F). However, for all 
these gene, expression was lower at PD100 than at PD40, except for Lpl, which was 
higher expressed at PD100 (Figure 4G). Moreover, the expression of these genes did 
not peak at day 12 of differentiation as observed at PD40, but earlier. In conclusion, 
late passage iBPAs differentiate less well into brown adipocytes than early passage 
iBPAs based on lipid droplet formation and brown fat marker gene expression.  
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 Figure 3. Comparison of the adipogenic potential of 2 different iBPA clones. (A) 
Protocol used to differentiate iBPAs towards brown adipocytes. (B) Phase contrast images 
showing the morphological changes associated with the adipogenic differentiation of clone 
#6 and #7 iBPAs of PD40. (C) RT-qPCR analysis of Ucp1, Prdm16, Ppargc1a, Pparg, 
Fabp4 and Lpl gene expression in clone #6 and #7 iBPAs at PD40 on the indicated days of 
adipogenic differentiation normalized to Rplp0 expression. Data are presented as means ± 
SEM (n=4).  






Figure 4. Adipogenic potential of massively amplified iBPA clones. 
(A-F) RT-qPCR analysis of Ucp1, Prdm16, Ppargc1a, Pparg, Fabp4 and Lpl gene 
expression in clone #6 and #7 iBPAs at PD100 on the indicated days of adipogenic 
differentiation normalized to Rplp0 expression. (G) Peak expression of the selected marker 
genes in clone #6 and #7 iBPAs at PD40 and PD100 during adipogenic differentiation. Gene 
expression levels are expressed relative to those of clone #6 at PD40, which were set at 1. 
Data are presented as means ± SEM (n=4).  
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β3-adrenoceptor agonists stimulate lipolysis in adipogenically differentiated 
iBPAs 
To investigate the response of adipogenically differentiated iBPAs to adrenergic 
stimulation, the cells were stimulated with the general adrenergic agonist NA28 or with 
the specific β3 adrenoceptor agonist CL31624329,30and glycerol release was quantified. 
The glycerol concentration in the culture medium was significantly increased upon 8 
hours of stimulation with NA (+1659%, P < 0.001 for clone #6, +2028%, P < 0.001 
for clone #7) and CL316243 (+1647%, P < 0.001 for clone #6, +1598%, P < 0.001 for 
clone #7) pointing to increased intracellular lipolysis (Figure 5A). Furthermore, Ucp1 
expression was determined after 8 hours of NA and CL316243 incubation. Consistent 
with the increased lipolysis, Ucp1 expression was significantly increased after NA 
(+231%, P < 0.001 for clone #6, +121%, P < 0.05 for clone #7) or CL316243 (+155%, 
P < 0.01 for clone #6, +181%, P < 0.01 for clone #7) stimulation in both clones 




Figure 5. Effect of adrenergic stimulation on Ucp1 expression and lipolysis of 
adipogenically differentiated iBPAs. (A, B) Clone #6 and #7 iBPAs of PD46 at 
differentiation day 12 were stimulated with 1 µM NA or 10 µM CL316243 for 8 hour after 
which glycerol release in the supernatant (A), and Ucp1 RNA levels (B) were measured. Data 
are means ± SEM (n=4). 
  






Monoclonal lines of BPAs with inducible proliferation ability 
Permanent immortalization of BPAs has been proven to be an effective tool to study 
brown adipocyte biology and responses to pharmacological treatments14-18. However, 
the rapid loss of robust adipogenic capacity during cell amplification and the potential 
effects of exogenous expression of immortalization genes such as LT on BPAs remain 
unresolved issues using this approach. In this study, we developed a system enabling 
the robust and tightly controlled expansion of monoclonal populations of BPAs by 
endowing the cells with a dox-regulated SV40 LT expression module. The presence of 
dox in the culture medium induced LT expression and caused rapid iBPA expansion, 
while removing dox released the proliferation pressure and prepared the cells for 
subsequent adipogenic differentiation. Our monoclonal iBPA lines allow synchronous 
adipogenic differentiation of BPAs, providing a clear advantage in the assessment of 
differentiation stage-dependent gene expression profiles and epigenetic changes. 
Moreover, the use, in previous studies, of permanent immortalization gene expression 
to generate BPA lines poses a problem to their application in transplantation 
experiments, whereas the tightly controlled LT expression system used in this study 
created an opportunity for this iBPAs to become a transplantable cell source. Also, 
recent studies have shown that mature brown adipocytes retain proliferative 
capacity28,29, although the mechanism(s) involved is/are largely unknown. It will 
hence be of interest to investigate what happens when adipogenically differentiated 
iBPAs are re-exposed to dox. If this would cause them to start dividing again, it might 
(i) provide a good model system to gain more insight into the pathways involved in 
BAT hyperplasia and (ii) allow dox-dependent regulation of the size of the brown fat 
compartment in vivo.    
 
LT expression in adipocyte differentiation 
Mature lipid-filled adipocytes are post-mitotic, requiring BPAs to exit the cell cycle 
for terminal differentiation. This may limit the differentiation potential of BPA lines 
with permanent immortalization gene expression. In addition, studies have shown that 
LT inhibits white adipogenesis but facilitates brown adipogenesis by inactivation of 
the pRB pathway20,30,31. A better understanding of the role of LT in adipogenesis will 
help to further understand the mechanisms of brown adipogenesis as well as the 
conversion of white into brown fat cells and vice versa. iBPAs are unique in their 
ability to vary the timing of LT expression and therefore pocket protein activity in 
relation to the moment of adipogenic stimulation. This property makes iBPAs 
particularly attractive for studying the role of cell cycle regulators including those 
directly targeted by LT in BPA differentiation.  
 
Long-term differentiation capacity of iBPAs 
iPBAs retained full adipogenic capacity for at least 64 PDs, implying that > 1019 
brown adipocytes could be generated from a single preadipocyte. This provides an 
abundant cell source for cell-based disease modelling and raises the possibility to 
endow mice with extra brown fat tissue via cell transplantation. This brown fat tissue 
could be provided with new properties by ex vivo genetic engineering thereby creating 
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additional opportunities for fundamental and applied research. Beyond 64 PDs, the 
cells show a less pronounced differentiated brown adipocyte phenotype based on the 
reduced expression of Ucp1 and other brown fat markers at PD100 in comparison to 
PD40. The reason could be that proliferation of iBPAs causes gradual loss of the 
epigenetic modifications required for maintaining their cell type-specific memory32,33, 
resulting in a progressive decrease in adipogenic capacity upon repeated passaging. 
 
Difference in adipogenic capacity between diffent iBPA clones  
As shown in Supplementary Figure 2, different iBPA clones differ in their ability to 
differentiate into brown fat cells. The reason for this is unclear but it may have to do 
with (i) some (intrinsic) heterogeneity of the starting material and/or (ii) the number 
and location of the chromosomally integrated transgenes. A comparison of the 
transcriptional signatures of iBPAs from a single source but with different adipogenic 
capacity may be help to broaden the understanding of the molecular pathways 
orchestrating brown fat formation. 
 
Conclusion 
In this study, we established lines of conditionally immortalized murine brown 
preadipocytes with long-term proliferation ability (at least 100 PDs) and adipogenic 
capacity (at least 64 PDs). Following adipogenesis , these cells displayed a 
multilocular appearance, gene expression signature and metabolic capacity alike 
brown adipocytes. The generated cell lines could have many applications and, for 
example, be used to investigate BPA proliferation and differentiation, brown 
(pre)adipocyte metabolism and regulation of Ucp1 activity and thermogenesis, for 
brown (pre)adipocyte-based disease modelling and for BPA transplantation studies. 
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Supplementary Figure 1. Fluorescence images of iBPAs maintained in growth medium 
before (0) and at 6 days after dox removal immunostained for the proliferation marker 
Ki-67 (green). Nuclei are visualized with Hoechst 33342 (blue). 
  





Supplementary Figure 2. RT-qPCR analysis of Ucp1 expression in 10 different iBPA 
clones on differentiation day 12 normalized to Rplp0 expression. Data are presented as 





Supplementary Figure 3. Light microscopic images showed the morphology of clone #6 
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Background-Ventricular arrhythmias due to unintentional blockade of the Kv11.1 
(hERG) channel are a major safety concern in drug development. In past years, 
several highly prescribed drugs have been withdrawn for their ability to cause such 
proarrhythmia. Here, we investigated whether the proarrhythmic risk of existing drugs 
could be reduced by Kv11.1 allosteric modulators. 
 
Methods and Results-Using [3H]dofetilide binding assays with membranes of human 
Kv11.1-expressing HEK293 cells, two existing compounds (VU0405601 and ML-
T531) and a newly synthesized compound (LUF7244) were found to be negative 
allosteric modulators of dofetilide binding to the Kv11.1 channel with LUF7244 
showing the strongest effect at 10µM. The Kv11.1 affinities of typical blockers (i.e., 
dofetilide, astemizole, sertindole and cisapride) were significantly decreased by 
LUF7244. Treatment of confluent neonatal rat ventricular myocyte (NRVM) 
monolayers with astemizole or sertindole caused heterogeneous prolongation of action 
potential (AP) duration and a high incidence of early afterdepolarizations upon 1-Hz 
electrical point stimulation, occasionally leading to unstable, self-terminating 
tachyarrhythmias. Pretreatment of NRVMs with LUF7244 prevented these 
proarrhythmic effects. NRVM monolayers treated with LUF7244 alone displayed 
electrophysiological properties indistinguishable from those of untreated NRVM 
cultures. Prolonged exposure of NRVMs to LUF7244 or LUF7244 plus astemizole did 
not affect their viability, excitability and contractility as assessed by molecular, 
immunological and electrophysiological assays. 
 
Conclusion-Allosteric modulation of the Kv11.1 channel efficiently suppresses drug-
induced ventricular arrhythmias in-vitro by preventing potentially arrhythmogenic 
changes in AP characteristics, raising the possibility to resume the clinical use of 










Drug-induced ventricular arrhythmias (DiVAs) are a frequently encountered clinical 
problem, which has resulted in restricted use or market withdrawal of existing cardiac 
and non-cardiac drugs and still represents a major obstacle for the development of 
new drugs.1 Inhibition of the rapid component of the delayed rectifier K+ current (IKr) 
has been identified as the major culprit in the development of DiVAs. The 
consequential slowing of cardiac repolarization, manifested in the surface 
electrocardiogram as a prolongation of the QT interval, increases the likelihood of 
early afterdepolarizations (EADs), which may give rise to ectopic beats. Drug-induced 
IKr blockade also increases spatial dispersion of repolarization and refractoriness 
thereby further increasing proarrhythmic risk.2 Together these electrophysiological 
alterations promote the development of a special type of polymorphic ventricular 
arrhythmias known as “Torsades de Pointes” (TdPs), which mostly resolve 
spontaneously but occasionally degenerate into fatal ventricular fibrillation.3 The 
Kv11.1 protein, which is encoded by the KCNH2 gene (also known as ether-à-go-go–
related gene 1 [ERG or ERG1]), represents the pore-forming α-subunit of the IKr 
channel.4 Several structural features of Kv11.1 render the central cavity of the IKr 
channel particularly susceptible to blockade by a heterogeneous collection of chemical 
compounds including various non-cardiac drugs (e.g., astemizole, sertindole and 
cisapride). 
An obvious strategy to reduce the proarrhythmic risk of drugs with unintended 
IKr-blocking effects is by lowering their Kv11.1 affinities via chemical modifications. 
Alternatively, supplementary drugs that decrease the proarrhythmic risk of inadvertent 
Kv11.1 blockers can be developed potentially allowing (i) reintroduction of medicines 
previously recalled from the market because of their Kv11.1-related cardiotoxicity and 
(ii) admission of new drugs with fortuitous IKr-blocking activity. Paradoxically, 
screening of drugs for possible IKr-blocking side effects has resulted in the 
serendipitous discovery of various Kv11.1 activators.5 Besides their potential 
usefulness in treating inherited long QT syndrome (LQTS), these Kv11.1 activators 
may also be used to counteract Kv11.1 blockade-associated DiVAs. Indeed, Kang et al. 
showed that the action potential (AP) duration (APD)-prolonging effect of the IKr-
blocking, class III antiarrhythmic drug dofetilide could be counterbalanced by the first 
identified synthetic Kv11.1 activator designated RPR260243.6 However, due to their 
APD-shortening effect, Kv11.1 activators may induce short QT syndrome.5 Recently, 
Potet et al. described a compound designated VU0405601 that upon pretreatment 
significantly reduced the APD-prolonging effect of dofetilide in Langendorff-perfused 
rabbit hearts and dose-dependently mitigated the Kv11.1-blocking effects of seven 
different drugs in HEK293 cells stably overexpressing the human KCNH2 gene 
(HEK293Kv11.1 cells).7 VU0405601 exerted its effects on the Kv11.1 channel in 
whole-cell voltage-clamp experiments using HEK293Kv11.1 cells only when applied 
extracellularly. This suggests that VU0405601 binds to the extracellular domain of the 
Kv11.1 channel rather than to its central cavity leading us to hypothesize that 
VU0405601 counteracts the APD-prolonging effect of Kv11.1 blockers by an 
allosteric mechanism. 
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Allosteric modulators bind their targets at a site topologically different from 
that of the endogenous ligand. From this so-called allosteric site they generally display 
higher selectivity across receptor subtypes and thus provide a safer pharmacological 
profile than ligands binding to the orthosteric site.8 Notably, since the Kv11.1 channel 
does not have an endogenous ligand, the authors refer to the site where typical 
blockers (i.e., dofetilide and astemizole) bind as the orthosteric site. Whereas 
allosteric modulators targeting ligand-gated ion channels and G protein-coupled 
receptors have been well established as research tools and therapeutic agents,8-10 little 
progress has been made in the discovery and clinical development of such compounds 
for voltage-gated ion channels. 
In this study, in-vitro radioligand binding assays were used to investigate 
whether two previously reported compounds (i.e., VU04056017 and ML-T53111) and 
a new compound designated LUF7244 could allosterically modulate binding of the 
potent Kv11.1 blocker dofetilide to the channel’s central cavity.12,13 Radioligand 
binding assays were also employed to study LUF7244’s influence on the interaction 
between (i) the Kv11.1 channel and three different blockbuster drugs (i.e., astemizole, 
sertindole and cisapride) that have been withdrawn from the market due to their 
Kv11.1-related cardiotoxicity14 and (ii) astemizole and its intended target, the human 
histamine H1 receptor (hH1R, see Data Supplement). The radioligand binding assays 
were complemented with optical voltage mapping experiments in confluent 
monolayers of neonatal rat ventricular myocytes (NRVMs). These experiments were 
performed in the absence and presence of LUF7244 and/or any of the three 
blockbuster drugs. Electrophysiological parameters analyzed included conduction 
velocity (CV), APD at 40 and 90% repolarization (APD40 and APD90, respectively), 
APD dispersion and EAD incidence. In addition, the effects of LUF7244 alone and 
together with astemizole on the viability, excitability and contractility of NRVMs 
were investigated (see Data Supplement). The results of this study indicate that 
negative allosteric modulation of the Kv11.1 channel may provide a safe and effective 








Materials and Methods 
 
Radioligand Binding Studies 
Radioligand displacement assays and kinetic dissociation assays were performed on 
membranes of HEK293Kv11.1 cells using [3H]dofetilide as radioligand essentially as 
described before.15 
 
Isolation and Culture of NRVMs 
NRVMs were isolated from the hearts of neonatal rats and cultured as previously 
detailed.16 The use of these animals was approved by the Animal Experiments 
Committee of Leiden University Medical Center and conformed to the Guide for the 
Care and Use of Laboratory Animals as stated by the US National Institutes of Health. 
 
Immunocytochemical Analyses 
NRVMs were plated on fibronectin-coated, 15-mm diameter round glass coverslips at 
a density of 4×104 cells. At day 9 of culture, the cells were washed with ice-cold 
phosphate-buffered saline (PBS), fixed in buffered 4% formaldehyde and 
permeabilized with 0.1% Triton X-100 in PBS. Next, the cells were double-
immunostained for Kv11.1 and α-actinin. Incubation with primary antibodies (diluted 
1:200 in PBS-0.1% normal donkey serum) and corresponding donkey Alexa Fluor 
488/568-conjugated secondary antibodies (1:400 dilution) lasted for 2 hours. To 
visualize their nuclei, the cells were incubated with 10µg/mL Hoechst 33342 in PBS. 
After each processing step, the cells were washed with PBS. Coverslips were mounted 
in VECTASHIELD mounting medium. Photomicrographs were obtained using a 
Nikon Eclipse 80i digital color camera-equipped fluorescence microscope. 
 
Reverse Transcription-Quantitative Polymerase Chain Reaction Analyses 
Total RNA extracted from NRVMs and from neonatal rat cardiac fibroblasts (NRCFs; 
maintained in NRVM medium) using the QIAGEN RNeasy Mini kit was reverse 
transcribed with the Bio-Rad iScript cDNA synthesis kit and the resulting cDNA was 
amplified by PCR using the Bioline SensiFAST SYBR No-ROX kit. PCR 
amplifications of rat Kcnh2- and rat 18S rRNA (Rn18s)-specific cDNA (for primer 
sequences, see Data Supplement) were carried out in a CFX96 Touch Real-Time 
PCR detection system (Bio-Rad) using a 2-step cycling protocol (20-40 cycles of 
95°C 10 sec, 60°C 30 sec) after a 5-minute incubation at 95°C. Quantitative analyses 
were based on the 2-ΔΔCT method using CFX Manager software (Bio-Rad). 
 
Optical Mapping Experiments 
Optical mapping experiments were done in confluent monolayers of NRVMs using 
the potentiometric dye di-4-ANEPPS as voltage indicator following previously 
described methods.17 To validate the experimental model, cells were incubated for 20 
minutes in culture medium containing 0, 10, 30, 100 or 300nM of the hH1R antagonist 
and unintended Kv11.1 blocker astemizole and dimethylsulfoxide (DMSO) at a final 
concentration of 0.03%. In a subsequent experiment, NRVM cultures were first 
exposed for 30 minutes to 10μM LUF7244 or its solvent (i.e., culture medium 
containing 0.1% DMSO). Next, astemizole (final concentration of 100nM) or vehicle 
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was added to the culture medium raising the DMSO concentration to 0.13%. 
Following an incubation period of 30 minutes at 37°C, optical recordings were started 
in the continued presence of the appropriate vehicle/drug combinations. 
 
Data Analysis 
Radioligand binding assay data were analyzed with GraphPad Prism 5.0 (GraphPad 
Software, San Diego, CA). Half maximal inhibitory concentrations (i.e., IC50 values), 
apparent inhibitory binding constants (Ki values), dissociation rate constants (koff) and 
half maximal effective concentrations (i.e., EC50 values) were calculated as previously 
described.18 Values obtained from the radioligand binding assays are from three 
different experiments each consisting of two independent samples. Data are expressed 
as mean±standard error of the mean (SEM) for the radioligand binding assays or as 
mean±standard deviation (SD) for the optical voltage mapping experiments. 





Characterization of Allosteric Modulators of [3H]Dofetilide Binding to the Kv11.1 
Channel 
The interaction of two previously reported ligands VU405601 and ML-T531 as well 
as the newly designed and synthesized compound LUF7244 (Figure 1A) with the 
human Kv11.1 channel was studied in different [3H]dofetilide binding assays. As 
shown in Figure 1B and Table I in the Data Supplement, all three compounds 
reduced [3H]dofetilide binding to the Kv11.1 channel with relatively low affinities, i.e., 
with IC50 values of 7.8±0.4μM, 12±1μM and 3.9±0.7μM for VU0405601, ML-T531 
and LUF7244, respectively. Moreover, all displacement curves demonstrated Hill 
coefficients different from unity (i.e., -1.1±0.03 for ML-T531, -1.2±0.01 for 
VU0405601 and -1.3±0.1 for LUF7244), implying that VU0405601, ML-T531 and 
LUF7244 might not competitively displace [3H]dofetilide from the Kv11.1 channel but 
may bind elsewhere to the channel protein to allosterically modulate radioligand 
binding. 
Subsequently, single-point dissociation assays were performed to screen for 
allosteric effects of these compounds on the binding of [3H]dofetilide to the Kv11.1 
channel. At a concentration of 10µM, VU0405601, ML-T531 and LUF7244 
significantly increased the dissociation of [3H]dofetilide from the Kv11.1 channel, 
indicating that these compounds are negative allosteric modulators of dofetilide 
binding to the channel (Figure 1C and Table I in the Data Supplement). LUF7244 
appeared to be the most potent negative allosteric modulator with 44±2% dofetilide 
binding left compared to control conditions, while 10µM VU0405601 and ML-T531 
reduced dofetilide binding to 63±3% and 77±3%, respectively. 
The allosteric effects of VU0405601, ML-T531 and LUF7244 on the Kv11.1 
channel were further investigated in traditional radioligand dissociation experiments 
to determine whether co-administration of these compounds with an excess unlabeled 
dofetilide would change the dissociation rate of [3H]dofetilide from the Kv11.1 
channel. To obtain larger effects, the three compounds were tested at a concentration 




of 50µM instead of 10µM as used in the single-point dissociation assays. As shown in 
Figure 1D and Table I in the Data Supplement, all compounds significantly 
accelerated the dissociation of dofetilide, in line with the results from the single-point 
dissociation experiments. The off-rate of [3H]dofetilide was allosterically increased 
2.0-fold (from 0.21±0.02 to 0.42±0.04min-1) with 50µM VU0405601. The koff value 
of [3H]dofetilide rose to 0.33±0.02min-1 in the presence of 50µM LUF7244, which 
was comparable to the effect of ML-T531 (koff,dofetilide=0.30±0.03min-1).  
 
Effects of LUF7244 on the Binding of Typical Kv11.1 Blockers to the Channel 
Since LUF7244 was the most potent amongst the three allosteric modulators at the 
lower test concentration of 10µM and may therefore have the best safety profile, its 
potency to increase the dissociation of [3H]dofetilide from the Kv11.1 channel was 
investigated. From the corresponding concentration-effect curve (Figure 2A), the 
modulatory potency (i.e., the EC50) of LUF7244 was calculated to be 4.6±0.8µM. 
Notably, LUF7244 could not completely abrogate [3H]dofetilide binding by 
accelerating its dissociation from the Kv11.1 channel. 
To investigate the effects of LUF7244 on the binding affinities of other 
compounds besides dofetilide to the Kv11.1 channel, three additional Kv11.1 blockers 
(i.e., astemizole, sertindole and cisapride) from distinct therapeutic classes were 
selected (Figure 2B). As shown in Figure 2C-D, the [3H]dofetilide displacement 
curves of all four drugs were shifted rightwards in the presence of 10µM LUF7244, 
implicating that their Kv11.1 affinities were diminished by this negative allosteric 
modulator. The Ki values of dofetilide, astemizole, sertindole and cisapride in the 
absence or presence of 10µM LUF7244 are listed in Table II of the Data 
Supplement. LUF7244 most strongly modulated cisapride binding to the Kv11.1 
channel, increasing its Ki value by 4.0-fold from 21±1 to 85±6nM. Similarly, the 
Kv11.1 affinities of astemizole, dofetilide and sertindole were reduced by 3.8-, 3.2- 
and 2.2-fold in the presence of LUF7244. Thus, the negative allosteric effect of 
LUF7244 on the Kv11.1 channel significantly lowered the channel’s affinities for 
several chemically and therapeutically distinct Kv11.1 blockers. 
 
Analysis of Kv11.1 Protein Expression in NRVMs 
Next, the electrophysiological consequences of allosteric modulation of the binding of 
typical Kv11.1 blockers to the channel by LUF7244 (see Figure 3A for experimental 
setup) were examined in confluent monolayers of NRVMs (Figure 3B) as relevant in-
vitro model for studying cardiac arrhythmias.19 Double immunostaining for Kv11.1 
and sarcomeric α-actinin showed that all cardiomyocytes in the NRVM cultures 
expressed the Kv11.1 protein (Figure 3C). The Kv11.1 signal had a punctate or linear 
appearance and was concentrated around nuclei and along the sarcolemma (Figure 
3C). No significant Kv11.1 protein expression was observed in the low percentage of 
α-actinin- cells (mainly NRCFs) present in the NRVM cultures. Consistently, 
comparison of Kcnh2 transcript levels between NRVMs and NRCFs by reverse 
transcription-polymerase chain reaction (RT-PCR) analysis demonstrated ± 40-fold 
higher Kcnh2 mRNA expression in NRVMs than in NRCFs (Figure 3D). 
 




Figure 1. Characterization of allosteric modulators of dofetilide binding to the Kv11.1 
channel in a [3H]dofetilide binding assay performed with membranes of HEK293Kv11.1 
cells. A: Chemical structures of VU0405601, ML-T531 and LUF7244. B: Displacement 
curves of VU0405601, ML-T531 and LUF7244. C: Percentage specific binding of 
[3H]dofetilide to the Kv11.1 channel after 6 minutes of dissociation induced by 10µM 
dofetilide in the absence (control) or presence of 10µM of VU0405601, ML-T531 or 
LUF7244. The specific binding of [3H]dofetilide in the absence of the test compounds was 
set as Bcontrol, while the specific binding in their presence was set as B. **P<0.01. D: Time-
dependent dissociation of [3H]dofetilide induced by 10µM dofetilide in the absence (control) 
or presence of 50µM VU0405601, ML-T531 or LUF7244. 
 
  





Figure 2. Assessment of the effects of LUF7244 on the binding of Kv11.1 blockers to the 
channel in a [3H]dofetilide binding assay performed with membranes of HEK293Kv11.1 
cells. A: Effect of different concentrations of LUF7244 on the dofetilide-induced dissociation 
of [3H]dofetilide from the Kv11.1 channel. After preincubating HEK293Kv11.1 cell 
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membranes with [3H]dofetilide, radioligand dissociation was induced by 10µM dofetilide in 
the absence or presence of different concentrations of LUF7244 and the incubation was 
terminated after 6 minutes. Results are expressed as the ratio of the specific binding of 
[3H]dofetilide in the presence of 10µM dofetilide plus various concentrations of negative 
allosteric modulators (B) over that in the presence of 10µM dofetilide alone (Bcontrol). B: 
Chemical structures of dofetilide, astemizole, sertindole and cisapride. C: Displacement 
curves of dofetilide and astemizole in the absence or presence of 10µM LUF7244. D: 
Displacement curves of sertindole and cisapride in the absence or presence of 10µM 
LUF7244. 
 
Figure 3. Biochemical characterization of the NRVM model. A: Basic setup of the optical 
voltage mapping experiments. B: Phase-contrast image of a typical confluent NRVM 
monolayer used for optical voltage mapping. C: Immunocytological analysis of Kv11.1 
protein expression in NRVM cultures. The Kv11.1 protein (green) is mainly located around 
the nucleus (blue) and at the sarcolemma of the α-actinin (red)-positive NRVMs and hardly 
detectable in the α-actinin-negative non-cardiomyocytes. D: Analysis of Kcnh2 mRNA levels 
in NRVMs and NRCFs by RT-PCR. 






Figure 4. Electrophysiological characterization of the NRVM model by optical voltage 
mapping following 1-Hz electrical stimulation. Representative filtered optical signal traces 
(A and C), corresponding APD dispersion and activation maps (E and G, respectively) and 
quantitative analyses (bar graphs in B, D, F and H) of NRVM cultures exposed for 30 
minutes to 100nM astemizole or vehicle (control) and subjected to optical voltage mapping 
immediately afterwards. Astemizole treatment resulted in APD prolongation (APD40 and 
APD90, A and B), the occurrence of EADs (C and D) and an increase in APD40 dispersion (E 
and F) but did not significantly alter CV (G and H). ***P<0.001 and ****P<0.0001. 
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Electrophysiological Consequences of Kv11.1 Blockade by Astemizole in NRVMs 
Due to its relatively high specificity for the Kv11.1 channel,20 astemizole was selected 
to study the electrophysiological consequences of Kv11.1 blockade by optical voltage 
mapping (Figure 4). NRVMs treated with astemizole displayed a concentration-
dependent increase in APD and EAD incidence (Figure I in the Data Supplement). 
As displayed in Figure 4A-B, APD40 and APD90 values of NRVMs were increased 
from 112±16 and 295±62ms in vehicle-treated cultures (n=24) to 156±39 and 
355±66ms in cultures containing 100nM astemizole (n=24, P<0.0001 and P<0.001, 
respectively). Furthermore, exposure to 100nM astemizole resulted in the occurrence 
of EADs in 25% of the NRVM cultures, whereas no EADs were observed under 
control conditions (Figure 4C-D). As shown in Figure 4E-F, the APD40 dispersion 
between NRVMs in the presence of 100nM astemizole was significantly higher than 
that in its absence (39±11 vs 16±5ms; P<0.0001), indicative of aggravated 
repolarization heterogeneity due to inhibition of IKr by astemizole. Occasionally, the 
astemizole-induced APD prolongation resulted in short-lasting, irregular 
tachyarrhythmias (Figure II in the Data Supplement) reminiscent of spontaneously 
terminating TdP episodes. Importantly, as indicated by the activation maps (Figure 
4G) and corresponding quantitative analysis (Figure 4H), the CV in NRVM cultures 
was not significantly influenced by 100nM astemizole (20±4cm/s vs 21±3cm/s in 
control cultures; P=0.1254). Collectively, these data validate the utility of NRVM 
cultures as an in-vitro model for investigating the AP-prolonging and associated 
proarrhythmic effects of Kv11.1 blockers like astemizole. 
 
Effects of LUF7244 on Kv11.1 Blockade-Associated Proarrhythmic Changes in 
NRVM Cultures 
To investigate the functional consequences of negative allosteric modulation of 
Kv11.1’s interaction with typical Kv11.1 blockers, di-4-ANNEPS-loaded NRVM 
cultures were incubated for 20 minutes in culture medium containing 10µM LUF7244 
before addition of astemizole, sertindole or cisapride. Since the Ki values of sertindole 
and cisapride for Kv11.1 are more than 10 times higher than that of astemizole (Table 
II in the Data Supplement), these drugs were tested at a final concentration of 1µM 
instead of 100nM as was used for astemizole. After incubation for 30 minutes, the 
NRVMs were optically mapped. As shown in Figure 5A, the APD-prolonging and 
EAD-promoting effects of astemizole were effectively suppressed by LUF7244. 
APD40 and APD90 were significantly shortened from 156±39ms to 118±18ms (n=24, 
P<0.0001) and from 355±66ms to 282±63ms (n=24, P<0.001), respectively, i.e., 
LUF7244 was able to reduce APD40 and APD90 to control values (Figure 5B). 
Moreover, in the presence of 10µM LUF7244 EADs were no longer observed in 
NRVM cultures exposed to 100nM astemizole (Figure 5C). LUF7244 also prevented 
the increase in APD40 dispersion caused by astemizole (Figure 5D-E). Importantly, 
the CVs in NRVM cultures treated with vehicle, LUF7244, astemizole or LUF7244 
plus astemizole did not significantly differ (data not shown). Also, at a final 
concentration of 10µM LUF7244 per se did not reduce APD or significantly affect 
APD40 dispersion (Figure 5F-H and Figure III in the Data Supplement), suggesting 
that this negative allosteric modulator poses very little, if any, risk for the 
development of arrhythmias associated with abnormal APD shortening. Very similar 




results of LUF7244 were obtained in NRVM cultures exposed to sertindole or 
cisapride (Figure IV in the Data Supplement). LUF7244 can thus suppress the 
proarrhythmic side effects of drugs from different therapeutic classes by allosteric 
modulation of the Kv11.1 channel without exerting, by itself, any obvious adverse 




Figure 5. Assessment by optical voltage mapping of the ability of LUF7244 to counteract 
the proarrhythmic effects of astemizole on NRVMs. Representative filtered optical signal 
traces (A and F), APD dispersion maps (D) and quantitative analysis (bar graphs in B, C, E, 
G and H) of control NRVM cultures and of NRVM cultures that had been treated with 
100nM astemizole or with 10µM LUF7244 followed by 100nM astemizole immediately 
before optical voltage mapping. Pretreatment of NRVM cultures with LUF7244 completely 
prevented the astemizole-induced APD prolongation (APD40 and APD90; B), occurrence of 
EADs (C) and increase in APD40 dispersion (D and E). Treatment of NRVM cultures with 
10µM LUF7244 only did not change AP morphology (F), APD (G) or APD40 dispersion (H). 
***P<0.001 and ****P<0.0001.  





In radioligand binding assays the structurally related compounds VU0405601, ML-
T531 and LUF7244 were found to weaken the interaction between the human Kv11.1 
channel and the class III antiarrhythmic agent dofetilide as well as the unintended 
Kv11.1 blockers astemizole, sertindole and cisapride. VU405601, ML-T531 and 
LUF7244 exerted their negative effects on the binding of typical Kv11.1 blockers to 
the channel’s central cavity by an allosteric mechanism. Importantly, LUF7244 
decreased the Kv11.1 affinity of astemizole without influencing its affinity at the hH1R, 
being astemizole’s intentional target (Figure V in the Data Supplement). Optical 
voltage mapping showed that incubation of NRVM monolayers with astemizole, 
sertindole or cisapride led to a significant increase in APD, APD dispersion and, 
except for cisapride, EAD incidence demonstrating the usefulness of this cellular 
model system for studying Kv11.1 blockade-related proarrhythmic risk. Pretreatment 
of NRVMs with 10µM LUF7244 effectively prevented the proarrhythmic changes 
induced by astemizole, sertindole and cisapride without significantly shortening APD 
by itself and without adversely affecting NRVM viability, excitability and 
contractility (Figure VI in the Data Supplement). These findings provide a rationale 
for further exploring allosteric modulation as a strategy to prevent DiVAs. 
 
NRVM Monolayers as Model for Studying Drug-Induced LQTS 
Many different methods have been exploited to assess drugs for their Kv11.1 
blockade-associated arrhythmogenicity.3,21 The interaction between a drug and the 
Kv11.1 channel is usually first investigated by computational and biochemical assays. 
Next, the Kv11.1 liabilities of suspicious drugs are typically evaluated by 
electrophysiological measurements on CHO or HEK293 cells expressing the human 
Kv11.1 channel. Despite their practical advantages, these non-excitable cellular 
models do not recapitulate the complex regulatory circuits governing Kv11.1 channel 
activity in cardiomyocytes and are unsuitable for studying AP generation and 
propagation. To overcome these shortcomings, human induced pluripotent stem cell-
derived cardiomyocytes (hiPSC-CMs) are now often used for cardiotoxicological 
screenings.22 However, thus far hiPSC-CMs cannot produce dense monolayers of 
phenotypically homogeneous ventricular cardiomyocytes for high-resolution optical 
mapping.23 We hence employed NRVM monolayers to study the effects of LUF7244 
on the proarrhythmic potential of three inadvertent Kv11.1 blockers by optical voltage 
mapping. The reasons to specifically use NRVMs for this purpose are that these cells 
(i) can be relatively easily isolated and cultured, (ii) are well-characterized and (iii) 
express functional Kv11.1 channels.24 However, this is the first study using NRVMs to 
test compounds for their ability to prevent DiVAs resulting from unintended Kv11.1 
blockade. 
Although mechanistic insight into DiVAs is limited, there is broad consensus 
about spatial dispersion of repolarization and EAD-induced triggered activity 
providing the substrate and trigger for the genesis of drug-induced TdP, respectively.2 
The EADs typically arise during phase 2 of the cardiac AP due to drug-dependent 
decreases in IKr causing increases of APD and QT interval. In support of the validity 




of our model, astemizole dose-dependently increased APD and EAD incidence in 
monolayers of NRVMs (Figure I in the Data Supplement). Also sertindole and 
cisapride had APD-prolonging effects (Figure IVA and IVD in the Data Supplement) 
and each of the three fortuitous Kv11.1 blockers increased APD dispersion (Figure 4F, 
Figure IVC and IVF in the Data Supplement). While 100nM astemizole, 1µM 
sertindole and 1µM cisapride increased APD and APD dispersion to a similar extent, 
cisapride did not significantly increase EAD incidence in contrast to the other two 
drugs (Figure 4D, Figure IVB and IVE in the Data Supplement). This finding may 
be explained by cisapride’s inhibitory effect on the ICa,L in NRVMs.25 
Initially, EAD-dependent ectopic activity at multiple competing foci was 
thought to generate the undulating electrocardiographic patterns of TdP. Recently, 
meandering ICa,L-mediated reentrant circuits initiated by EADs at single foci have 
been proposed as an alternative explanation for the highly characteristic 
electrocardiographic signature of TdP.26,27 Although we did observe several instances 
of short-lasting, irregular tachyarrhythmias exclusively in NRVM cultures exposed to 
Kv11.1 blockers, they did not allow us to make specific claims about the underlying 
electrophysiological mechanisms. Pretreatment with LUF7244 rendered NRVM 
monolayers unsusceptible to the Kv11.1-blocking effects of astemizole, sertindole and 
cisapride. In the presence of LUF7244, these Kv11.1 blockers no longer caused 
heterogeneous APD prolongation and, due to the reduced opportunity for L-type Ca2+ 
channel reactivation, no longer gave rise to EADs. This raises the perspective to use 
LUF7244 as an antiarrhythmic additive to drugs with unintended IKr-suppressing 
effects. Thus, radioligand binding assays in combination with optical voltage mapping 
experiments of NRVM cultures offer convenient preclinical test systems for 
evaluating chemical entities that can potentially reduce Kv11.1-related cardiotoxicity. 
 
LUF7244’s Mode of Action 
The chemical structure of LUF7244 resembles those of ML-T531 and VU0405601. In 
a recent study, 10µM of ML-T531 was shown to reduce the APD of hiPSC-CMs from 
an LQT1 patient to that of control cells by augmenting IKr.11 However, the effects of 
ML-T531 on the APD of hiPSC-CMs from a healthy individual and ML-T531’s 
ability to inhibit the APD-prolonging effects of unintended Kv11.1 blockers were not 
investigated. Voltage-clamp recordings of Kv11.1-expressing CHO cells showed that 
ML-T531 reduces the deactivation rate of the Kv11.1 channel and causes a shift of its 
inactivation curve towards more positive voltages. Shortly after the discovery of ML-
T531, VU0405601 was identified as a compound that, at a final concentration of 5µM, 
protected Langendorff-perfused rabbit hearts from the proarrhythmic effects of 
exposure to 100nM dofetilide.7 Although VU0405601 only partially reversed the 
dofetilide-dependent increase in APD, its administration prior to dofetilide strongly 
reduced the pacing-induced arrhythmia incidence from 42% to 4%, which was very 
close to the 2% of pacing-induced premature ventricular contractions observed in 
untreated hearts.7 Exposure of isolated rabbit ventricular myocytes to 5µM of 
VU0405601 only marginally reduced APD, which is consonant with our finding that 
10µM LUF7244 did not noticeably affect the APD of NRVMs. However, at a final 
concentration of 50µM, VU0405601 decreased the APD50 and APD90 of rabbit 
ventricular myocytes by 35±6% and 32±4%, respectively. Patch-clamp analysis of 
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HEK293Kv11.1 cells linked the APD-shortening effect of 50µM VU0405601 to shifts 
in the V½ of activation and inactivation and to changes in the kinetics of (de)activation 
and (de)inactivation causing an increase in IKr. 
In this study, we found that VU0405601, ML-T531 and LUF7244 displayed 
comparatively low Kv11.1 affinities with Hill coefficients significantly different from 
unity for their [3H]dofetilide displacement curves. This suggests that these ligands 
bind to the Kv11.1 channel at sites distinct from that of dofetilide, indicative of an 
allosteric mode of action.10,28,29 The binding of a drug to a receptor at an allosteric site 
(i.e., a site topologically distinct from that of the test ligand) triggers a conformational 
change within the receptor ultimately causing an alteration of the ligand’s dissociation 
rate from its cognate (i.e., orthosteric) binding site.10,30 Altered ligand dissociation 
rates have been found representative of allosteric interactions in various drug targets 
such as muscarinic and adenosine receptors.10, 31-33 Consistently, VU0405601, ML-
T531 and LUF7244 significantly accelerated the dissociation of dofetilide from the 
Kv11.1 channel, strengthening the conclusion that they are negative allosteric 
modulators of dofetilide binding to the Kv11.1 channel. Our finding for VU0405601 is 
in agreement with the results of Potet et al., who presented indirect evidence that 
VU0405601 binds from outside to the ectodomain of the Kv11.1 channel,7 while 
astemizole, cisapride, dofetilide and sertindole all bind to the channel’s central cavity 
from inside.34-36 In addition, the [3H]dofetilide displacement curves of dofetilide, 
astemizole, sertindole and cisapride were shifted rightwards by LUF7244 (Figure 2C-
D) providing further proof for its negative allosteric effect.10,33 Collectively, the results 
of the different radioligand binding assays provide strong evidence that VU0405601, 
ML-T531 and LUF7244 are negative allosteric modulators of dofetilide binding to the 
Kv11.1 channel. Binding of VU0405601, ML-T531 and LUF7244 likely alters the 3D 
structure of the Kv11.1 channel, which decreases its affinity for typical Kv11.1 
blockers by increasing the dissociation rates of these blockers from the channel. 
Notably, the vast majority of fortuitous Kv11.1 blockers exert their effects by 
occupying the central cavity of the Kv11.1 channel and thereby obstructing the 
transport of K+ ions through the channel’s pore.37 There are, however, also examples 
of drugs that reduce IKr by inhibiting, directly or indirectly, the trafficking of Kv11.1 to 
the plasma membrane.38 Given their specific mode of action, it is unlikely that the IKr-
inhibiting effects of these drugs can be abolished by LUF7244 or a related compound. 
The ability of LUF7244 to counteract astemizole-, sertindole- and cisapride-
related arrythmogenesis may be the combined result of its inhibitory allosteric effect 
on the binding of these unintended Kv11.1 blockers to the channel and of its direct 
enhancing effect on the Kv11.1 channel’s activity. Indeed, at concentrations ≥25µM, 
LUF7244 caused APD shortening (Figure III in the Data Supplement) suggesting 
that LUF7244 can directly act as (allosteric) Kv11.1 activator like VU0405601 and 
ML-T531.7,11 However, the fact that exposure of NRVMs to 10µM LUF7244 alone 
did not significantly change AP characteristics suggests that LUF7244’s Kv11.1-
activating activity is not of critical importance for its ability to suppress the 
proarrhythmic effects of inadvertent Kv11.1 blockers. The absence of a noticeable 
change in AP shape and duration following exposure of NRVMs to 10µM LUF7244 
also argues against a possible effect of this allosteric modulator on cardiac ion 
channels different from the Kv11.1 channel. In keeping with this notion, Nav1.5 and 




Kv1.5 currents and IKs were not affected or only slightly reduced by 50µM 
VU0405601.7 Likewise, ML-T531 at a final concentration of 10µM had a minor 
suppressive effect on IKs and did not influence Nav1.5, Cav1.2, Kv4.3 or Kir2.1 
activities.11 Thus, the antiarrhythmic propensity of LUF7244 is dominated by its 
negative allosteric impact on the binding of typical Kv11.1 blockers to the channel. 
Since LUF7244 significantly decreased the Kv11.1 affinities of drugs with very 
different chemical structures (Figure 2B) in radioligand binding assays and prevented 
these drugs from causing APD prolongation in NRVMs, LUF7244 may be effective in 
reducing the cardiotoxicity of a broad range of Kv11.1 blockers. Further support for 
this notion comes from the fact that VU0405601, which was here shown to inhibit 
dofetilide’s interaction with the Kv11.1 channel by a similar mechanism to LUF7244, 
could abolish the blockade of Kv11.1 by seven different drugs.7 The different degree 
to which LUF7244 increased the Ki values of dofetilide, astemizole, sertindole and 
cisapride suggests that the sensitivity of different Kv11.1 blockers to conformational 
changes in the Kv11.1 proteins differs. Accordingly, different LUF7244 
concentrations may be required to abrogate the proarrhythmic effects of distinct 
Kv11.1 blockers. 
Although at a final concentration of 50µM LUF7244’s ability to weaken the 
interaction between [3H]dofetilide and the Kv11.1 channel was similar to those of 
VU0405601 and ML-T531 (Figure 1D), the new modulator was much more effective 
than the other two compounds at a final concentration of 10µM (Figure 1C). 
Moreover, even 50µM VU0405601 only modestly inhibited the APD-prolonging 
effect of 1µM dofetilide (Ki for human Kv11.1: 6.0nM) on rabbit ventricular 
myocytes,7 while 10µM LUF7244 totally blocked the APD prolongation caused by 
exposure of NRVMs to 100nM astemizole (Ki for human Kv11.1: 1.2nM). These 
findings together with the substantial decrease in the APD of normal rabbit ventricular 
myocytes caused by 50µM VU0405601 (see above), suggests that LUF7244 may 
possess a more favorable safety profile than VU0405601 or ML-T531. 
 
Limitations 
Due to the difficulty to obtain and culture adult human ventricular myocytes, NRVMs 
were used as 2D model system to investigate the effects of LUF7244 on Kv11.1 
blockade-associated proarrhythmic changes in cardiac electrophysiology. However, 
ventricular adult human and neonatal rat cardiomyocytes have different AP 
morphologies because of qualitative and quantitative differences in the molecular 
components shaping the APs. Also, changes in cardiomyocyte electrophysiological 
properties may work out differently in a 2D cell layer than in the (3D) heart. 
Nonetheless, studies on NRVM monolayers have greatly contributed to our current 
understanding of cardiac electrophysiology. Moreover, in spite of the differences in 
ventricular ion channel composition between humans and rats, their Kv11.1 proteins 
are very similar showing 95% amino acid identity for the largest isoforms. 
Consistently, the results of the radioligand binding assays, which were carried out 
with the human Kv11.1 protein, correlated very well with those of the optical mapping 
studies using NRVMs. Yet, ultimately, the ability of LUF7244 to counteract the 
proarrhythmic effects of unintended Kv11.1 blockers should be investigated in human 
subjects. 
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As mentioned above, LUF7244 did not inhibit the binding of astemizole to its 
intended target in radioligand binding assays (Figure V in the Data Supplement) and 
did not compromise the viability, excitability or contractility of NRVMs (Figure VI 
in the Data Supplement) at a concentration sufficient to fully abrogate the 
proarrhythmic consequences of drug-induced Kv11.1 blockade in these cells. Despite 
these encouraging results, certainty about the lack of specific adverse/interfering 
effects of this negative allosteric modulator of Kv11.1 channel in humans can only be 
obtained through clinical studies. Moreover, now that the ability of LUF7244 to 
reduce the channel binding affinities of Kv11.1 blockers has been established, 
allosteric modulators with higher safety and/or efficacy than LUF7244 are likely to 
arise in the near future. The design of such compounds may benefit from identification 




Allosteric modulators of the Kv11.1 channel could provide a new pharmacological 
treatment for drug-induced LQTS by preventing the potentially arrhythmogenic 
changes in AP characteristics caused by unintended Kv11.1 blockers. Through 
combined administration with a negative allosteric modulator, use of “old” drugs that 
have been banned because of their “Kv11.1 liabilities” may be resumed and new drugs 
with Kv11.1-blocking effects may not have to be excluded from clinical application. 
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Dofetilide was synthesized in-house as previously described.1 Bovine serum albumin 
(BSA, fraction V) and the fortuitous Kv11.1 blockers astemizole, sertindole and 
cisapride were purchased from Sigma-Aldrich (St. Louis, MO). Tritium-labeled 
dofetilide (specific activity: 82.3 Ci/mmol) and astemizole (specific activity: 78.4 
Ci/mmol) were obtained from PerkinElmer (Groningen, the Netherlands). The 
synthesis and chemical analysis of VU0405601, ML-T531, as well as the design, 
synthesis and chemical analysis of LUF7244 will be detailed elsewhere. G418 was 
purchased from Stratagene (Cedar Creek, TX). All other chemicals were of analytical 
grade and obtained from standard commercial sources. HEK293Kv11.1 cells, i.e., 
HEK293 cells stably overexpressing the human KCNH2 gene, were kindly provided 
by Dr. Eckhard Ficker (Case Western Reserve University, Cleveland, OH).2 Plasmid 
pcDNA3.1-hH1Rwt encoding the human histamine H1 receptor (hH1R) was a gift of 
Prof. Thue W. Schwartz (University of Copenhagen, Copenhagen, Denmark). This 
plasmid was used to generate HEK293hH1R cells, i.e., cells transiently overexpressing 
the human HRH1 gene (see “HEK293 Cell Culture and Transfection”). 
All animal experiments were approved by the Animal Experiments Committee 
of Leiden University Medical Center and conformed to the Guide for the Care and 
Use of Laboratory Animals as stated by the US National Institutes of Health. 
 
Methods 
HEK293 Cell Culture and Transfection 
HEK293 cells were cultured in a humidified atmosphere at 37°C and 7% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, catalog number: 
D6546) supplemented with 10% fetal bovine serum (Sarstedt, Nümbrecht, Germany), 
50 IU/mL penicillin (Sarstedt) and 50 μg/mL streptomycin (Sarstedt). When the cells 
had reached 50-60% confluence, the culture medium was refreshed and 500 µL of 150 
mM NaCl containing 15 μg of pcDNA3.1-hH1Rwt DNA and 45 μg of linear 25-kDa 
polyethylenimine (Polysciences Europe, Eppelheim, Germany) was added per 100-
mm culture dish (Sarstedt). The resulting HEK293hH1R cells were harvested 48 hours 
after transfection. 
 
Preparation of Membrane Samples 
HEK293Kv11.1 cells were cultured and membranes were prepared and stored as 
detailed previously.3 Membranes of HEK293hH1R cells, were prepared and stored as 
described for HEK293Kv11.1 cells except that incubation buffer I (50 mM Tris-HCl 
[pH 7.4]) was used instead of incubation buffer II (10 mM HEPES-NaOH [pH 7.4], 
130 mM NaCl, 60 mM KCl, 0.8 mM MgCl2, 1 mM EGTA, 10 mM glucose, 0.1% 
BSA). 
 
Radioligand Displacement Assays with [3H]dofetilide 
[3H]Dofetilide binding assays for the Kv11.1 channel were performed in incubation 
buffer II as described previously.3 Briefly, membrane aliquots containing 20 µg 
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protein were incubated with 5 nM [3H]dofetilide in a total volume of 100 μL at 25°C 
for 1 hour. Radioligand displacement experiments were carried out with various 
concentrations of the test compounds. Total binding was determined in the presence of 
unsupplemented incubation buffer II, whereas non-specific binding was evaluated in 
incubation buffer II containing 10 µM astemizole. Displacement experiments with 
different concentrations of dofetilide, astemizole, sertindole and cisapride were 
conducted in the absence (control) or presence of 10 µM LUF7244. Incubations were 
terminated by dilution with ice-cold wash buffer (25 mM Tris-HCl [pH 7.4], 130 mM 
NaCl, 60 mM KCl, 0.8 mM MgCl2, 0.05 mM CaCl2, 0.05% BSA). Free radioligand 
was separated from bound [3H]dofetilide by rapid filtration through a UniFilter-96 
GF/B microplate using a PerkinElmer MicroBeta Filtermate-96 harvester. The filter-
bound radioactivity was determined using a Wallac 1450 MicroBeta TriLux liquid 
scintillation counter (PerkinElmer) after extraction with 25 µL MicroScint 20 
(PerkinElmer).  
 
Radioligand Displacement Assays with [3H]astemizole 
[3H]Astemizole binding assays for the hH1R were performed in incubation buffer I. 
Membrane aliquots containing 15 µg protein were incubated with 3.5 nM 
[3H]astemizole in a total volume of 100 μL at 25°C for 3 hours. Total binding was 
determined in the presence of unsupplemented incubation buffer I, whereas non-
specific binding was evaluated in incubation buffer I containing 100 µM astemizole. 
LUF7244 displacement assays were carried out with various concentrations of this 
compound, while displacement assays with different concentrations of astemizole 
were conducted in the absence (control) or presence of 10 µM LUF7244. Incubations 
were terminated by dilution with ice-cold wash buffer (50 mM Tris-HCl [pH 7.4]). 
Samples were processed further as described under “Radioligand Displacement 
Assays with [3H]dofetilide”. 
 
Kinetic Dissociation Assays with [3H]dofetilide 
Kinetic dissociation assays of [3H]dofetilide were performed as described previously3 
with the following modifications. Single-point dissociation experiments were 
conducted by addition of 10 µM dofetilide in the absence (control) or presence of 10 
or 50 µM of the selected compounds after preincubating membranes with 
[3H]dofetilide at 25°C for 2 hours. After 6 minutes of dissociation, incubations were 
terminated and samples were obtained as described under “Radioligand Displacement 
Assays with [3H]dofetilide”. Traditional dissociation experiments were carried out 
with 10 µM dofetilide in the absence (control) or presence of 50 µM of the test 
compounds at 25°C for a total period of 2 hours after preincubation with the 
radioligand. The amounts of [3H]dofetilide still bound to the receptor were measured 
at various time intervals. The concentration-dependent effect of LUF7244 was 
determined by addition of 10 µM dofetilide in the absence (control) or presence of 
different concentrations of LUF7244. After 6 minutes of dissociation, incubations 
were terminated and samples were obtained as described under “Radioligand 
Displacement Assays with [3H]dofetilide”. The non-radiolabeled dofetilide was 
applied at a concentration 1667-fold higher than the Ki for the interaction of dofetilide 




with Kv11.1 (Table II), to avoid a significant contribution of reassociation of the 
radioligand with the channel to the results of the kinetic dissociation assays. 
 
Isolation and Culture of Neonatal Rat Ventricular Myocytes (NRVMs) 
NRVMs were isolated and cultured as described previously.4 Briefly, neonatal rats 
were anaesthetized with 4-5% isoflurane inhalation anesthesia. After adequate 
anesthesia had been confirmed by the absence of reflexes, the heart was quickly 
excised. Ventricles were separated from the remainder of the heart, cut into small 
pieces with a fine scissor and a scalpel and dissociated by collagenase type l 
(Worthington, Lakewood, NJ) digestion. The resulting cell suspension was applied to 
Primaria culture dishes (Corning Life Sciences, Amsterdam, the Netherlands) and 
incubated for 75 minutes at 37°C in a humidified atmosphere of 5% CO2 to allow 
preferential attachment of cardiac fibroblasts. The unattached cells (mainly 
cardiomyocytes) were collected, passed through a cell strainer (70-μm mesh pore size; 
BD Biosciences, Breda, the Netherlands) and applied at a density of 8×105 cells/well 
of a 24-well cell culture plate (Corning Life Sciences) to fibronectin (Sigma-Aldrich)-
coated, round glass coverslips. Proliferation of residual cardiac fibroblasts (10-15%) 
was inhibited by incubating the cells for 2 hours in culture medium containing 10 
µg/mL mitomycin C (Sigma-Aldrich) at 24 hours after seeding (i.e., at day 1 of 
culture). Cells were subsequently maintained in a 1:1 mixture of DMEM (Life 
Technologies Europe, Bleiswijk, the Netherlands, catalog number: 22320) and Ham’s 
F10 medium (Life Technologies Europe, catalog number: 11550) supplemented with 
5% horse serum (Life Technologies Europe), 2% BSA and sodium ascorbate to a final 
concentration of 0.4 mM. This so-called NRVM medium was replaced daily. 
 
Immunocytochemical Analyses 
NRVMs were plated on fibronectin-coated, 15-mm diameter round glass coverslips at 
a density of 4×104 cells. At day 9 of culture, the cells were washed thrice with ice-cold 
phosphate-buffered saline (PBS), fixed for 30 minutes in buffered 4% formaldehyde 
(Added Pharma, Oss, the Netherlands) of 4°C and permeabilized by a 10-minute 
incubation at room temperature (RT) with 0.1% Triton X-100 in PBS. Next, the cells 
were double-immunostained for Kv11.1 (rabbit polyclonal antibodies raised against 
the C terminus of human Kv11.1, Merck Millipore, Billerica, MA, catalog number: 
AB5930) and α-actinin (mouse monoclonal antibody, Sigma-Aldrich, clone: EA-53). 
Incubation with primary antibodies (diluted 1:200 in PBS-0.1% normal donkey serum) 
and corresponding donkey Alexa Fluor 488/568-conjugated secondary antibodies 
(1:400 dilution, Life Technologies Europe) lasted for 2 hours. To visualize their nuclei, 
the cells were incubated for 10 minutes at RT with 10 µg/mL Hoechst 33342 (Life 
Technologies Europe) in PBS. After each processing step, the cells were washed three 
times with PBS of RT. To minimize photobleaching, coverslips were mounted in 
VECTASHIELD mounting medium (Vector Laboratories, Burlingame, CA). 
Photomicrographs were obtained with the aid of a digital color camera-equipped 
fluorescence microscope (Nikon Eclipse 80i; Nikon Instruments Europe, Amstelveen, 
the Netherlands). 
 
Reverse Transcription-Quantitative Polymerase Chain Reaction Analyses 
178│ Chapter 6  
 
Cultures of NRVMs and of neonatal rat cardiac fibroblasts (NRCFs; maintained in 
NRVM medium) were washed once with ice-cold PBS after which the cells were 
lysed in TRIzol reagent (Life Technologies Europe) and total RNA was isolated using 
the RNeasy Mini kit (QIAGEN Benelux, Venlo, the Netherlands). The RNA was 
reverse transcribed with the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) and 
the resulting cDNA was amplified by PCR using the Bioline SensiFAST SYBR No-
ROX kit (GC biotech, Alphen aan den Rijn, the Netherlands). The forward and 
reverse primers for the amplification of rat Kcnh2-specific cDNA were localized in 
different exons and had the following sequences, respectively: 5′ 
TAGCCTCCTCAACATCCC 3′ and 5′ CCATGTCTGCACTTAGCC 3′. For 
normalization purposes, rat 18S rRNA (Rn18s)-specific cDNA was amplified in 
parallel using the following forward and reverse primer, respectively: 5’ 
GTAACCCGTTGAACCCCATT 3’ and 5’ CCATCCAATCGGTAGTAGCG 3’. 
PCR amplifications were carried out in a CFX96 Touch Real-Time PCR detection 
system (Bio-Rad) using a 2-step cycling protocol (20-40 cycles of 95°C 10 sec, 60°C 
30 sec) after a 5-minute incubation at 95°C. Quantitative analyses were based on the 
2-ΔΔCT method using CFX Manager software (Bio-Rad). For these analyses, PCRs 
were performed in triplo on three independent samples. 
 
Optical Voltage Mapping 
Action potentials (APs) were investigated on a whole-culture scale by optical voltage 
mapping using the potentiometric dye di-4-ANEPPS (Life Technologies Europe) as 
described previously.5 The measurements were carried out at 37°C on 9-day-old 
confluent NRVM monolayer cultures (Figure 3B in the Main Manuscript). Optical 
signals were captured using a MiCAM ULTIMA-L imaging system (SciMedia, Costa 
Mesa, CA). To validate the experimental model, cells were incubated for 20 minutes 
in culture medium containing 0, 10, 30, 100 or 300 nM of the hH1R antagonist and 
unintended Kv11.1 blocker astemizole and dimethylsulfoxide (DMSO) at a final 
concentration of 0.03%. In a subsequent experiment, NRVM cultures were first 
exposed for 30 minutes to 10 μM LUF7244 or its solvent (i.e., culture medium 
containing 0.1% DMSO). Next, astemizole (final concentration of 100 nM) or vehicle 
was added to the culture medium raising the DMSO concentration to 0.13%. 
Following an incubation period of 30 minutes at 37°C, optical recordings were started 
in the continued presence of the appropriate vehicle/drug combinations (see Figure 
3A in the Main Manuscript for a scheme of the basic experimental setup). Optical 
traces were analyzed using Brain Vision Analyzer 1208 software (Brainvision, Tokyo, 
Japan). To minimize noise artifacts, calculations were based on the average of the 
signals at a selected pixel and its eight nearest neighbors. Conduction velocity (CV), 
AP duration (APD) at 40 and 90% repolarization (APD40 and APD90, respectively), 
APD dispersion and early afterdepolarizations (EADs) incidence were determined 
using NRVM cultures showing uniform AP propagation and 1:1 capture after 1-Hz 
local stimulation. Each of these electrophysiological parameters was the average of 
values obtained from 6 different positions equally distributed across the cell cultures. 
The effects of LUF7244 on the Kv11.1-inhibiting antipsychotic drug sertindole 
and gastroprokinetic agent cisapride were assessed in the same way as for astemizole 
expect that the final concentration of sertindole and cisapride was 1 µM. 




To study the effects of long-term Kv11.1 allosteric modulation in the absence 
and presence of an unintended Kv11.1 blocker on cardiac excitability, confluent 
NRVM cultures were incubated for 3 days in culture medium containing 100 nM 
astemizole and/or 10 µM LUF7244 prior to potentiometric dye loading, short-term 
drug treatment (see above) and optical mapping in the continued presence of drug(s) 
at culture day 9. Confluent NRVM monolayers exposed to culture medium containing 
vehicle (i.e., DMSO at a final concentration of 0.13%) only, served as negative 
controls for this experiment. Just prior to optical mapping, movies of the cells were 
made using a Carl Zeiss Axiovert 40C microscope equipped with a LD A-Plan 
20×/0.3 Ph1 objective (Zeiss Nederland, Sliedrecht, the Netherlands) to record their 
contractions upon electrical field stimulation using two epoxy-coated platinum 
electrodes with an interelectrode spacing of 13 mm. The electrical stimulus consisted 
of a 1.5-ms rectangular pulse of 12V produced at a frequency of 1 Hz by a model 
EV4543 miniature temporary cardiac pacemaker (PACE Medical, Waltham, MA). 
 
Apoptosis Assay 
To investigate the effects of long-term Kv11.1 allosteric modulation in the absence or 
presence of simultaneous Kv11.1 blockade on cell viability, externalized 
phosphatidylserine (as early marker of apoptosis) was detected using Alexa Fluor-
568-conjugated annexin V (Life Technologies Europe). NRVM cultures in 24-well 
plates were treated cells for 72 hours with 100 nM astemizole and/or 10 µM LUF7244 
as described under “Optical Voltage Mapping”. Mock-treated cells and cells 
incubated for 24 hours in culture medium containing 1 µM doxorubicin (Sigma-
Aldrich) served as negative and positive controls, respectively. Next, the cells were 
washed once with ice-cold PBS and incubated for 15 minutes at RT with annexin V 
conjugate diluted 40-fold in binding buffer (10 mM HEPES-NaOH [pH 7.4], 140 mM 
NaCl, 2.5 mM CaCl2) of 4°C containing 10 µg/mL Hoechst 33342. After a single 
wash with binding buffer of 4°C, photomicrographs were taken using a Leica 
DMI6000 B inverted microscope equipped with a Leica DFC300 FX digital color 
camera (both from Leica Microsystems, Rijswijk, the Netherlands). 
 
Data Analysis 
Data of the radioligand binding assays were analyzed with GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA). Half maximal inhibitory concentrations (i.e., 
IC50 values) in displacement assays were directly obtained from non-linear regression 
analysis of dose-response curves. Half maximal inhibitory concentrations (i.e., IC50 
values) in displacement assays were directly obtained from non-linear regression 
analysis of dose-response relationships by four-parameter logistic curve fitting. 
Apparent inhibitory binding constants (Ki values) were derived from the IC50 values 
according to the Cheng-Prusoff relationship6: Ki=IC50/(1+[L*]/KD), where [L*] is the 
concentration of radioligand and KD is its dissociation constant determined by 
saturation assay7. Dissociation rate constants (koff) were obtained by computer analysis 
of the exponential decay of [3H]dofetilide bound to the Kv11.1 channel. Half maximal 
effective concentrations (i.e., EC50 values) from kinetic dissociation assays were 
calculated by non-linear regression analysis of concentration-effect curves of 
dissociation in the presence of different concentrations of unlabeled ligands. Values 
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obtained from the radioligand binding assays are means of three independent 
experiments performed in duplicate. The number of samples per experimental group 
in the optical voltage mapping experiments varied from 6 to 24 as indicated. Data are 
expressed as mean±standard error of the mean (SEM) for the radioligand binding 
assays or as mean±standard deviation (SD) for the optical voltage mapping 
experiments. Statistical analysis of all the results were done using non-parametric tests, 
Mann-Whitney U test for comparison of two groups and Kruskal-Wallis test for 
comparison of more than two groups. Statistical analysis of the results of radioligand 




Comparison of the Concentration-dependent Effects of LUF7244 and 
VU0405601 on APD in NRVMs 
Given the known APD-shortening effect of VU04056018 in rabbit ventricular 
cardiomyocytes and the similarities in chemical structure between LUF7244 and 
VU0405601, a side-by-side comparison of the concentration-dependent effects of 
these 2 compounds on the APD of NRVMs was performed. Consistent with the results 
shown in Figure 5F and 5G of the Main Manuscript, at a final concentration of 10 
µM, LUF7244 did not significantly affect the APD in NRVMs as assesses by optical 
voltage mapping (Figure IIIA). In contrast, exposure of NRVM monolayers to 25 or 
62.5 µM of LUF7244 decreased APD40 and significantly decreased APD90 to a similar 
extent. While the APD-shortening effect of LUF7244 was first observed at a final 
concentration of 25 µM, VU0405601 already caused a decrease of APD40 and a 
significant decrease APD90 at a final concentration of 10 µM (Figure IIIB). Raising 
the VU0405601 concentration to 25 or 62.5 µM did not lead to further APD 
shortening. Moreover, LUF7244 and VU0405601 had very similar maximum effects 
on the APD. Importantly, neither LUF7244 nor VU0405601 significantly changed the 
conduction velocity in the NRVM cultures at the 3 concentrations tested. These 
findings suggest that both LUF7244 and VU0405601 can increase IKr density but that 
VU0405601 is a more potent Kv11.1 activator than LUF7244. 
 
Effects of LUF7244 on the Binding of [3H]Astemizole to the hH1R 
To be of practical use in preventing drug-induced ventricular arrhythmias, LUF7244 
should not interfere with the desired activities of unintended Kv11.1 blockers. We 
therefore tested whether LUF7244 affected binding of the antihistamine drug 
astemizole to the hH1R. As displayed in Figure VA, LUF7244 did not decrease the 
binding of [3H]astemizole to the hH1R. Furthermore, the displacement curve of 
astemizole binding to the hH1R was not significantly shifted rightwards by LUF7244 
(Figure VB). Thus, LUF7244 reduces the affinity of the Kv11.1 channel for 
astemizole without affecting the binding of astemizole to its intended target receptor 
(i.e., the hH1R). 
 
Effects of Prolonged Exposure of NRVMs to LUF7244 and/or Astemizole on Cell 
Viability, Excitability and Contractility 




To study the effects of prolonged allosteric modulation and/or blockade of the Kv11.1 
channel on the viability of cardiomyocytes, 6-day-old NRVM cultures were incubated 
for 72 hours in culture medium containing 10 µM LUF7244 and/or 100 nM 
astemizole. Subsequent staining with fluorescently labeled annexin V to detect cell 
surface-exposed phosphatidylserine yielded only very weak signals for cells exposed 
to vehicle, LUF7244, astemizole or LUF7244 plus astemizole, while NRVMs 
incubated for 24 hours with the proapoptotic drug doxorubicin displayed strong 
annexin V fluorescence (Figure VIA). These results indicate that prolonged exposure 
to 10 µM LUF7244 alone or in combination with 100 nM astemizole does not trigger 
programmed cell death. 
Optical voltage mapping of 9-day-old NRVM cultures that had been mock-
treated or treated for 72 hours with 10 µM LUF7244 and/or 100 nM astemizole 
produced very similar results as were obtained for cells that had only briefly been 
exposed to these compounds (compare Figure 4 and 5 of the Main Manuscript with 
Figure VIB and VIC) and provided no indications for a drug-related reduction in 
excitability. Moreover, after electrical field stimulation cells in all four treatment 
groups displayed rhythmic contractions following the pacing frequency of 1 Hz (see 




Figure I. Assessment, by optical voltage mapping, of the effect of different concentrations of 
astemizole on APD40 and APD90 (A) and EAD incidence (B) in NRVM monolayers. *P<0.05, 




Figure II. Optical voltage trace showing an unstable, self-terminating tachyarrhythmia in an 
astemizole-treated NRVM culture following 1-Hz electrical point stimulation. 




Figure III. Assessment, by optical voltage mapping, of the effect of different concentrations 
of LUF7244 (A) or VU0405601 (B) on APD40 and APD90. Depicted are the pairwise average 
changes in APD (ΔAPD) caused by the treatment of NRVM cultures with vehicle or the 
indicated concentrations of LUF7244 or VU0405601 for 30 min. *P<0.05 and **P<0.01 vs 
vehicle-treated NRVM cultures. No significant differences in APD40 and APD90 were 
observed between the cell cultures exposed to 25 and 62.5 µM LUF7244 and between the 




Figure IV. Assessment, by optical voltage mapping, of the ability of LUF7244 to counteract 
the proarrhythmic effects of sertindole and cisapride on NRVMs. Pretreatment of NRVM 
cultures with LUF7244 completely prevented the increase in APD40 and APD90 (A and D), 
EAD incidence (B and E) and APD40 dispersion (C and F) induced by exposure of the cells 
to 1 µM sertindole (A, B and C) or 1 µM cisapride (D, E and F). *P<0.05, **P<0.01, 
***P<0.001 and ****P<0.0001. 






Figure V. Assessment of the effects of LUF7244 on the binding of astemizole to the hH1R in 
a [3H]astemizole binding assay performed with membranes of HEK293hH1R cells. A: 
Displacement curve of LUF7244. B: Displacement curve of astemizole in the absence or 
presence of 10 µM LUF7244. 
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Figure VI. Effects of prolonged exposure of NRVMs to LUF7244 and/or astemizole on cell 
viability and excitability. A: Analysis by Alexa Fluor-568-conjugated annexin V staining of 
cell surface expression of phosphatidylserine as early marker of apoptosis. NRVM cultures 
exposed for 72 hours to vehicle, 10 µM LUF7244, 100 nM astemizole or 10 µM LUF7244 
plus 100 nM astemizole showed very weak signals, while NRVMs incubated for 24 hours 
with 1 µM of the proapoptotic drug doxorubicin displayed strong annexin V-associated red 
fluorescence. The blue fluorescence corresponds to cell nuclei stained with the DNA-binding 
due Hoechst 33342. B: Quantitative comparison of APD40 and APD90 in NRVM cultures 
exposed for 72 hours to vehicle, 10 µM LUF7244, 100 nM astemizole or 10 µM LUF7244 
plus 100 nM astemizole. **P<0.01. C: Quantitative comparison of CV in NRVM cultures 
exposed for 72 hours to vehicle, 10 µM LUF7244, 100 nM astemizole or 10 µM LUF7244 
plus 100 nM astemizole. (n=6 per group) 
 
  




Table I. The half maximal inhibitory concentrations (IC50), percentage specific 
binding of [3H]dofetilide to the Kv11.1 channel after 6 minutes of dissociation in the 
absence (control) or presence of 10 µM indicated compounds (%B/Bcontrol), and 
dissociation rate (koff) of [3H]dofetilide in the absence (control) or presence of 50 µM 
indicated compounds. 
 
 IC50 (nM)     %B/Bcontrol  koff (min-1) 
dofetilide    -     100±0.01   0.21±0.02   
+VU0405601 7,757±350      63±3**      0.42±0.04** 
+ML-T531  12,000±1,213      77±3**    0.30±0.03* 
+LUF7244 3,855±724           44±2**      0.33±0.02** 
 
All values for comparison are means (±SEM) of six samples except that koff values of 
dofetilide in the absence of indicated compounds or presence of 50 µM ML-T531 are 
derived from seven samples. Statistical analysis of the results is conducted by Mann-
Whitney U test (*P<0.05 vs control; **P<0.01 vs control). 
 
 
Table II. The Kv11.1 affinities (Ki) of dofetilide, astemizole, sertindole and cisapride 
in the absence (control) or presence of 10 µM LUF7244. 
 
 Ki (nM) Ki + 10 µM LUF7244 (nM) Fold Change 
dofetilide   6.2±0.3                     20±5* 3.2 
astemizole   0.97±0.04   3.7±0.2** 3.8 
sertindole 21±2                     47±7** 2.2 
cisapride 21±1                     85±6** 4.0 
 
All values for comparison are means (±SEM) of six samples. Statistical analysis of the 
results is conducted by Mann-Whitney U test (*P<0.05 vs control; **P<0.01 vs 
control).  




Clinical Applicability of Allosteric Kv11.1 Modulators 
A major concern and obstacle for medicinal chemists involved in the development of 
drugs to remedy congenital and acquired long QT syndrome is excessive APD 
shortening resulting in short QT syndrome (SQTS).9,10 For instance, at a concentration 
of 10 µM, the potent Kv11.1 activator ICA-105574 shortened the APD in 
Langendorff-perfused guinea pig hearts by 34% and induced non-“Torsades de 
Pointes”-like ventricular arrhythmias in 2 out of 8 animals.11 Likewise, in a transgenic 
rabbit model of LQT1, shortening of the QTc interval by another Kv11.1 activator 
designated NS1643 was accompanied by an increased incidence of pacing-induced 
ventricular fibrillation.12 However, the fact that LUF7244 at a concentration that 
completely abolished the proarrhythmic effects of astemizole, sertindole and cisapride 
does not shorten the APD of NRVMs and therefore may not give rise to drug-induced 
SQTS raises hope for its clinical applicability. 
For the experiments in NRVM monolayers, the final astemizole concentration 
was 100 nM in most cases, while sertindole and cisapride were used at a final 
concentration of 1 µM. These concentrations are much higher than the therapeutic 
blood concentrations of these fortuitous Kv11.1 blockers, which are 2-50 µg/L (i.e., 
4.4-109 nM) for astimizole, 40-80 µg/L (i.e., 86-172 nM) for cisapride and 50-100 
µg/L (i.e., 113-227 nM) for sertindole.13 The proarrhythmic effects of these drugs on 
NRVMs were completely prevented by 10 µM (i.e., 3.7 mg/L) LUF7244, a 
concentration that did not negatively influence the binding of astemizole to the hH1R 
and did not noticeably affect the viability, contractility and excitability of the 
cardiomyocytes (see “Effects of Prolonged Exposure of NRVMs to LUF7244 and/or 
Astemizole on Cell Viability, Excitability and Contractility”). Accordingly, blood 
LUF7244 concentrations well below 10 µM may suffice to counteract the 
proarrhythmic effects of unintended Kv11.1 blockers in humans. However, before 
LUF7244 or other KV11.1 allosteric modulators can be clinically applied as “co-drugs” 
or otherwise, they should be subjected to rigorous preclinical and clinical testing with 
appropriate pharmacokinetic and pharmacodynamics assessments to determine their 
benefit-risk profiles. 
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Sudden cardiac death secondary to drug-induced long QT syndrome is a major safety 
concern and has led to withdrawal of several high-profile drugs, such as cisapride and 
astemizole, from the market. Although these drugs have different chemical structures, 
they all block the rapid delayed rectifier K+ current (IKr) with high potency. The hERG 
channel (Kv11.1) encoded by the hERG gene is responsible for this current. This 
channel has a high affinity for wide spectrum of compounds compared with other ion 
channels mainly because of the presence of unique aromatic amino acids in the S6 
domain of hERG.1 This in turn has created a major challenge for development of new 
drugs.2 In fact, it is now a routine practice in the pharmaceutical industry to screen 
compounds for their ability to block hERG early in preclinical safety assessments 
according to the Food and Drug Administration guidelines. This in turn leads to 
elimination of a large number of potentially beneficial compounds from chemical 
libraries.  
Interestingly, screening libraries of compounds for their blocking effect on 
hERG has resulted in discovery of many hERG activators/modulators. These drugs 
increase current flow through hERG via various mechanisms that include slowing of 
deactivation, removal of inactivation, and facilitation of activation.3 In theory, hERG 
channel activators could have the potential to normalize the QT interval in acquired or 
congenital long QT syndromes.4 In fact, the proarrhythmic effects of dofetilide can be 
reversed, in vitro, by application of hERG channel activators.5 The draw back in the 
use of hERG activators clinically has been their inherent ability to shorten the QT 
interval, possibly to the point of causing arrhythmia.  
Given the strain that is placed on drug discovery and also withdrawal of several 
previously successful drugs because of their QT prolonging properties, it is important 
to develop reproducible, physiological, and clinically translatable techniques to 
examine the effect of hERG channel activators and their interaction with long QT 
inducing drugs. In this issue, Yu et al,6 by using membranes of HEK 293 cells 
expressing hERG for in vitro radioligand assay, show that a newly synthesized hERG 
modulator (LUF7244) diminishes the binding affinity of potent hERG blockers, such 
as dofetilide, astemizole, sertindole, and cisapride. Increased concentrations of this 
modulator resulted in reduced specific binding of radioactive dofetilide, with Hill 
coefficient >1, suggesting allosteric interaction rather than direct competition for the 
same binding site. This notion was fortified by demonstration of altered dissociation 
rate constant in the presence of LUF7244. This is in agreement with previous findings 
that openers/modulators may exert their effect by interacting with the channel at sites 
separate from the pore, where the class III drugs bind.7 Interestingly, the authors 
showcase a clever mean to assay the effect of LUF7244 on hERG channel blockers in 
a physiological setting by using cultured neonatal rate ventricular myocytes. They 
used high-resolution optical mapping to record action potentials from cells grown to 
confluence. With this technique, LUF7244 reversed the prolonging effect of 
astemizole on action potential duration and prevented induction of early after 
depolarization. Surprisingly, in the absence of hERG blockers, LUF7244 did not 
shorten action potential duration. 
Lack of shortening of action potential duration by LUF7244 was not examined 
further in their article. This could be because of off-target effect of LUF7244 on other 





current, which is responsible for slow delayed rectifier K+ current (IKs).8 If the ratio of 
blocking activity at hERG and KCNQ1 balance each other out, then action potential 
duration will not change significantly, which could be a beneficial feature as it would 
prevent short QT syndrome. Therefore, it is important to assess the effect of LUF7244 
and future hERG activators on a range of ion channels to ensure the absence of 
unwanted off-target effect. 
This article raises 2 interesting questions. First, can hERG 
modulators/activators be used in combination with drugs that are known to block 
hERG to mitigate the long QT side effect? This has an immense clinical prospect 
because it will allow for reintroduction of previously successful drugs and can 
potentially accelerate drug discovery and development. A significant number of 
chemicals are eliminated from libraries during drug discovery because of their affinity 
to hERG. Therefore, by having the ability to counteract this effect, there will be more 
compounds available to screen for use in variety of diseases. In the future, through 
mapping the binding site and mechanism of action of various activators, more potent 
activators will surely be developed.  
The second question is can the assays developed by Yu et al6 be used as a high 
throughput screening strategy? Although patch clamp remains the gold standard in 
studying the biophysical properties of channels and determining the details by which 
drugs interact with them, it is technically challenging with low throughput. Here, the 
authors demonstrate the use of cultured neonatal rat myocytes and optical mapping to 
assess for action potential duration. The advantage of this technique over existing 
assays is that it is a physiological screen, capable of determining the effect of a 
compound on the action potential duration and potential for evoking early after 
depolarization. Even so, patch-clamp studies of LUF7244 seem essential to clarify its 
detailed molecular mechanism(s) of action. A detailed understanding of its state-
dependent pharmacological affects seems critical. Sitedirected mutagenesis may 
provide insights as to the topology of its allosteric-binding site on the hERG (KCNH2) 
channel. Enhanced description of its electrophysiological effects seems an important 
next step.  
A recent article by Yu et al9 proposes interesting potential mechanism(s) for 
increased dissociation of 3H-dofetilide and 3H-astemizole from the hERG channel by 
an allosteric modulator (LUF6200). Potassium ions both enhance the allosteric effect 
of LUF6200 and shift the LUF6200 dose–response curve to the left. Furthermore, 
their studies suggested a positive cooperativity between LUF6200 and potassium ions. 
Residence of potassium ions in the selectivity filter of hERG is critical to the C-type 
inactivation process. Moreover, C-type inactivation state seems to play a pivotal role 
in stabilizing the dofetilide-associated state of the channel by preventing its 
dissociation. Alteration of the residence of potassium ions near the C-type inactivation 
gate (selectivity filter) would shift voltage dependence of inactivation. Modifying C-
type inactivation would thus allow dissociation of dofetilide and astemizole from its 
binding site in the pore. Patch-clamp studies will be necessary to test this hypothesis. 
Even so, there could be >1 binding site in hERG or binding sites in other ion channels 
that can indirectly alter dissociation of dofetilide and astemizole from their binding 
sites. Further studies of this interesting new compound are warranted. 
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Summary and future perspectives 




The general introduction of this thesis, Chapter 1, first describes the requirements of 
proper cell lines that need to be established for research models. Next, p53 and pocket 
proteins as main regulators in both senescence and quiescence are discussed. Finally, 
an overview is presented of the capacity of LT to immortalize cells via p53 and RB 
pathways bypassing senescence or inducing cell cycle reentry of arrested cells. 
In Chapter 2, the impacts of heterochromatin proteins on premature 
senescence is investigated. It is shown that the level of heterochromatin protein 1α 
(HP1α) associated with the nuclear matrix is significantly increased in premature 
MEFs. Upon DNA damage, HP1α phosphorylation is significantly compromised 
leading to delayed formation of γ-H2AX foci. Knocking down of HP1α alleviates the 
delayed DNA damage response and accelerates senescence. Hence, HP1α is identified 
as a new molecular and mechanistic insight into heterochromatin mis-organization, 
delayed DNA damage response, and early senescence, providing a promising 
intervention target for both progeria and normal aging. 
Chapter 3 describes a novel bipartite lentivirus vector to quantify cell-to-cell 
fusion by using the immortalized human myoblasts as a cell fusion model. To this 
purpose, immortalized human myoblasts are transduced either with a flippase-
activatable Gaussia princeps luciferase (GpLuc) expression unit (acceptor cells) or 
with a recombinant gene encoding FLPe, a nuclear-targeted and molecularly evolved 
version of flippase (donor cells). The key advantage of this system is the replacement 
of Photinus pyralis luciferase (PpLuc) by GpLuc, which is a secretory protein 
allowing repeated analysis of the same cell culture with a much higher specific 
luciferase activity than PpLuc. In addition, to investigate whether the speed of FLPe in 
myotubes is limited due to the presence of the nuclear localization sequence (NLS), 
the ability of FLPeNLS+ and an LV encoding an NLS-less version of FLPe (FLPeNLS-) 
to activate latent GpLuc genes are compared in myogenic fusion assays. The results 
show that both FLPeNLS+ and FLPeNLS- activate the latent GpLuc gene but when the 
percentage of FLPe-expressing myoblasts is limiting, FLPeNLS+ generally yields 
slightly higher signals than FLPeNLS-. While at low acceptor-to-donor cell ratios, 
FLPeNLS- is usually superior. However, at high FLPe concentrations the presence of 
the NLS negatively affects reporter gene expression. This study develops a rapid and 
simple chemiluminescence assay for quantifying cell-to-cell fusion progression based 
on GpLuc. 
In Chapter 4, a conditionally immortalized atrial myocytes (iAMs) line with 
preserved cardiomyogenic differentiation ability is established. Its proliferative and 
contractile phenotypes is controlled by a simple change in culture medium 
composition. Under proliferative conditions, the cells lose most of the properties 
typical for cardiomyocytes (CMCs) and proliferate with an average doubling time of 
38 hour. Under differentiation conditions, the cells stop dividing and gradually 
reacquire a phenotype resembling that of primary atrial myocytes (pAMs) in gene 
expression profile, sarcomeric organization, contractile behavior and electrical 
properties and response to ion channel-modulating compounds. Following high-
frequency electrical stimulation reentry is induced in monolayers of these cells 
resembling atrial fibrillation, which could be terminated by tertiapin treatment, just 
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like in pAMs monolayers. In addition, iAMs could readily engraft and undergo 
cardiomyogenic differentiation after injection in atrial tissue. In conclusion, by the 
controlled expansion and differentiation of iAMs, large numbers of functional CMCs 
were generated with properties far superior to any of the existing immortalized CMC 
lines. This cell line provides an attractive cardiac cellular model for disease modelling, 
drug screening, cell therapy, tissue engineering and fundamental research. 
Chapter 5 describes the generation of monoclonal lines of conditionally 
immortalized brown preadipocytes (iBPAs) using a few mouse brown preadipocytes 
as starting material. These cells retain long-term proliferation as well as adipogenic 
capacity. Multilocular lipid droplets are abundantly formed and brown fat markers 
including uncoupling protein 1 (Ucp1) are highly expressed in brown fat cells 
differentiated from iBPAs. Furthermore, the differentiated cells respond to β3-
adrenergic stimulation by increasing glycerol release and Ucp1 expression. Taken 
together, iBPA-derived brown fat cells represent a functional easy-to-use model 
system for fundamental and applied research into BAT. 
Chapter 6 shows an in vitro model for investigating the action potential (AP)-
prolonging and associated proarrhythmic effects of Kv11.1 blockers established by 
neonatal rat ventricular myocyte cultures. In this study, a newly designed and 
synthesized compound LUF7244 were proved to fully prevent drug-induced 
proarrhythmic effects as an allosteric modulator. This is the first study to proof that 
allosteric modulation of IKr could protect against drug-induced arrhythmias in vitro by 
preventing potentially arrhythmogenic changes in AP characteristics. This study could 
therefore provide a rationale to counteract drug-induced ventricular arrhythmias by 
pharmacological combination therapy relying on allosteric modulation of Kv11.1 
channel activity.  
 
  




Inhibition of premature aging  
Except the importance of HP1-mediated heterochromatin formation, heterochromatic 
gene silencing, chromatin remodelling and DNA damage response, HP1 involved in 
the repressive function of the retinoblastoma protein (pRB) by binding to the cyclin E 
promoter1. Besides, HP1 was found interacted with a number of other transcriptional 
repressors2, indicated that it might have a role in inhibiting many other promoters. 
Thus, a more general, genome-wide function of HP1 in suppressing gene transcription 
should be considered in the future study. Rapamycin represses mTOR pathway, which 
in turn inhibits DNA damage response, and therefore slowing down cellular 
senescence3,4. In the accelerated aging model, mTOR signaling contributes to stem 
cell dysfunction that occurs in response to endogenous DNA damage, which can be 
rescued by rapamycin treatment5. In this scenario, it would be interesting to examine 
whether rapamycin could rescue defective DNA repair in Zmpste24-null cells and to 
find the relationship between abnormal prelamin A/ HP1 and mTOR in future study. 
 
Improvement of the cell fusion assay  
In Chapter 3, an rapid and simple assay to quantify the cell-to-cell fusion progression 
is developed. However, the use of FLP-FRT system to active the latent Gpluc gene 
delays the real monitoring time for hours. The sensitivity of the current assay could be 
improved by changing FLP-FRT system to the bioluminescence resonance energy 
transfer (BRET) by using two interacted proteins6. Besides, the prompter driving 
monitor genes expression can be optimized by changing a higher activity one. 
 
Improvement of iAM1 differentiation 
Various studies have shown that TGFβ critically involved in cardiac differentiation. 
TGFβ family members have been found to promote cardiomyogenic differentiation in 
embryonic stem cells (ESCs) and critically involve in the expression of cardiac-
specific markers7-11. Besides, TGF-β1 significantly increases differentiation efficiency 
of human CMC progenitor cells into functional CMCs12. Apart from TGF-β1, factors 
such as neuregulin13, follistatin-like 114 and insulin-like growth factor15,16 have 
exhibited their cardioprotective effects which may further support the survival of the 
cells during differentiation. Although iAM1s spontaneously differentiate to functional 
CMCs in absence of dox with the properties very similar to that of primary AMs, 
these factors could be candidates to further improve the differentiation and maturation 
of iAM1s and this will be an interesting topic for future study.  
 
Improvement of the model for drug screening 
In Chapter 6, the use of neonatal rat ventricular CMC monolayer cultures and optical 
mapping to investigate compounds is a physiological screening, capable of 
determining their effects on action potential duration and pro-arrhythmic potential. 
However, this approach can be further improved by using conditional immortalized 
human ventricular myocytes. Although mammalian cardiac cell can predict drug 
responses and cardiotoxicity similar to human cardiac cells, a human system of course 
has the greater likelihood to mimic the responses in patients. Conditional 
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immortalized cardiac cells are able to rapidly divide and spontaneously differentiate, 
therefore they can generate large number of functional CMCs economically. 
Consequently, combination of these cells and voltage optical mapping can potentially 
be expanded to high throughput screening for developing drugs including allosteric 
modulators. In addition, changes in CMC electrophysiological properties upon drug 
treatment may display differently in a cell layer (2-dimension) than in the heart (3-
dimension). The use of Langendorff technique may have greatly contributed to our 
current understanding of the electrophysiology on the whole heart. 
 
Conditional immortalization in cardiac repair 
Heart failure is a growing epidemic caused by the loss of CMCs. Various cell sources 
have been used for cardiac regeneration and repair, each with its own advantages and 
challenges. 
Human ESCs17-22 and induced pluripotent stem cells (iPSCs)23-25 derived CMCs 
have shown their ability to improve the cardiac function in damaged heart of animal 
models. However, generation of CMCs from ESCs or iPSCs yields heterogeneous 
populations of mostly immature CMCs as well as non-CMCs. Their relatively 
immaturity reduces their efficacy and endogenous integration. Also, the contamination 
of immature stem cells can induce to teratoma formation after the 
transplantation26. Besides, injection of CMCs derived from human ESCs in damaged 
myocardium has proarrhythmic risk22. Since proper alignment of cardiomyocytes play 
an important role in the heart function including the electric propagation and the 
contractile force27, most likely the injected CMCs cannot align properly with the host 
CMCs which caused increased electric heterogeneity28. Moreover, delivery of high 
amount of donor cells into the damaged myocardium is very difficult. Cells 
transplanted in suspensions suffers from low engraftment and cell survival, since the 
cells may be squeezed out by the contractile force of the heart. Tissue engineering 
could help the alignment by using graft to guide the alignment of implanted CMCs, 
however, it is quite challenging to tightly adhere transplanted tissue on the contracting 
heart as well as subsequent vessel generation and blood supplement into the tissue. 
Several groups have directly reprogramed fibroblasts into “induced 
cardiomyocyte-like cells” (iCMs) using cardiac transcription factors to improve 
cardiac function29,30. These studies provide proof-of-concept that the same cells that 
cause scar can be reprogramed to replenish the lost CMCs. While much questions 
remain to be addressed before clinical translation. At present, identification of 
fibroblast to iCM reprogramming relies on genetic lineage tracing approaches, which 
may cause false positive by cell fusion and the leakage of Cre activity. Currently, all 
in vivo reprogramming studies have used integrating viruses, which have the potential 
risk of oncogenesis. Besides, the reprogramming efficiency, maturity and integration 
of iCMs need to be further improved. 
Many factors and pathways showed their functions on stimulation of CMC cell 
cycle re-entry which bring an attractive strategy to replenish CMCs lost in disease 
heart by inducing the re-entry of mature CMCs31-34. For instance, transgenic 
expression of Cyclin D2 significantly decreased the infarct size with effective cardiac 
regeneration35. miR-590 and miR-199a stimulated adult CMC proliferation and 
enhance myocardial recovery after myocardial infarction36. However, valid 
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measurements are required to monitor new CMC expansion as well as their 
therapeutic outcome. More insights about the molecular mechanisms and stronger pro-
mitogenic genes of CMC proliferation need to achieve far more than presently 
available. Moreover, this strategy is largely limited by the oncogenic potential of pro-
proliferative activity. 
Another alternative cell source for cardiac repair could be the conditional 
immortalized cardiac cells. Conditional immortalized CMCs have the ability to 
amplify sufficiently in vivo which avoid the difficulties to delivery large number of 
cells into the heart. The proliferation of these cells is tightly and reversibly controlled 
by inducer that provides a protection from oncogenic risk and a repetitive repair upon 
multiple damage, respectively. Most important, immortalized CMCs could rapidly and 
synchronously differentiate to pure and mechanically and electrically mature CMCs, 
in the meantime forming functional couplings with neighbour CMCs from the host. 
The use of conditional immortalized CMCs in cardiac regeneration would obviate 
many of the difficulties faced by other cell types, such as immune-compatibility, 
oncogenic rick, enough cell expansion or delivery of a large number of cells, 
differentiation, and functional integration.  
 
Future immortalization targets and their applications 
Many animals such as rat, mice, dog, and primates are sacrificed to acquire cells from 
different organs for research purpose which is costly, laborious and not animal-
friendly. Immortalization of cell lines from different animal spices and various organs 
will be an alternative way without sacrificing animals and with advantages. 
Disease modeling is important for understanding the mechanisms and finding 
treatments of the disease. For this reason, models should be able to fully mimic the 
disease microenvironment. Conditional immortalization of the disease cells caused by 
the mutations of genes will generate large number of disease cells for development of 
acquired disease models and identifying new therapeutic treatments. Moreover, 
immortalization of disease cells from individual patient could be helpful to develop 
patient specific therapeutics targets.  
In cell therapy, the transplanting of patient specific immortalized cells to the 
damage tissues may eliminate the chances of immune rejection. Similar for the gene 
therapy, patient specific cells can be genic corrected and amplified by immortalization 
in the laboratory and then transplanted to one's own body, hence there is no risk of 
immune rejection. Cell sheet-based tissue engineering is a new generational cell-based 
regenerative medicine which requires huge amount of functional cells. The 
conditional immortalization is an attractive cell sources for tissue engineering because 
it is able to provide pure, abundant, and fully functional cells by using only a few cells 
as start material.  
Cardiac toxicity is a big safety concern for drug development37. Immortalized 
cardiac cell line has shown its globally and efficiently respond to drug induce hazard 
in Chapter 4. Actually, immortalization of human ventricular myocyte would be the 
ideal cellular model for drug screening upon cardiac safety issue. Moreover, 
conditional immortalization has the potential to provide a plentiful source of patient-
derived cells to screen or test experimental drugs for disease treatment. 
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Human cell lines have the ability to produce proteins with full human post-
translational modifications (PTMs; most notably glycosylation) same to those 
synthesized naturally in humans, which are a frequently used expression system for 
biopharmaceutical manufacturing38. On one hand, the expression of oncogenes is 
required for cell lines to grow rapidly to achieve a high cell density and synthesize 
concentrated protein products. On the other hand, the possibility of transmitting 
oncogenes from the cell lines to human body raises safety concerns. In this case, 
conditional immortalization therefore provide an extra layer to protect from this issue.  
Moreover, conditional immortalized cell lines provide an attractive new model 
system for fundamental research. For instance, CMC proliferation and re-
differentiation is a potential therapeutic target for myocardial regeneration and repair. 
However, little is known, on the fundamental mechanisms underlying cell cycle re-
entry, proliferation and re-differentiation of CMCs. Given the highly attractive feature 
of the iAM1s that they spontaneously undergo cardiomyogenic differentiation in the 
absence of dox and fully differentiated iAM1s resume cell dividing ability in the 
presence of dox both in a highly synchronized way, this homogenies population 
provides an useful model to identify the crucial factors involved in cardiac 




Figure 1. Future immortalization targets and their possible applications. Cell of 
interesting isolated from different organs of species are used for the reversible 
immortalization, amplification, re-differentiation and subsequent application.  
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In de algemene introductie van dit proefschrift, Hoofdstuk 1,worden de voordelen 
van cellijnen als onderzoeksmodellen beschreven. Vervolgens worden de rollen van 
p53 en de “pocket proteins” als belangrijke regelaars van zowel “senescence” als 
“quiescence” bediscussieerd. Tenslotte wordt er een overzicht gegeven over het 
vermogen van het “simian virus 40” LT eiwit om cellen te immortaliseren via de p53 
en pRb signaaltransductieroutes, waardoor “senescence” wordt omzeild en in slapende 
cellen de celcyclus wordt gereactiveerd. 
In Hoofdstuk 2 wordt het effect van heterochromatine eiwitten op “premature 
senescence” onderzocht. In dit hoofdstuk wordt aangetoond dat de eiwitexpressie van 
aan de kernmatrix gebonden heterochromatine eiwit 1α (HP1α) significant verhoogd 
is in premature MEFs. Wanneer er DNA schade optreedt, leidt dit tot een significante 
verstoring in de fosforylering van HP1α, wat zorgt voor een vertraging in de formatie 
van γ-H2AX foci. 
Hoofdstuk 3 beschrijft een nieuw tweedelig lentiviraal vectorsysteem om fusie 
tussen cellen te kwantificeren door gebruik te maken van humane myoblasten als 
celfusie model. Voor dit doeleinde werden geïmmortaliseerde humane myoblasten 
getransduceerd met een flippase-activeerbaar Gaussia princeps luciferase (GpLuc) 
expressiemodule (acceptorcellen) of met een recombinant gen coderend voor FLPe, 
een naar de kern getransporteerde en moleculair geëvolueerde versie van flippase 
(donor cel). Het belangrijkste voordeel van dit systeem is het gebruik van GpLuc in 
plaats van Photinus pyralis luciferase (PpLuc). GpLuc heeft een veel hogere luciferase 
activiteit dan PpLuc en wordt bovendien uitgescheiden waardoor dezelfde celkweken 
meerdere keren geanalyseerd kunnen worden. Daarnaast hebben we onderzocht of de 
enzymatische activiteit van FLPe in myotubes gelimiteerd is door de aanwezigheid 
van een kernlokalisatiesignaal (NLS). In een myogene fusie assay werden wild-type 
FLPeNLS+ en een NLS-loze versie van FLPe (FLPeNLS-) gebruikt om latent GpLuc te 
activeren. De resultaten laten zien dat zowel FLPeNLS+ als FLPeNLS- het latente GpLuc 
gen activeren. Maar wanneer het percentage FLPe-expresserende myoblasten 
gelimiteerd is, wordt er in het algemeen een iets hoger signaal gedetecteerd in 
FLPeNLS+ ten opzichte van FLPeNLS- myoblasten, terwijl bij lage acceptor-donor cel 
ratio’s meestal FLPeNLS- beter functioneert. Echter, bij hoge FLPe concentraties heeft 
de aanwezigheid van de NLS een negatieve werking op de reporter genexpressie. 
Deze studie laat een snelle en simpele chemiluminiscentie assay zien voor het 
kwantificeren van fusie tussen cellen gebaseerd op GpLuc. 
In Hoofdstuk 4 wordt een conditioneel geïmmortaliseerde atriale myocyten 
(iAM) cellijn met geconserveerd cardiomyogene differentiatie eigenschappen gemaakt 
waarvan het fenotype (proliferatief of contractiel) kan worden gecontroleerd door een 
simpele verandering in de compositie van het kweekmedium. Onder proliferatieve 
condities verliezen de cellen het merendeel van hun eigenschappen die typische zijn 
voor cardiomyocyten (CMCs) en verdubbelen zich gemiddeld elke 38 uur. Onder 
differentiatiecondities stoppen de cellen met delen en verkrijgen geleidelijk aan een 
fenotype dat lijkt op het fenotype van primaire atriale myocyten (pAM) voor wat 
betreft genexpressieprofiel, sarcomere structuur, contractiel gedrag, elektrische 
eigenschappen en effecten van ionkanaal-modulerende stoffen. Hoog frequente 
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elektrische stimulatie induceerde rotors (zogenaamde elektrische stormen) in iAM 
monolagen lijkend op boezemfibrilleren welke beëindigd konden worden door 
toediening van tertiapin net zoals in monolagen van pAMs. Daarnaast bleken iAMs 
zich na injectie in boezemweefsel te kunnen differentiëren in CMCs die niet te 
onderscheiden waren van de omliggende endogene hartspiercellen. Concluderend kan 
dus worden gesteld dat met behulp van iAMs, grote hoeveelheden functionele CMCs 
geproduceerd kunnen worden via gecontroleerde proliferatie en differentiatie. De 
eigenschappen van deze hartspiercellen zijn superieur aan die van alle bestaande 
cellijnen van geïmmortaliseerde CMCs. De iAM cellijn is daardoor een aantrekkelijk  
cellulair modelsysteem voor het nabootsen van hartziekten, drug screening, 
celtherapie, “tissue engineering”, en fundamenteel onderzoek. 
Hoofdstuk 5 beschrijft de creatie van monoclonale cellijnen van conditioneel 
geïmmortaliseerde bruine pre-adipocyten (iBPAs) met enkele bruine pre-adipocyten 
uit muizen als startmateriaal. De iBPAs behouden langdurig zowel proliferatieve als 
adipogene eigenschappen. Multiloculaire vetdruppeltjes worden rijkelijk gevormd en 
markers van bruin vetweefsel, inclusief uncoupling protein 1 (Ucp1), komen sterk tot 
expressie in gedifferentieerde iBPAs. Daarnaast reageren deze cellen op β3-
adrenergische stimulatie door een verhoogde glycerolproductie en een verhoogde 
expressie van Ucp1. iBPA-afgeleide bruine vetcellen vertegenwoordigen dus een 
functioneel ”easy-to-use model” voor fundamentele en toegepaste wetenschap naar 
bruin vet. 
In Hoofdstuk 6 wordt een kweekmodel gebaseerd op neonatale ventriculaire 
myocyten van de rat beschreven om verlenging van de actiepotentiaal (AP) door 
zogenaamde Kv11.1 blokkers en de hiermee geassocieerde pro-aritmische effecten 
onderzoeken. Deze studie bewijst dat een nieuw ontworpen en gesynthetiseerde stof 
(LUF7244) pro-aritmische effecten volledig kan voorkomen via allosterische 
modulatie. Dit is de eerste studie die aantoont dat allosterische regulatie van IKr in 
vitro bescherming biedt tegen drug-geïnduceerde aritmiën door potentiele aritmogene 
veranderingen in de AP karakteristieken te voorkomen. Deze studie zou als basis 
kunnen dienen voor de ontwikkeling van farmacologische combinatietherapieën ter 
bestrijding van drug-geïnduceerde ventriculaire aritmiën. Effectieve geneesmiddelen 
die door hun remmende werking op het Kv11.1 ionkanaal en het hiermee gepaard 
gaande risico op plotselinge hartdood momenteel niet kunnen worden toegepast 
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